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Abstract 
Oral squamous cell carcinoma (OSCC) is associated with a high degree of morbidity 
and mortality. OSCCs are often preceded by oral potentially malignant disorders 
(OPMD) which have a higher propensity to undergo malignant transformation 
compared to clinically normal oral mucosa. However, traditional methods such as 
clinical and histopathological assessment of OPMD are unable to accurately predict 
clinical outcome. The search to identify the perfect biomarker for prognosticating 
malignant transformation in OPMD is still ongoing. This study was undertaken to 
construct a prognostic classifier for patients with OPMD by integrating clinical, 
histopathological and molecular factors as well as to discover a gene expression 
signature that characterises OPMD with a high risk of undergoing malignant 
transformation. The demographic and clinical features of a cohort of OPMD patients 
were studied in detail. Assessment and analysis of clinico-demographic features, 
histopathological features, differential gene expression, loss of heterozygosity 
(chromosomal regions 3p14.2, 9p21 and 17p13) and DNA ploidy status were 
performed on archived formalin-fixed paraffin-embedded tissue material from this 
cohort of patients. Gene expression studies revealed several genes that had 
statistically significant differential expression between cases that underwent 
malignant transformation and those that did not. A novel gene-signature for cases 
that had a propensity for undergoing malignant transformation was developed. 
Statistical model building was performed to construct a prognostic classifier for 
OPMD patients. A prognostic model composed of age at diagnosis, site of index 
OPMD, binary oral epithelial dysplasia grading and the novel gene-signature was 
found to be highly prognostic of clinical outcome for OPMD patients (concordance 
index: 0.85). Our findings show that a molecular biomarker driven prognostic 
classifier outperformed conventional methods for predicting clinical outcome in 
patients with OPMDs. The findings from this study have also reinforced that formalin-
fixed paraffin-embedded tissue can be used to generate a molecular classifier with 
clinical utility. 
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 Introduction 
1.1 Cancer  
A recently completed epidemiological project to assess the global incidence and 
prevalence of major types of cancers, GLOBOCAN 2012, estimated that globally 
around 14 million new cancers occurred in 2012 resulting in eight million cancer-
related deaths (Ferlay et al., 2015; Torre et al., 2015). Worldwide, lung cancer was 
the most common malignancy (excluding non-melanoma skin cancers) with regard to 
incidence and caused the majority of cancer-related deaths in 2012. Breast cancer 
was the most frequently diagnosed malignancy in women and second most common 
malignancy (excluding non-melanoma skin cancers) overall (Ferlay et al., 2015; Torre 
et al., 2015). In 2016, one in four deaths in the United Kingdom (UK) were cancer-
related and a recent study estimated that around 50% of individuals born since 1960 
in the UK will develop some form of cancer during their lifetime (Ahmad et al., 2015; 
Cancer Research UK, 2018).  
Cancers are the end result of a multistep process of accumulated genetic alterations 
(Balmain et al., 1993).  Fearon and Vogelstein (1990) through their study of 
colorectal cancers highlighted a molecular genetic model of carcinogenesis that is 
based on a multi-step progression from adenoma to carcinoma (Fearon and 
Vogelstein, 1990). This concept for carcinogenesis has also been adapted for other 
anatomical sites including the oral cavity (Califano et al., 1996; Kim and Califano, 
2004). Despite the heterogeneity of cancers, there are key molecular genetic events 
in carcinogenesis defined as the “Hallmarks of Cancer” (Figure 1.1) (Hanahan and 
Weinberg, 2000; Hanahan and Weinberg, 2011). 
1.2 Oral Cancer  
1.2.1 Introduction 
Tumours arising in the upper aerodigestive tract can be broadly classified by site into 
tumours of the oral cavity, pharynx (nasopharynx, oropharynx, laryngopharynx), 
sinonasal complex, salivary glands, oesophagus and larynx. Currently, there is no 
standardised definition for oral cancer and researchers report epidemiological data 
using differing combinations of International Classification of Diseases (ICD) codes 
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(ICD 10 C00-C06, C09-C10 and C14) (World Health Organisation, 2016). In previous 
years, due to the close proximity of the oral cavity and oropharynx, tumours involving 
these two sites were often discussed together (Barnes et al., 2005). This may cause 
some inconsistency in clinical coding and care is required when comparing different 
epidemiological studies. The recently published 4th edition of the World Health 
Organization (WHO) Classification of Head and Neck Tumours however has 
classified oropharyngeal squamous cell carcinoma (OPSCC) as a distinctly separate 
disease to conventional oral cavity squamous cell carcinoma (OSCC) (El-Naggar et 
al., 2017). The oral cavity extends from the palatoglossal folds to the lips. Oral cavity 
cancers are usually further subdivided into two anatomical sub-sites: lip cancers and 
intra-oral cancers. This study will focus on intra-oral cancers as most lip cancers 
have a different aetiology (solar radiation) and better prognosis compared to oral 
cavity cancers (Moore et al., 1999; Barnes et al., 2005; Warnakulasuriya, 2009; El-
Naggar et al., 2017).   
Epidemiological studies estimate that more than 300,000 new cases and 145,400 
deaths from oral cancers (inclusive of lip cancers) occur (Torre et al., 2015; Bray et 
al., 2018). Approximately two-thirds of the new oral cancer cases occurred in men 
and around 77% of oral cancer (inclusive of lip cancers) deaths were in less-
developed nations (Ferlay et al., 2015). In 2012, it was the 15th most common cancer 
globally and was the most prevalent cancer in Indian men (Bray et al., 2013; Ferlay 
et al., 2015; Torre et al., 2015).  
In the United Kingdom (UK), in 2013, there were 7,591 new cases of oral and 
oropharyngeal cancers reported (around 21 people per day per annum) accounting 
for 2% of all new cancer cases (Cancer Research UK, 2015; Welsh Cancer 
Intelligence and Surveillance Unit, 2018; ISD Scotland, 2018; Northern Ireland 
Cancer Registry, 2018; Office for National Statistics, 2018). Furthermore, oral and 
oropharyngeal cancers have increased by more than 92% since the late 1970s 
(Cancer Research UK, 2015; ISD Scotland, 2018; Northern Ireland Cancer Registry, 
2018; Office for National Statistics, 2018; Welsh Cancer Intelligence and Surveillance 
Unit, 2018). The north of England has higher levels of oral and oropharyngeal cancer 
than the south, possibly due to the complex relationship between lifestyle factors and 
socio-economic determinants (Johnson and Warnakulasuriya, 1993; Edwards and 
Jones, 1999; Quinn et al., 2001; Conway et al., 2006). Over the past few decades, an 
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increasing incidence of oral and oropharyngeal cancers has also been recorded in 
younger, middle aged adults (Macfarlane et al., 1996; Mork, 1998; Koch et al., 1999; 
Barnes et al., 2005; Parkin et al., 2005).  
Most oral cancers are oral squamous cell carcinomas (OSCCs) (Barnes et al., 2005). 
OSCC is a malignant epithelial neoplasm exhibiting varying degrees of squamous 
differentiation and has a propensity for regional lymph node metastasis (Barnes et 
al., 2005; El-Naggar et al., 2017). Most OSCC arise in the floor of the mouth, ventro-
lateral surface of the tongue, sublingual sulcus and retromolar region (Johnson and 
Warnakulasuriya, 1993). The five-year survival rate for lip cancers is in the order of 
80 - 95%, which is much better than the 30 - 50% five-year survival rate for intra-oral 
cancers (Johnson and Warnakulasuriya, 1993; Moore et al., 1999; Moore et al., 
2000; Barnes et al., 2005; Warnakulasuriya, 2009). This is possibly because SCCs of 
the lip are usually detected early due to their location as well as due to their differing 
aetiology. 
It has been established that OSCC has a high rate of mortality (Moore et al., 1999; 
Moore et al., 2000; Barnes et al., 2005; Warnakulasuriya, 2009; El-Naggar et al., 
2017). Survivors have high morbidity and risk of developing further upper 
aerodigestive tract cancers (Barnes et al., 2005; El-Naggar et al., 2017). Around 30-
50% of patients with OSCC die from the disease within five years and survival rates 
have not improved over the last 30 years (Barnes et al., 2005; Warnakulasuriya, 
2009). These trends have mostly been attributed to delayed detection of the disease, 
because improved outcomes are achievable if the disease is treated in its earlier 
stages (Barnes et al., 2005; Goodson and Thomson, 2011; El-Naggar et al., 2017). 
Delayed detection is often attributed to the fact that most OSCC are painless during 
the early stages and tumours may have reached a considerable size before the 
patient notices them or seeks medical attention (Barnes et al., 2005). Early detection 
is feasible because many OSCC are preceded by clinically identifiable lesions termed 
‘oral potentially malignant disorders’ (OPMDs) (Barnes et al., 2005; Warnakulasuriya 
et al., 2007; van der Waal, 2009; El-Naggar et al., 2017). A good opportunity for early 
detection of OSCC exists as the mouth is easily accessible for regular routine 
screening by healthcare professionals (Sankaranarayanan et al., 2013). 
However, more frequently these tumours would have already metastasized to the 
regional lymph nodes by the time the patient presents at a clinic due to delayed 
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detection (Barnes et al., 2005; El-Naggar et al., 2017). Patients with advanced or late 
stage lesions are challenging to manage as complete surgical clearance is often not 
feasible due to the complex anatomy of the head and neck region. Inadequate 
clearance increases the risk of recurrent loco-regional disease (Woolgar et al., 1999; 
Slootweg et al., 2002).  
Furthermore, the phenomenon of “field cancerisation” first described by Slaughter 
more than 60 years ago, is thought to predispose these patients to development of 
second primary tumours (SPTs) (Slaughter et al., 1953; Day and Blot, 1992; 
Braakhuis et al., 2003; Barnes et al., 2005; El-Naggar et al., 2017). Patients treated 
successfully for early primary OSCC may eventually succumb to SPTs. The concept 
of field change suggests that although the oral mucosa may appear normal clinically 
(and even histologically normal) in these patients, the mucosa has undergone 
genetic and molecular change that increases its propensity for malignant 
transformation. This concept is supported by accumulating evidence on the 
molecular genetic features of oral carcinogenesis (Bedi et al., 1996; Scholes et al., 
1998; Braakhuis et al., 2003; Wood et al., 2015; Wood et al., 2017). 
Despite advances in management strategies, treatment outcomes are still rather poor 
and neither surgery, radiotherapy nor chemotherapy separately or in combination can 
effect a cure from OSCC (Johnson and Warnakulasuriya, 1993; Moore et al., 1999; 
Moore et al., 2000; Barnes et al., 2005; Warnakulasuriya, 2009; El-Naggar et al., 
2017). This fact combined with the increased morbidity associated with the treatment 
for OSCC highlight the importance of early detection and more effective management 
of OSCC (Barnes et al., 2005; Goodson and Thomson, 2011; El-Naggar et al., 2017). 
1.2.2 Aetiology 
The aetiopathogenesis of OSCC is complex and multifactorial in nature, 
characterised by clinical and pathologic heterogeneity. As such, a multitude of 
environmental factors are thought to be involved in triggering the genetic aberrations 
and modifications involved in the initiation, progression and development of OSCC 
(Califano et al., 1996; Forastiere et al., 2001; Barnes et al., 2005; Leemans et al., 
2011). 
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Historically, tobacco, alcohol and betel-quid use have been considered as the most 
contributory risk factors in the development of OSCC (Blot et al., 1988; Johnson and 
Warnakulasuriya, 1993; Gupta et al., 1996; Moore et al., 1999; Balaram et al., 2002). 
All forms of tobacco use have been strongly implicated in the aetiology of OSCC with 
cigar and pipe smoking being linked to a greater risk than cigarette smoking (Smith, 
1973; Maier et al., 1992; Johnson and Warnakulasuriya, 1993; Gupta et al., 1996; 
McDowell, 2006). Tobacco use can be divided into either being smokeless (snuff, 
chewing) or smoke-producing (cigar, cigarette, pipe). Smoke-producing usage 
creates a higher number and level of carcinogens than smokeless tobacco as the 
majority of carcinogens are produced during combustion (Hecht, 2003). Tobacco 
products contain numerous carcinogenic elements that can act as either initiators or 
promoters of carcinogenesis (Maier et al., 1992; Gupta et al., 1996; Hecht, 2003; 
McDowell, 2006).  Alterations at guanine residues of DNA induced by carcinogenic 
derivatives of tobacco products can cause nucleotide modifications in key genes 
involved in carcinogenesis such as the tumour-suppressor gene TP53 (Brennan et 
al., 1995; Gupta et al., 1996; Hecht, 2003).  
Increased intake of alcohol is a well-known risk factor for the development of OSCC 
(Smith, 1973; Johnson and Warnakulasuriya, 1993; Rodriguez et al., 2004; Hashibe 
et al., 2009). Although not fully understood yet, alcohol is believed to exert its 
deleterious effects through several different ways (Boffetta and Hashibe, 2006; Seitz 
and Stickel, 2007).  The primary metabolite of ethanol, acetaldehyde, is thought to be 
the primary alcohol derived carcinogen involved with development of OSCC.  
Acetaldehyde is believed to interfere with DNA synthesis as well as forming DNA 
adducts. Acetaldehyde also binds to various proteins such as enzymes and 
glutathione, resulting in altered structure and function (Boffetta and Hashibe, 2006; 
Seitz and Stickel, 2007; Hashibe et al., 2009).  
Alcohol is also believed to facilitate absorption of other carcinogens such as 
nitrosonornicotine (a tobacco-specific nitrosamine) by increasing the permeability of 
the oral mucosa (Squier et al., 1986). Alcohol also induces the cytochrome p450 
enzyme CYP2E1 dependent microsomal biotransformation system in the liver and 
mucosa that is believed to be associated with the activation of several pro-
carcinogens found in tobacco and other substances (Boffetta and Hashibe, 2006; 
Seitz and Becker, 2007; Hashibe et al., 2009). Combined use of both alcohol and 
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tobacco increases the risk of OSCC by a factor of 15 to 20, compared with 
individuals who use neither; but the effects of tobacco and alcohol are time and dose 
dependent (Smith, 1973; Maier et al., 1992; Johnson and Warnakulasuriya, 1993; 
Rodriguez et al., 2004; McDowell, 2006).   
Heavy alcohol intake alone was shown by some studies to increase the risk of 
developing OSCC by about three- to five-fold (Rodriguez et al., 2004; Hashibe et al., 
2009). This dose dependent influence is possibly due to several reasons; one being 
the increased amount of acetaldehyde found in the saliva, derived primarily from 
alcohol metabolism and the other being nutritional deficits due to reduced intake of 
micronutrients, impaired intestinal absorption and changes in the metabolic pathways 
(Maier et al., 1992; Boffetta and Hashibe, 2006; Seitz and Becker, 2007; Hashibe et 
al., 2009).  The recent implication that alcohol containing mouthwashes may play 
some role in oral carcinogenesis is controversial with no conclusive evidence 
(McCullough and Farah, 2008; La Vecchia, 2009). 
The relationship between areca/betel nut and OSCC has long been established (Muir 
and Kirk, 1960; Hoffmann et al., 1994; Zain et al., 1999; Jeng et al., 2001). Areca nut 
used in combination with a number of different substances such as tobacco, slaked 
lime and betel leaf is prevalent in the Indian sub-continent as well as parts of Eastern 
Asia (Zain et al., 1999). The main alkaloid in areca nut, arecoline, is believed to alter 
gene expression, repress DNA repair and inhibit p53 in human epithelial cells 
(Sundqvist et al., 1989; Tsai et al., 2008). Slaked lime when used as a component of 
the betel-quid may act as a tissue-eroding agent due to its alkalinity (Zain et al., 
1999).  
High-risk human papillomavirus (HR-HPV) infection, specifically HPV-16, has been 
classified by the International Agency for Research on Cancer (IARC) as a causative 
agent for a subset of OSCC and OPSCC (IARC, 2007). Several studies have 
demonstrated the presence of HR-HPV in a subset of OSCC and OPMD, however its 
role in OPMD is still inconclusive especially since clinically “normal” mucosa has also 
been shown to be positive for HR-HPV (Miller and White, 1996; Elamin et al., 1998; 
McKaig et al., 1998; Smith et al., 1998; McCord et al., 2013; Woo et al., 2013; El-
Naggar et al., 2017; Lerman et al., 2017). Although HR-HPV associated oral 
epithelial dysplasia (OED) has been recognised as a distinct entity characterised by 
unique histopathological features as well as the presence of transcriptionally active 
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HR-HPV, the natural history of such lesions is as yet unclear (McCord et al., 2013; 
Woo et al., 2013; El-Naggar et al., 2017). 
Candida albicans has also been postulated to be a possible causative agent due to 
its ability to produce N-nitrobenzylmethylamine, a carcinogen. Chronic hyperplastic 
candidiasis (CHC) is a well-recognized oral lesion that has been considered as an 
OPMD (Speight and Morgan, 1993). Another infective agent thought to be associated 
with OSCC is Treponema pallidum which causes syphilis. Tertiary syphilis is known 
to cause changes to the oral epithelium making it more atrophic and susceptible to 
the effects of carcinogens. Sir Jonathan Hutchinson suggested the possible 
association between syphilis and tongue cancer (Hutchinson, 1887). A possible 
reason for the increased rate of tongue cancer in these patients may be due to the 
fact that the chemical agents used to “treat” tertiary syphilis decades ago have now 
been recognised as being carcinogenic (Michalek et al., 1994). As such, it is quite 
difficult to conclude that syphilis is a possible causative agent for OSCC.  
Nutritional deficiencies have also been linked to the development of OSCC. The most 
well-known nutritional factor associated with SCC of the upper aerodigestive tract is 
iron deficiency, seen in sideropenic dysphagia (Patterson – Kelly/Plummer-Vinson 
syndrome) (Watts, 1961). This syndrome typically affects middle-aged women and 
the presenting signs and symptoms are usually: a painful red tongue, mucosal 
atrophy and dysphagia caused by oesophageal webs (Watts, 1961; McDowell, 
2006). The atrophic changes seen in the oral mucosa of sideropenic patients may 
adversely affect the epithelium making it more susceptible to carcinogens. It has 
been shown that diets rich in fresh fruit and vegetables confer a protective effect 
against OSCC due to the effects of vitamins A, C and E (Tavani et al., 2001; 
Marchioni et al., 2002).  
Inheritable conditions such as ataxia telangiectasia, xeroderma pigmentosum, 
Fanconi anaemia, dyskeratosis congenita, systemic sclerosis, Li-Fraumeni syndrome 
and Bloom syndrome (to name a few) are known to predispose individuals to an 
increased risk of developing head and neck SCC (HNSCC) (Jacobsen et al., 1998; 
Prime et al., 2001; Kutler et al., 2003; Kuo et al., 2012; Kutler et al., 2016; Martínez 
and Blasco, 2017; Furquim et al., 2018). Genetic predisposition is also considered to 
be an important risk factor as first-degree relatives of HNSCC patients appear to 
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have a higher chance of developing HNSCC compared to the general population 
(Copper et al., 1995; Foulkes et al., 1996; Jefferies et al., 1999).  
Other factors historically considered to be significant in the aetiology of OSCC such 
as chronic trauma/irritation and poor oral hygiene are thought to be “modifiers or 
promoters” rather than initiators of OSCC, meaning that if a cancer is initiated from 
another reason, these promoters could hasten the process (Brandner et al., 1986; 
Perez et al., 2005).  
1.2.3 Molecular pathogenesis 
Califano et. al. (1996) in a landmark paper proposed a model for head and neck 
squamous cell carcinoma (HNSCC) based on the premises outlined by Fearon and 
Vogelstein (1990) for the development of colorectal carcinomas (Figure 1.2) 
suggesting a progressive change from hyperplasia through dysplasia to squamous 
cell carcinoma implicating the involvement of several cancer-related genes (Fearon 
and Vogelstein, 1990; Califano et al., 1996). The two most widely studied groups of 
cancer related genes are oncogenes and tumour suppressor genes (Field, 1992; 
Scully, 1993; Ha et al., 2009; Leemans et al., 2011).  
Oncogenes are genes that promote growth, survival and proliferation of cells as well 
as allowing cells to escape normal growth control mechanisms (Field, 1992; Scully, 
1993; Scully et al., 2000b; Ha et al., 2009; Leemans et al., 2011). Over-activity or 
over-expression of these genes can lead to the development of a tumour. Several 
oncogenes have been established as being commonly associated with OSCC; 
epidermal growth factor receptor (EGFR), receptor tyrosine kinase MET and Cyclin 
D1 (CCND1), with EGFR being the most widely studied (Ozanne et al., 1986; Inaba 
et al., 1992; Opitz et al., 2001; Hama et al., 2009; Seiwert et al., 2009; Sheu et al., 
2009; Leemans et al., 2011; Bates et al., 2016).  
The EGFR gene is located on chromosome 7p11 and it encodes a cell surface 
tyrosine kinase receptor expressed in squamous epithelia. Activation of EGFR can 
initiate numerous signalling pathways that contribute to cell proliferation and 
angiogenesis (Herbst, 2004; Normanno et al., 2006; Sheu et al., 2009). Several 
studies have shown that EGFR is over-expressed in many HNSCC suggesting an 
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important role of EGFR in carcinogenesis of HNSCC (Ozanne et al., 1986; Grandis 
and Tweardy, 1993; Bonner et al., 2006; Hama et al., 2009).  
Tumour suppressor genes are normally involved with the control of growth through 
cell cycle regulation, apoptosis, cell adhesion and DNA repair (Field, 1992; 
Sugerman et al., 1995; Leemans et al., 2011). A defect or inhibition of these genes 
may result in the proliferation of tumour cells. At present, the two most widely studied 
tumour suppressor genes in OSCC are TP53 and CDKN2A (Field, 1992; Burns et al., 
1993; Brennan et al., 1995; Sugerman et al., 1995; Reed et al., 1996; Rheinwald et 
al., 2002; Gasco and Crook, 2003; Angiero et al., 2008; Ha et al., 2009; Agrawal et 
al., 2011; Stransky et al., 2011; Cancer Genome Atlas, 2015).  TP53 is located at 
chromosome 17p13 and genetic aberrations have been identified in the majority of 
OSCC (Somers et al., 1992; Scully et al., 2000b; Gasco and Crook, 2003; Leemans 
et al., 2011). TP53 is involved in cell cycle regulation mainly in the G1 phase of the 
cell cycle detecting DNA damage and initiating apoptosis if the damage is irreparable 
(Scully et al., 2000b; Gasco and Crook, 2003; Leemans et al., 2011). Changes in the 
TP53 gene usually represent an early stage in carcinogenesis especially in tobacco 
related OSCC (Brennan et al., 1995; Leemans et al., 2011).  
CDKN2A is located on chromosome 9p21 and has been found to be inactivated in 
many head and neck squamous cell carcinomas (HNSCCs) (Reed et al., 1996; 
Agrawal et al., 2011; Stransky et al., 2011; Cancer Genome Atlas, 2015). The 
inactivation usually occurs through a combination of promoter methylation defects, 
gene mutations, chromosomal loss or homozygous deletion (Reed et al., 1996; 
Forastiere et al., 2001). CDKN2A encodes p16INK4a, an inhibitor of cyclin-dependant 
kinases involved in cell cycle regulation and acts as a checkpoint in cellular growth 
control (Reed et al., 1996; Forastiere et al., 2001; Leemans et al., 2011). 
Aside from the above-mentioned genes, numerous candidate genes are being 
studied to develop a better understanding of the molecular events in oral 
carcinogenesis (Leemans et al., 2011; Cancer Genome Atlas, 2015; Leemans et al., 
2018). By using gene expression profiling, Chung et al (2004) found that HNSCC 
could be categorised into four subgroups with differing molecular profiles and 
prognoses (Chung et al., 2004). Rapid advances in the field of next-generation 
sequencing and proteomics has led to improved understanding of the diverse 
pathways involved in the various sub-types of HNSCC (Chung et al., 2004; Molinolo 
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et al., 2009; De Cecco et al., 2015; Keck et al., 2015). The recent genomic 
characterization of HNSCC has  also reinforced the heterogeneous nature of HNSCC 
(Cancer Genome Atlas, 2015). 
The original genetic progression model proposed by Califano et al in 1996 (Figure 
1.2) though remarkable in its own right, is now considered to be rather simplistic. The 
availability of next-generation sequencing and proteomics have made it possible to 
further expand this original model by elucidating the various pathways involved in the 
aetiopathogenesis of OSCC. 
1.2.4 Clinical and histopathological features 
OSCC has a heterogeneous clinical presentation ranging from ulcers to white 
plaque-like lesions (Barnes et al., 2005). The primary tumour site is typically 
dependent on the aetiological agent involved, with the floor of mouth, retromolar area 
and latero-ventral surface of tongue being more commonly involved in tobacco-
associated OSCC whilst the buccal mucosa and gingiva are more frequently affected 
in betel-quid chewers (Gupta et al., 1980; Moore et al., 2000; Barnes et al., 2005; 
Warnakulasuriya and Ariyawardana, 2016; Speight et al., 2018). 
As OSCC is a malignant tumour of the mucosal epithelium, the key histological 
feature is invasion of underlying connective tissue by malignant epithelial cells with 
squamous differentiation. Grading of OSCC is performed according to the degree of 
similarity of the tumour cells to normal squamous epithelium (histological 
differentiation; Broders classification), however it is a poor prognostic predictor of 
clinical outcome (Broders, 1920; Bryne et al., 1989; Roland et al., 1992; Barnes et 
al., 2005). Several other histological parameters such as nuclear pleomorphism, 
mitotic activity, pattern of invasive front, positive surgical resection margins and 
perineural or vascular invasion, provide a more accurate prognostic indicator when 
used in combination as a multi-factorial grading system (Bryne et al., 1989; Close et 
al., 1989; Odell et al., 1994; Slootweg et al., 2002; Rahima et al., 2004; Barnes et al., 
2005). 
1.2.5 Staging of oral squamous cell carcinoma 
Oral squamous cell carcinoma (OSCC) is usually staged using the “Tumour, Node & 
Metastasis” (TNM) system developed by the International Union Against Cancer 
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(Barnes et al., 2005; Sobin et al., 2009; Brierley et al., 2017). By combining the 
clinical and radiological findings for each of the TNM component, an overall clinical 
stage for the specific patient is obtained. The clinical stage is then used to formulate 
a treatment plan. The clinical stage may eventually be modified following the findings 
from the histopathological assessment of resection specimens; pathologic staging 
(Sobin et al., 2009; Brierley et al., 2017; El-Naggar et al., 2017).  
1.2.6 Treatment and outcome  
Surgery with or without radiotherapy is still the favoured treatment modality for most 
OSCC (Woolgar et al., 1999; Barnes et al., 2005; Scully and Bagan, 2009; Shah and 
Gil, 2009; El-Naggar et al., 2017). However, treatment planning is highly dependent 
on the clinical staging, patient factors as well as anatomical location of the tumour 
with management being directed towards the elimination of the lesion while 
attempting to preserve function and quality of life.  
Patients with low stage tumours (Stage I & II) are usually treated with surgery alone 
while patients with higher clinical staging (Stage III & IV) usually require adjuvant 
radiotherapy with or without chemotherapy (Mazeron et al., 2009; Scully and Bagan, 
2009; Shah and Gil, 2009; Specenier and Vermorken, 2009). Treatment of OSCC is 
debilitating due to the complex anatomy of the craniofacial region. Although 
advances in treatment techniques with the addition of organ-preservation protocols 
have improved post-treatment quality of life, there are still some unavoidable side 
effects resulting from surgery and/or radiotherapy (Vissink et al., 2003; Vergeer et al., 
2009; Tolentino Ede et al., 2011).  
As TNM staging of OSCC is related to prognosis (Sciubba, 2001; Barnes et al., 2005; 
Sobin et al., 2009; Brierley et al., 2017; El-Naggar et al., 2017; Tirelli et al., 2018), an 
effective method to improve patient outcome would be detection of OSCC whilst still 
in Stage I or when the lesions are at a “pre-invasive” stage (Sciubba, 2001; Goodson 
and Thomson, 2011). A proportion of OSCC are thought to be preceded by these 
“pre-invasive” lesions that were previously called “precancerous lesions”. As not all of 
these types of lesions progress or transform to OSCC, the terminology of “oral 
potentially malignant disorder” (OPMD) was suggested (Warnakulasuriya et al., 2007; 
van der Waal, 2009). 
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1.3 Oral Potentially Malignant Disorders (OPMD) 
1.3.1 Introduction 
A number of OSCC are preceded by clinical entities termed ‘oral potentially 
malignant disorders’ (OPMDs) (Warnakulasuriya et al., 2007; van der Waal, 2009; El-
Naggar et al., 2017; Speight et al., 2018). OPMDs are defined as clinical disorders 
having an increased risk of developing OSCC in oral mucosa; either in recognisable 
lesions or clinically “normal” oral mucosa  (van der Waal, 2009; El-Naggar et al., 
2017). The term OPMD was adopted following a workshop coordinated by the World 
Health Organisation (WHO) Collaborating Centre for Oral Cancer and Precancer held 
in London in 2005 to replace previously used terminology such as ‘oral precancer’, 
‘precursor lesions’ or ‘premalignant lesions’ (Warnakulasuriya et al., 2007).  
OPMD is thought to be a more accurate terminology to include all lesions and 
conditions/diseases that have a risk of malignant transformation to OSCC as it also 
indicates that not all patients with such lesions/conditions will undergo malignant 
transformation (Warnakulasuriya et al., 2007; Napier and Speight, 2008; van der 
Waal, 2009; El-Naggar et al., 2017; Speight et al., 2018). Even in cases where there 
is an obvious identifiable lesion, OSCC may arise at a different site in the oral cavity 
due to the “field-change” phenomenon. It also must be emphasised that the majority 
(around 90%) of these lesions/conditions either remain unchanged or actually 
undergo regressive changes (Mehanna et al., 2009; Shariff and Zavras, 2015; 
Warnakulasuriya and Ariyawardana, 2016; Thomson et al., 2017b). The precise 
number of OSCC arising from OPMD however is still unclear. A new terminology, 
“potentially premalignant oral epithelial lesion” (PPOEL), was introduced by Nikitakis 
et al (2018) as an alternative to OPMD, once again showing that terminology of such 
lesions still continues to be a contentious area (Nikitakis, 2018; Speight et al., 2018). 
For this study, the term OPMD will be used to represent these precursor lesions as 
implemented in the recently published 4th edition of the WHO Classification of Head 
and Neck Tumours (2017) (El-Naggar et al., 2017). 
OPMD encompasses numerous entities that are clinically and histologically diverse 
(Table 1.1) (El-Naggar et al., 2017). Most OPMDs present as distinct oral mucosal 
lesions such as leukoplakia, erythroplakia, chronic hyperplastic candidosis and 
erythroleukoplakia, but more generalised disorders including oral submucous fibrosis 
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and proliferative verrucous leukoplakia also come under this umbrella term of OPMD 
(Barnes et al., 2005; Warnakulasuriya et al., 2007; van der Waal, 2009; El-Naggar et 
al., 2017). The distinction between oral potentially malignant conditions and oral 
potentially malignant lesions is thought to be redundant as both are associated with 
field change (Warnakulasuriya et al., 2007; van der Waal, 2009).  
1.3.2 Epidemiology 
Due to the diversity of OPMDs, truly representative epidemiological data on OPMDs 
is lacking. The majority of studies and reports concerning OPMDs have been about 
oral leukoplakia, oral submucous fibrosis (OSMF) and oral lichen planus. Oral 
leukoplakia and OSMF are the most frequently encountered OPMDs, whilst 
erythroplakia is thought to have the highest risk for malignant transformation (Petti, 
2003; Reichart and Philipsen, 2005; Warnakulasuriya et al., 2007; van der Waal, 
2009; Warnakulasuriya et al., 2011; El-Naggar et al., 2017; Mello et al., 2018). 
According to a recent systematic review and meta-analysis, OPMDs have an 
estimated global prevalence of 4.47% (CI: 2.43, 7.48) (Mello et al., 2018).  
Although clinicians are able to detect OPMD and obtain histopathological information, 
accurately predicting the clinical behaviour of these lesions is still difficult (Napier and 
Speight, 2008). Several articles have highlighted that the natural history of OPMD is 
poorly understood (Gupta et al., 1980; Speight, 2007; Napier and Speight, 2008; 
Speight et al., 2018), nevertheless, a recent systematic review looking at malignant 
transformation (MT) in oral leukoplakia focusing on observational studies estimated 
the overall MT rate to be around 3.5% (ranging from 0.13 – 34%) (Warnakulasuriya 
and Ariyawardana, 2016). This figure is similar to the MT rate of 4.8% in a hospital-
based cohort of OPMD patients from the north-east of England (Thomson et al., 
2017a; Thomson et al., 2017b). Additionally, a range of between 10 – 12 % rate of 
malignant transformation in lesions with oral epithelial dysplasia (OED) was 
calculated from two recent meta-analysis (Mehanna et al., 2009; Shariff and Zavras, 
2015).  
However, the findings from these systematic reviews and meta-analyses must be 
read with caution as the studies included were not randomised controlled trials and 
were mostly hospital-based studies (Mehanna et al., 2009; Shariff and Zavras, 2015). 
Hospital based studies also have an inherent referral bias of high-risk OPMD patients 
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and thus may not reflect the true incidence of malignant transformation in dysplastic 
OPMDs which is likely to be much lower.  
1.3.3 Clinical and histopathological features 
Clinically, OPMDs can appear as either white, red or mixed red and white lesions. 
They can also be homogenous or non-homogenous. It must be remembered that 
terminology such as leukoplakia or erythroplakia are clinical and a biopsy is required 
to ascertain the presence of epithelial dysplasia or malignant change (Barnes et al., 
2005; El-Naggar et al., 2017; Speight et al., 2018). Other OPMDs that are commonly 
encountered are oral lichen planus/lichenoid reaction (a chronic inflammatory muco-
cutaneous disorder demonstrating an immune-mediated pathogenesis) and oral 
submucous fibrosis (a chronic disorder usually seen in betel-quid chewers) (Barnes 
et al., 2005; Warnakulasuriya et al., 2007; van der Waal, 2009; Speight et al., 2018).  
Several studies have reported that non-homogenous leukoplakia (speckled, nodular, 
verruciform etc.) undergo malignant transformation more frequently than 
homogenous lesions (Pindborg et al., 1963; Silverman et al., 1976; Gupta et al., 
1980; Holmstrup et al., 2006). Even though the clinical features of OPMD may give 
some indication as to the risk of malignant transformation, they are non-specific and 
overlap with other disease processes. As such, clinico-pathologic correlation is 
always necessary (Barnes et al., 2005; van der Waal, 2009; Warnakulasuriya et al., 
2011; El-Naggar et al., 2017; Speight et al., 2018). 
Histopathological examination of OPMD can show a diverse spectrum of findings 
ranging from hyperkeratosis to severe oral epithelial dysplasia. Due to the difficulty 
and relatively subjective nature of interpreting histological features in OPMDs, 
assigning a precise diagnosis is known to be liable to intra- and inter-observer 
inconsistencies (Barnes et al., 2005; Kujan et al., 2007; El-Naggar et al., 2017). The 
presence of oral epithelial dysplasia (OED) has been widely considered as an 
indicator of the risk of malignant transformation in OPMD (Reibel, 2003; van der 
Waal, 2009; Liu et al., 2011; Warnakulasuriya et al., 2011; Sperandio et al., 2013). 
OED is characterised by cytological and architectural changes. The diagnosis and 
grading of oral epithelial dysplasia (OED) as such is based upon the presence and 
degree of individual criteria within the cytological and architectural categories (Table 
1.2) (Barnes et al., 2005; El-Naggar et al., 2017). However, it must be remembered 
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that such changes can also be seen in reactive and reparative epithelium, once again 
emphasizing the need for clinico-pathological correlation (Macdonald and Rennie, 
1975; Barnes et al., 2005; El-Naggar et al., 2017; Speight et al., 2018). 
Several grading systems have been proposed for grading OED with the most widely 
used grading system being the World Health Organization (WHO) classification 
system that originally sub-divided OED into hyperplasia, mild dysplasia, moderate 
dysplasia, severe dysplasia and  carcinoma in-situ (Barnes et al., 2005). However, 
the most recent version of the WHO grading system has merged the severe 
dysplasia and carcinoma in-situ categories into a single category of severe dysplasia 
and dropped the hyperplasia category thus making it a three-tiered grading system 
(El-Naggar et al., 2017).  
In recent years, there has been a suggestion to replace this classification scheme 
with a binary system consisting of “low-grade” and “high-grade” lesions (Kujan et al., 
2006; Warnakulasuriya et al., 2008; Nankivell et al., 2013; Gale et al., 2014). The cut-
off point between low-grade and high-grade OED as originally suggested by Kujan et 
al (2006) was OED having ≥ 4 architectural and ≥ 5 cytological changes (Table 1.2), 
however Nankivell et al (2013) suggested that a cut-off point of  ≥ 4 architectural and 
≥ 4 cytological changes may improve the predictive strength of the binary grading 
system (Kujan et al., 2006; Nankivell et al., 2013). However, as this is a relatively 
new grading system for OED, it requires further validation before routine clinical 
application.  
The binary grading system is believed to have better intra- and inter-observer 
variation as there are fewer categories/levels (Kujan et al., 2006; Kujan et al., 2007). 
Regardless of the classification system used, there is always the issue of inter-
observer variability (Kujan et al., 2006; Kujan et al., 2007). Diagnostic reliability 
however, may be improved via a consensus grading after review by more than one 
pathologist and a well-outlined set of criteria (Fleskens et al., 2011; Speight et al., 
2015). Even though the presence/severity of OED is thought to be indicative of a 
higher risk of malignant transformation, non-dysplastic OPMD such as oral lichen 
planus have been reported to undergo malignant change as well (Mattsson et al., 
2002; Hsue et al., 2007; van der Meij et al., 2007; Bagan et al., 2011). As such, there 
are no specific histopathological features that accurately predict the progression of 
OPMD to OSCC (van der Waal, 2009; van der Waal, 2014). 
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Although the role of HR-HPV in oral carcinogenesis is unclear, several research 
groups have described a histopathologically distinct subset of OED harbouring 
transcriptionally active HR-HPV (McCord et al., 2013; Woo et al., 2013; El-Naggar et 
al., 2017). Diagnosis of HPV associated OED is through a defined set of 
histopathological features in conjunction with demonstration of HR-HPV through p16 
immunohistochemistry and molecular techniques (McCord et al., 2013; Woo et al., 
2013; El-Naggar et al., 2017). Due to the relative rarity of HPV associated OED, the 
natural history and prognosis of this entity is still unclear. 
1.3.4 Prognosis and outcome 
There are several possible outcomes for OPMD, the lesion remains unchanged, it 
increases in size, it regresses in size, it disappears completely or undergoes 
malignant transformation (Banoczy and Sugar, 1972; Gupta et al., 1980; Schepman 
et al., 1998; Napier and Speight, 2008). Several epidemiological studies conducted in 
different areas of the world have shown that most OPMD do not undergo malignant 
transformation although they may persist (Banoczy and Sugar, 1972; Mehta et al., 
1972; Silverman et al., 1976; Gupta et al., 1980; Liu et al., 2011).  
Many of the studies on malignant change in OPMD are focused on leukoplakia and 
OED. The reported rates of malignant transformation from these studies have a wide 
variation ranging from 0.13% to 26.8% (Banoczy and Sugar, 1972; Mehta et al., 
1972; Silverman et al., 1976; Silverman et al., 1984; Lumerman et al., 1995; Liu et 
al., 2011). The presence of oral epithelial dysplasia in OPMDs is indicative of an 
increased risk for malignant transformation, with one meta-analysis reporting a mean 
overall malignant transformation rate of 12.1% in OED from a combined cohort of 
992 patients from 14 studies (Mehanna et al., 2009). A recent systematic review and 
meta-analysis however concluded that the pooled MT rate of OED was 10.5% in a 
combined cohort of 3708 patients from 16 studies (Shariff and Zavras, 2015). The 
difference in MT rate between the two meta-analysis is possibly due to the increased 
number of studies included in the meta-analysis by Shariff & Zavras (2015). 
However, the studies included in both meta-analyses were considerably 
heterogeneous with regard to study design making it difficult to draw definitive 
conclusions (Mehanna et al., 2009; Shariff and Zavras, 2015).   
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Although malignant transformation may not be the most frequently encountered 
outcome, the fact that there is no precise way to predict which OPMD will undergo 
malignant transformation underlies the principle that all patients with OPMD should 
be on long-term follow up regardless of the type of OPMD as well as the treatment 
received (Barnes et al., 2005; Napier and Speight, 2008; van der Waal, 2014; 
Warnakulasuriya and Ariyawardana, 2016; El-Naggar et al., 2017). 
1.3.5 Management 
Currently, there is no consensus for the management of OPMD with treatment 
approaches differing between centres and even different specialists in a single centre 
(Brennan et al., 2007; Mehanna et al., 2009; van der Waal, 2009; Nankivell and 
Mehanna, 2011; Arnaoutakis et al., 2013; Balasundaram et al., 2014; Thomson et al., 
2017a). Treatment can be divided into either surgical or non-surgical. For surgical 
treatment, excision is most often based on the severity of dysplasia (if present) 
despite not having much clinical evidence. Some surgeons prefer using carbon 
dioxide (CO2) LASER to excise and/or ablate OPMD (Thomson and Wylie, 2002). 
The evidence for surgical intervention in preventing malignant transformation is 
rather weak with most studies being retrospective or observational in nature and 
some studies reporting no significant advantage of surgical intervention over non-
surgical management (Einhorn and Wersall, 1967; Vedtofte et al., 1987; Chiesa et 
al., 1993; Schepman et al., 1998; Thomson and Wylie, 2002; Holmstrup et al., 2006; 
van der Waal, 2009; Nankivell and Mehanna, 2011; Diajil et al., 2013; Balasundaram 
et al., 2014; Lodi et al., 2016; Thomson et al., 2017a).  
A recent meta-analysis on OED composed mostly of level II to III evidence revealed 
that a lower number of malignant transformations were seen in cases treated with 
surgical excision (5.4%) compared to cases not treated surgically (14.6%) (Mehanna 
et al., 2009). However, surgical treatment may not always be feasible due to the 
anatomical location and extent of the lesion in the oral cavity. 
Non-surgical modalities include modification of risk factors such as tobacco 
cessation, elimination of other possible causes, topical/systemic retinoids and 
photodynamic therapy (van der Waal, 2009; Ribeiro et al., 2010; van der Waal, 2010; 
Kumar et al., 2013; Villa and Woo, 2017). Many clinicians also tend to follow up these 
patients on a regular basis (at least 6 monthly) for the rest of their lives. Several 
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research groups have also undertaken clinical trials using anti-inflammatory agents 
and molecular targeted therapy as chemo-preventive measures for the management 
of OPMD, however none have proven to be very successful (Mulshine et al., 2004; 
Papadimitrakopoulou et al., 2008; William et al., 2016). Regardless of the treatment 
modality employed, continued follow-up and active surveillance is advisable due to 
the phenomenon of “field change” and because no single treatment is completely 
effective in eliminating the chance of malignant transformation in these patients 
(Holmstrup et al., 2006; Brennan et al., 2007; Napier and Speight, 2008; Mehanna et 
al., 2009; van der Waal, 2009; van der Waal, 2010).  
1.3.6 Prognostic factors for clinical outcome 
Several demographic and clinical factors (Table 1.3) have been associated with a 
higher risk of malignant transformation in OPMDs (van der Waal, 2009; 
Warnakulasuriya et al., 2011; Speight et al., 2018). Studies have shown that there is 
an increased risk of malignant transformation in older patients which may be due to 
the longer period of exposure to risk factors and increased opportunity for cumulative 
genetic/molecular damage predisposing to carcinogenesis (Banoczy and Sugar, 
1972; Mehta et al., 1972; Schepman et al., 1998; Napier and Speight, 2008; 
Warnakulasuriya et al., 2011). The literature appears to be divided when it comes to 
gender differences as some studies have shown that malignant transformation 
occurs more frequently in women (Silverman et al., 1984; Schepman et al., 1998; 
Cowan et al., 2001; Amagasa et al., 2006), others show a male preponderance 
(Gupta et al., 1980; Hsue et al., 2007; Warnakulasuriya et al., 2011; Goodson et al., 
2015) and a number of studies showed no obvious gender difference when it comes 
to clinical outcome (Einhorn and Wersall, 1967; Arduino et al., 2009; Ho et al., 2012; 
Bates et al., 2016). 
Certain anatomical sub-sites are thought to have a higher risk of malignant 
transformation compared to other oral sub-sites with two recent systematic reviews 
highlighting the fact that tongue lesions have a higher risk than other oral sub-sites 
(Banoczy, 1977; Silverman et al., 1984; Mehanna et al., 2009; Warnakulasuriya and 
Ariyawardana, 2016). However, several studies have shown that oral sub-sites are 
not statistically significantly associated with malignant transformation (Schepman et 
al., 1998; Holmstrup et al., 2006; Liu et al., 2011; Brouns et al., 2014). The size of 
OPMD lesions is also believed to have some degree of relationship to malignant 
    
19 
transformation with larger lesions having a higher risk than smaller lesions (Napier et 
al., 2003; Ho et al., 2012; Brouns et al., 2014). 
One of the most commonly studied prognostic features of malignant transformation is 
the presence and degree of OED. Some studies have suggested that dysplastic 
lesions have a higher transformation rate when compared to non-dysplastic lesions 
and several studies have also evaluated the risk of malignant transformation with the 
degree of OED suggesting that the grade of dysplasia is somewhat prognostic of 
malignant change (Mincer et al., 1972; Banoczy and Csiba, 1976; Pindborg et al., 
1977; Silverman et al., 1984; Lumerman et al., 1995; Lee et al., 2000; Cowan et al., 
2001; Mehanna et al., 2009; Warnakulasuriya et al., 2011; Sperandio et al., 2013). 
However, studies by Dost et al (2014) and Holmstrup et al (2006) found no 
statistically significant relationship between degree of OED and malignant change 
indicating that the current grading system for OED lacks clinical utility as a predictor 
of malignant change (Holmstrup et al., 2006; Dost et al., 2014).  
Consequently, to compensate for the limitations of histopathological features in 
predicting malignant change, biomarkers have been sought based on an improved 
understanding of the underlying molecular pathogenesis of OSCC. Biomarkers are 
molecular, biochemical or genetic features that can be assessed to identify presence 
or progress of pathological processes. Numerous studies have assessed the 
prognostic ability of various biomarkers in OPMD and OED, however none have 
proved to be particularly useful in clinical practice (Reibel, 2003; Pitiyage et al., 2009; 
Smith et al., 2009; Lingen et al., 2011; Nankivell and Mehanna, 2011; Nikitakis et al., 
2018; Speight et al., 2018). Discovering a biomarker that is altered in OPMD and 
indicative of the early stages of oral carcinogenesis as well as being quantifiable in 
small incisional biopsies is highly desirable to affect appropriate early intervention. 
This may pave the way for more personalized management protocols for individual 
patients with OPMD underpinning improved clinical outcomes. A list of promising 
prognostic biomarkers is shown in Table 1.4.  
Two of the more promising biomarkers for OPMDs are loss of heterozygosity (LOH) 
and DNA ploidy analysis. Loss of heterozygosity (LOH) refers to allelic loss from one 
chromosomal locus in a chromosomal pair and can be identified by assessing DNA 
polymorphism patterns between normal and abnormal tissue (Scully et al., 2000a; 
Beder et al., 2003; Kasamatsu et al., 2011). LOH at chromosomal regions 3p14, 
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9p21 and 17p13 have been shown by some studies to be a useful adjunct to predict 
malignant transformation of OPMD (Califano et al., 1996; Mao et al., 1996; Rosin et 
al., 2000; Zhang and Rosin, 2001; Zhang et al., 2012). A systematic review however 
highlighted the fact that many of these studies have a small sample size, were 
conducted in single centres and most are retrospective in nature (Smith et al., 2009). 
Interestingly, a recently concluded randomised clinical trial showed that LOH profiling 
was useful as a prognostic marker of oral cancer risk in patients with OPMDs 
(William et al., 2016) . The increasing body of evidence supporting the use of LOH 
has prompted the WHO to recommend LOH as an adjunctive/complimentary 
biomarker to be used in conjunction with traditional methods for assessment of 
OPMDs, however there is currently insufficient evidence to recommend LOH as a 
sole prognostic biomarker for OPMDs (El-Naggar et al., 2017). 
Irregular nuclear DNA content is a feature of malignant cells and their precursors 
(Sen, 2000; Danielsen et al., 2016). Aneuploidy can be detected in tumours at a very 
early stage and is considered to be a marker of genomic instability, an enabling 
characteristic for tumour development and progression (Pihan and Doxsey, 1999; 
Duesberg et al., 2000; Leemans et al., 2011; Danielsen et al., 2016). Several studies 
have shown that DNA ploidy can be a useful tool in identifying malignant change in 
OPMD (Klanrit et al., 2007; Torres-Rendon et al., 2009b; Bradley et al., 2010; 
Bremmer et al., 2011; Sperandio et al., 2013). The study by Sperandio et al (2013) 
demonstrated that image-based DNA ploidy analysis worked as well as conventional 
dysplasia grading in predicting clinical outcome and combining both OED grading 
and DNA ploidy status gave a slightly better prognostic value (Sperandio et al., 
2013). An even more recent study showed that DNA ploidy analysis has some value 
in prognosticating clinical outcome in oral lichen planus, a non-dysplastic OPMD 
(Sperandio et al., 2016). However, gross alterations of DNA content are not 
demonstrable in all cases of malignant change and this subset of patients may have 
a different oncogenic pathway or profile (Bradley et al., 2010; Bremmer et al., 2011; 
Sperandio et al., 2013; Danielsen et al., 2016).  
Tumour suppressor genes have also been studied as potential biomarkers with many 
studies focusing on TP53 that encodes for the transcription factor p53 (Opitz et al., 
2001; Gasco and Crook, 2003; Angiero et al., 2008; Pitiyage et al., 2009; Smith et al., 
2009; Denaro et al., 2011; Lingen et al., 2011; Nasser et al., 2011; de Oliveira et al., 
    
21 
2012). Although extensively studied, the prognostic utility of p53 protein expression in 
malignant transformation of OPMD is poor as shown in a recent systematic review on 
biomarkers in OED (Smith et al., 2009). In the review, the pooled relative risk for 
malignant transformation amongst OED in p53 positive cases was calculated to be 
0.96 (CI 0.65, 1.42) (Smith et al., 2009). MDM2 a gene that has a regulatory role with 
regard to TP53 has also been studied in relation to head and neck cancers with 
overexpression of MDM2 protein being seen in some OPMDs suggesting a role for 
MDM2 in oral carcinogenesis (Agarwal et al., 1999; Lothaire et al., 2006; Perez-
Ordonez et al., 2006; Denaro et al., 2011).  
The roles of two other members of the p53 family of transcription factors, p63 and 
p73, in oral carcinogenesis and OPMD have also been investigated though not as 
extensively as p53. ΔNp63 has been reported to be overexpressed in OPMDs that 
transformed to OSCC by some studies (Chen et al., 2005; Saintigny et al., 2009; 
Matsubara et al., 2011; Varun et al., 2014). However, the study by Bortoluzzi et al 
(2004) could not demonstrate any obvious relationship between OED grading and 
p63 staining patterns (Bortoluzzi et al., 2004). Chen et al (2004) attempted to assess 
the relationship between p73 expression in OED of the buccal mucosa and OSCC 
and found that there was increased suprabasal expression in dysplastic epithelium 
compared to normal (Chen et al., 2004). However, the association with malignant 
transformation was inconclusive (Chen et al., 2004). The incremental expression 
pattern of p63 and p73 described by Choi et al (2002) in head & neck squamous 
carcinoma led the authors to suggest that p63 and p73 may play a role in 
carcinogenesis, however this has yet to be convincingly replicated in studies on 
OSCC/OPMD (Choi et al., 2002). The relative paucity of studies regarding the 
usefulness of ΔNp63 and p73 as potential biomarkers for malignant change in OPMD 
necessitate the need for more research to determine their utility as prognostic 
markers of MT (Smith et al., 2009; Lingen et al., 2011; Nankivell and Mehanna, 
2011).  
The CDKN2A gene which encodes the tumour suppressor protein p16 has also been 
studied in OSCC and OPMD. p16 is involved in cell cycle regulation through 
inhibition of the formation of the cyclin D and CDK4/6 complex which phosphorylates 
the RB protein. Though studied extensively, the prognostic value of CDKN2A and 
p16 in OPMD for clinical outcome is inconclusive (Reed et al., 1996; Kresty et al., 
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2002; Angiero et al., 2008; Lingen et al., 2011; Nasser et al., 2011; Nankivell et al., 
2014). The recognition of HPV-associated OED further complicates assessment of 
p16 as a prognostic biomarker for clinical outcome in OPMD as the natural history of 
HPV-associated OED is as yet unclear (McCord et al., 2013; Woo et al., 2013; El-
Naggar et al., 2017; Lerman et al., 2017). 
Biomarkers associated with cellular proliferation and cycle such as proliferating cell 
nuclear antigen (PCNA), Ki-67, minichromosome maintenance protein 2 (MCM2), 
and cyclin D1 (CCND1) have also been studied in relation to their role in oral 
carcinogenesis (Kodani et al., 2001; Rousseau et al., 2001; Shintani et al., 2002; 
Turatti et al., 2005; Kovesi and Szende, 2006; Pitiyage et al., 2009; Smith et al., 
2009; Torres-Rendon et al., 2009a; Lingen et al., 2011; Poh et al., 2012). Although 
most studies agree that there is a correlation between dysplasia grade and Ki-67 
expression, the association between its expression and malignant transformation is 
not very clear (Kodani et al., 2001; Bortoluzzi et al., 2004; Takeda et al., 2006; 
Pitiyage et al., 2009; Torres-Rendon et al., 2009a; Vered et al., 2009; Lingen et al., 
2011). As expected of a proliferation marker, reactive lesions showed an almost 
similar proliferation index to dysplastic tissue (Takeda et al., 2006; Pitiyage et al., 
2009; Vered et al., 2009; Lingen et al., 2011). Expression of CCND1 has been shown 
to be increased in both dysplasia and OSCC, however, similar to Ki-67, its utility as a 
prognostic marker of MT is not very clear (Rousseau et al., 2001; Turatti et al., 2005; 
Kovesi and Szende, 2006). Both PCNA and MCM2 have been shown to have some 
association with progressive changes in epithelial tissue from normal to dysplasia to 
malignancy (Kodani et al., 2001; Shintani et al., 2002; Torres-Rendon et al., 2009a; 
Lingen et al., 2011), however due to the limited evidence and obvious overlap with 
proliferative/reactive lesions, the role of proliferation markers would need further 
assessment before refuting or supporting their utility as prognostic biomarkers. 
Another widely studied biomarker is the epidermal growth factor receptor (EGFR). 
EGFR has roles in cellular proliferation, apoptosis, angiogenesis, invasion and 
metastasis. EGFR is known to have many downstream carcinogenesis associated 
signalling targets and increased EGFR expression is seen in many OSCC with its 
expression correlating to poorer outcome (Nicholson et al., 2001; Ciardiello and 
Tortora, 2003; Kalyankrishna and Grandis, 2006; Normanno et al., 2006; Taoudi 
Benchekroun et al., 2010).  EGFR may also play a role in OPMDs that undergo 
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malignant change (Nagatsuka et al., 2001; Taoudi Benchekroun et al., 2010; Bates et 
al., 2016). Nagatsuka et al (2001) reported the amplification of EGFR in OED that 
appeared to increase with the grade of dysplasia and in a more recent study, OPMD 
with irregular EGFR gene copy number had a higher tendency to undergo malignant 
transformation (Nagatsuka et al., 2001; Bates et al., 2016). Although these results 
suggest that EGFR gene copy number gain and amplification may be associated with 
malignant transformation in OPMD, large prospective studies are required to verify 
these findings (Grandis and Tweardy, 1993; Pitiyage et al., 2009; Smith et al., 2009; 
Taoudi Benchekroun et al., 2010; Lingen et al., 2011; Nankivell and Mehanna, 2011; 
Poh et al., 2012; Bates et al., 2016).   
The association between OPMDs and matrix metalloproteinases (MMPs) specifically 
MMP1, MMP2 and MMP9 have been investigated by several groups (Sutinen et al., 
1998; Jordan et al., 2004; Chen et al., 2008b; de Carvalho Fraga et al., 2014; 
Chandolia et al., 2016). MMP9 was found to be the more promising biomarker 
amongst the MMPs and has been shown to have altered expression between normal 
tissue and OPMDs as well as some association with OPMDs that undergo MT 
(Jordan et al., 2004; Chen et al., 2008b; Chandolia et al., 2016; Venugopal and Uma 
Maheswari, 2016). The role of MMPs in MT of OPMD is however still not confirmed 
due to the relative scarcity of studies examining this association. 
Podoplanin, a transmembrane glycoprotein that is a stem cell marker, has been 
studied as a potential prognostic biomarker in OED. Podoplanin overexpression has 
been shown to be associated with lymphatic metastasis and poorer outcome in 
HNSCC (Yuan et al., 2006). It has also been shown that podoplanin in expressed in 
OED and may be of value as a prognostic indicator of malignant change in OPMD 
(Kawaguchi et al., 2008; Inoue et al., 2012; Kreppel et al., 2012; Swain et al., 2014). 
Kawaguchi et al (2008) demonstrated that podoplanin expression was a statistically 
independent factor in predicting malignant change in OPMD (Kawaguchi et al., 
2008). But yet again, these findings have yet to be replicated in larger cohorts. 
An inhibitor of apoptosis, survivin, has recently emerged as a protein of interest in 
OSCC with a recent meta-analysis concluding that expression of survivin has 
prognostic value in OSCC (Xie et al., 2015). Although there is limited data on its role 
in MT of OPMD, several studies have indicated that an overexpression of survivin is 
associated with MT in OPMD and OED (Lo Muzio et al., 2003; Tanaka et al., 2003; 
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Zhou et al., 2010). A protease, cathepsin L, was shown to be overexpressed in oral 
carcinomas using gene expression profiling by Alevizos et al (2001) (Alevizos et al., 
2001). Assessment of both mRNA and protein levels of cathepsin L by Macabeo-Ong 
et al (2003) however showed no statistically significant difference between OED that 
underwent MT and those that did not (Macabeo-Ong et al., 2003). There is very 
scarce evidence in the literature to refute or support the prognostic utility of cathepsin 
L in OPMDs.  
The relatively recent discovery of non-coding RNAs (ncRNA) have added another 
paradigm to the altered gene regulation process in carcinogenesis. There is some 
evidence that non-coding RNA are associated with development and progression of 
malignant neoplasms (Guttman et al., 2009; Li et al., 2013; Lv et al., 2013; Wu et al., 
2014; Conway et al., 2015). The two members of the ncRNA family that have been 
studied most extensively with regard to carcinogenesis are microRNA (miRNA) and 
long non-coding RNA (lncRNA). 
MicroRNA are small (18-22 nucleotide in length) non-coding molecules and to date, 
more than one thousand miRNA have been identified (Ambros, 2004; Griffiths-Jones, 
2004). In carcinogenesis, studies have shown that miRNAs can behave as 
oncogenes or tumour suppressor genes and exert their effects by affecting the 
translation of the target mRNA (Calin and Croce, 2006; Esquela-Kerscher and Slack, 
2006; Osada and Takahashi, 2007). In a recent review on epigenetics in oral cancer, 
D’Souza and Saranath (2015) discussed the deregulated expression of miRNA in 
oral cancers and highlighted several miRNA that may be regulators of invasion and 
metastasis in OSCC (D'Souza and Saranath, 2015). A study by Cervigne et al (2009) 
showed that the overall miRNA expression profiles could distinguish progressing and 
non-progressing oral leukoplakia (Cervigne et al., 2009). MiR-31 has been recently 
shown to be upregulated in OPMDs compared to normal oral mucosa and OPMDs 
that underwent malignant transformation had a further increased expression of miR-
31 (Hung et al., 2014; Hung et al., 2016). Research investigating the possibility of 
using miRNA to predict malignant transformation in OPMD has led to several groups 
creating panels using miRNA expression to improve prediction of malignant 
transformation in OPMD (Philipone et al., 2016; Chang et al., 2018). However, a 
recent systematic review concluded that there is currently insufficient evidence to 
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validate the utility of miRNA expression profile as a prognostic marker of malignant 
transformation in OPMDs (El-Sakka et al., 2018). 
Long non-coding RNAs (lncRNA) have recently emerged as possible biomarkers in 
carcinogenesis. LncRNA have been shown to be dysregulated during carcinogenesis 
and metastasis (Lv et al., 2013; Wu et al., 2014; Zhang et al., 2014; Conway et al., 
2015). Conway et al (2015) highlighted several anti-sense HOX transcripts as being 
differentially expressed between “normal” and tumour samples as well as between 
“normal” and dysplastic samples (Conway et al., 2015). However, at this point in time 
there is very limited data available concerning its role in the development and 
malignant transformation of OPMD. 
Numerous other biomarkers have been studied with little progress being made. 
Though promising initially, most biomarkers have yet to be validated as prognostic 
indicators of malignant change in OPMD with LOH and DNA ploidy analysis being 
the two most promising biomarkers thus far (Pitiyage et al., 2009; Smith et al., 2009; 
Lingen et al., 2011; Zhang et al., 2012; Sperandio et al., 2013; Nikitakis et al., 2018; 
Speight et al., 2018). With the advent of next generation sequencing techniques, 
newer biomarkers are being discovered and studied. 
Despite the extensive research that has gone into the discovery and validation of 
prognostic biomarkers, the standard and quality of reporting of such studies have 
been found to be lacking in detail (McShane et al., 2005; Sauerbrei et al., 2018). To 
address this issue, a set of recommendations for reporting such findings was 
developed; the “Reporting Recommendations for Tumour Marker Prognostic Studies 
(REMARK)” (McShane et al., 2005). This set of recommendations is composed of 20 
suggestions that would improve the standard of reporting biomarker-related studies 
(Appendix A) (McShane et al., 2005). These recommendations however, are not only 
suitable for tumour marker studies but can be extended to any biomarker study in the 
biomedical field (McShane et al., 2005; Sauerbrei et al., 2018). Although the 
recommendations made are for reporting study findings, a more robust study can be 
designed by taking into consideration these recommendations during the early 
stages of a research.  
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1.4 Differential Gene Expression Profiling 
From a developmental point of view, cells are thought to differentiate through 
differential gene expression (DGE). As such, by studying DGE between normal and 
abnormal tissue, in-depth understanding of the genetic pathways involved in 
carcinogenesis can be elucidated. Studies based on DGE have allowed researchers 
to dissect and examine the cancer transcriptome in a way that was not possible using 
conventional molecular biological methods (Perou et al., 2000; Sorlie et al., 2001; 
Sorlie et al., 2003; Molinolo et al., 2009; Conway et al., 2015; De Cecco et al., 2015; 
Wood et al., 2015; Zhu et al., 2015; Makarev et al., 2017; Wood et al., 2017). 
Rapid advances in genomic laboratory techniques and bioinformatic analysis have 
enabled the analysis of thousands of expressed genes simultaneously in various 
tissues providing a unique way to identify molecules with varying expression between 
normal, dysplastic and malignant tissue. Such studies may also help improve our 
understanding of the complex nature of malignancies (Perou et al., 2000; Sorlie et 
al., 2001; Sorlie et al., 2003; Carey et al., 2015; De Cecco et al., 2015). DGE has 
also contributed to the paradigm shift away from single biomarkers for diagnosis or 
prognosis (Perou et al., 2000; Sorlie et al., 2001; Sorlie et al., 2003). Rather than 
depending on a single prognostic variable, combining several variables to construct a 
prognostic model seems more robust (Harrell et al., 1996; Royston et al., 2009; 
Steyerberg et al., 2013; Moons et al., 2015). One way to add strength to conventional 
risk-stratification methods is by integrating or combining gene-signatures with clinico-
pathologic parameters to add a further dimension in enhancing individualised patient 
care (Saintigny et al., 2011; Sperandio et al., 2013). 
The ability to identify patient clusters with similar molecular patterns in different 
tumour types have enabled researchers to define new molecular cancer sub-types 
enhancing better targeted therapy and patient care. The paradigm is breast cancer 
where at least five molecular sub-types with prognostic correlation were discovered 
(Perou et al., 2000; Sorlie et al., 2001; Sorlie et al., 2003; Hu et al., 2006). The 
findings were then further refined and validated resulting in the predictive PAM50 
gene signature (Hu et al., 2006; Parker et al., 2009).  
The lack of prognostic biomarkers in OPMD is a cogent reason to perform DGE 
based studies to identify gene-signatures for early diagnosis, therapy or prognosis in 
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OPMD to inform targeted therapy (Chung et al., 2004; Chen et al., 2008a; Saintigny 
et al., 2011; van Hooff et al., 2012; Abdulmajeed and Farah, 2013; Sumino et al., 
2013). A recent meta-analysis performed by De Cecco et al. (2015) demonstrated 
the usefulness of DGE studies in stratifying HNSCC into six sub-types characterized 
by their respective clinico-pathological features and dysregulation of relevant 
signalling pathways (De Cecco et al., 2015). 
There are only a few DGE studies on OPMD/OED (Chen et al., 2008a; Saintigny et 
al., 2011; Conway et al., 2015; Zhu et al., 2015).  As yet, only one truly investigated 
DGE between OPMD that transformed to OSCC and those that did not (Saintigny et 
al., 2011). Saintigny et al (2011) proposed gene expression-based prediction models 
that showed superior prognostic accuracy when compared to models using clinico-
pathologic risk factors (Saintigny et al., 2011). Though highly interesting, a major 
limitation of this study that may have influenced the prognostic gene-signature was 
that all the patients were enrolled in a clinical chemo-prevention trial, which may have 
influenced the outcome of the OPMD as well as the gene expression. As such, 
further studies in DGE between OPMD that undergo malignant transformation versus 
those that do not would provide much needed insight into the molecular mechanisms 
that translate into malignant transformation in OPMDs.  
Whole transcriptome sequencing methods such as total RNA sequencing (RNASeq) 
provide a method to detect both coding and non-coding RNA. This enables 
investigators to measure transcript abundance and identify both known and novel 
genes that are differentially expressed between malignant transforming and non-
transforming OPMDs.  
Formalin-fixed paraffin-embedded (FFPE) tissue are an invaluable resource for 
molecular biology research as they are linked to various patient and disease related 
information. Though FFPE may contain ample genetic material, formalin fixation is 
known to adversely affect the quality of nucleic acids hampering downstream 
applications such as gene expression microarrays (von Ahlfen et al., 2007). A 
relatively new gene expression profiling system that relies on direct measurement of 
transcripts using colour coded probe-based technology, the NanoString nCounter 
platform (NanoString Technologies, Seattle, USA), has been able to provide accurate 
gene expression data using RNA obtained from FFPE material (Geiss et al., 2008; 
Reis et al., 2011).  
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Recent studies have shown that mRNA expression analysis using the NanoString 
platform were equivalent to that achieved through quantitative real-time polymerase 
chain reaction (qPCR) and possibly superior to microarrays (Geiss et al., 2008; Reis 
et al., 2011; Balko et al., 2012; Veldman-Jones et al., 2015a; Veldman-Jones et al., 
2015b). There are several advantages of NanoString compared to PCR-based 
techniques: NanoString is hybridisation-based which means that there is no reverse 
transcription, no amplification and no enzymes involved. This reduces handling of the 
sample, minimizing errors and amplification bias. An additional advantage of this 
platform is that the mRNA level is determined for every individual sample and 
normalised against “housekeeping/internal reference” genes within the same sample 
(Geiss et al., 2008; Reis et al., 2011; Veldman-Jones et al., 2015a). NanoString 
allows detection of up to 800 targets (genes or regions) in a single reaction. Recently 
a genomic assay based on the PAM50 gene-signature for assessing long-term risk of 
breast cancer recurrence using NanoString technology, Prosigna (NanoString 
Technologies, Seattle, USA), has been approved for use in the UK by the National 
Institute for Health and Care Excellence (NICE) (National Institute for Health and 
Care Excellence, 2015b). NanoString technology has also been used successfully by 
a group studying molecular classification of B-Cell lymphomas (Carey et al., 2015).   
1.5 Multivariate Prognostic Models 
Prognostic models are composed of two or more variables (or determinants) which 
convert observed values into prognostic scores by assigning relative weightage to 
each factor (Moons et al., 2009; Steyerberg, 2009). In a healthcare setting, such 
models are constructed to aid in diagnosing disease or to predict whether a specific 
event will occur in the future. From a prognostic aspect, such models are useful when 
planning interventions or treatments based on a specific risk of developing a 
particular condition (Moons et al., 2009; Steyerberg, 2009). Risk estimates for 
treatment planning are almost never based on a single predictor as clinicians will 
invariably integrate patient parameters and other predictive/prognostic markers 
(Steyerberg et al., 2013). Some well-known predictive and prognostic models include 
the Nottingham Prognostic Index for breast cancers (Haybittle et al., 1982), Ottawa 
Ankle Rules for ankle/foot fractures (Stiell et al., 1992), Framingham Risk Score for 
cardiovascular disease risk (Anderson et al., 1991), PREDICT for prognosis following 
surgery for breast cancer (Wishart et al., 2010) and EuroSCORE for risk of mortality 
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following cardiac surgery (Nashef et al., 1999). To be of clinical use as a prognostic 
tool in personalised medicine, prognostic models need to be converted into a 
statistically relevant numerical value.  
Although such prognostic models are invaluable, developing, validating and reporting 
multivariate prognostic models can be challenging. The quality of reports on 
prediction models have been critically reviewed and evaluated several times with 
most reviews concluding that the quality of reporting is poor with inadequate detail 
being provided regarding all areas of model development and validation (Mallett et 
al., 2010; Collins et al., 2011; Bouwmeester et al., 2012; Collins et al., 2013; Collins 
et al., 2014; Moons et al., 2014). Appropriate assessment of prediction models can 
only be performed if reports provide clear and sufficient information on all aspects of 
the model construction and validation.  
To overcome this problem, a guideline for reporting studies developing and/or 
validating multivariate prediction/prognostic models, the “Transparent Reporting of a 
multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD) 
Statement” was developed recently and published in several medical journals 
simultaneously (Collins et al., 2015; Moons et al., 2015). The TRIPOD statement is 
composed of a 22-item checklist (Appendix B) that covers a minimum set of 
recommendations focusing on how the study was designed, performed, analysed 
and interpreted (Collins et al., 2015; Moons et al., 2015).  
Despite the global health burden and relatively poor prognosis associated with 
OSCC, a robust prognostic biomarker or prognostic model for predicting malignant 
transformation in OPMD has yet to be developed and validated. The clinical, 
histopathological and genetic heterogeneity of OPMD and OSCC are major 
contributing factors to this problem. DGE provides a suitable method to explore and 
discover novel biomarkers as well as genetic signatures that may be useful not only 
as prognostic indicators of disease outcome but also in furthering our understanding 
of the pathogenesis of OPMD and OSCC. Instead of focusing on single prognostic 
biomarkers, models made up of several factors may be more suitable in providing 
personalised assessment/prognostication for patients with OPMDs (Moons et al., 
2009; Royston et al., 2009; Collins et al., 2011; Steyerberg et al., 2013; Moons et al., 
2015). 
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1.6 Aims 
This study will test the hypothesis that a multi-parameter biomarker driven prognostic 
classifier for OPMD is better than conventional prognostic methods that are based 
only on clinical and histopathological findings. The aims of this study are: 
1. To identify two separate cohorts (training and validation cohorts) of OPMD 
patients with known clinical outcomes and adequate archived FFPE tissue 
for relevant tests. 
2. To compare efficacy of two different OED grading systems as prognostic 
indicators for clinical outcome in OPMDs. 
3. To assess the utility of two molecular techniques (DNA ploidy analysis and 
LOH analysis) as prognostic indicators for clinical outcome in OPMD using 
archived FFPE tissue. 
4. To identify differentially expressed genes between OPMD that undergo 
malignant transformation and OPMD that do not undergo malignant 
transformation using archived FFPE tissue. 
5. To discover a gene expression signature that characterises OPMDs with a 
high risk of undergoing malignant transformation. 
6. To develop a composite clinical, histopathological and molecular 
prognostic classifier for patients with OPMD. 
7. To validate the developed classifier on an external cohort of OPMD 
patients with known clinical outcomes (validation cohort). 
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Table 1.1 List of Oral Potentially Malignant Disorders (OPMD). 
OPMD 
Leukoplakia 
Erythroplakia 
Erythroleukoplakia 
Proliferative verrucous leukoplakia 
Oral submucous fibrosis 
Oral lichen planus 
Palatal lesions in reverse smoking 
Actinic cheilitis 
Dyskeratosis congenita 
Fanconi anaemia 
Sideropenic dysphagia 
Discoid lupus erythematosus 
Cheilitis glandularis 
Syphilis 
Chronic hyperplastic candidosis 
*Adapted from Barnes et al (2005) and El-Naggar et al (2017). 
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Table 1.2 Histological features of Oral Epithelial Dysplasia. 
Cytological changes Architectural changes 
Abnormal variation in nuclear size Irregular epithelial stratification 
Abnormal variation in nuclear shape Loss of polarity of basal cells 
Abnormal variation in cell size Drop shaped rete ridges 
Abnormal variation in cell shape Increased number of mitotic figures 
Increased nuclear to cytoplasmic ratio Abnormally superficial mitotic figures 
Atypical mitotic figures Premature keratinization of single cells 
Increased number and size of nucleoli Loss of epithelial cell cohesion 
Hyperchromasia Keratin pearls in rete processes 
*Adapted from Barnes et al (2005) and El-Naggar et al (2017). 
 
 
Table 1.3 Demographic and clinical risk factors associated with increased risk of 
malignant transformation in OPMD. 
Demographic risk factor Clinical risk factor 
Age (> 50 years) Clinical appearance (homogenous vs non-
homogenous, leukoplakia vs erythroplakia, etc) 
Sex (female) Anatomical sub-site (tongue and floor of mouth) 
Risk habits (tobacco usage, 
betel quid usage, alcohol 
consumption, etc) 
Size of lesion (> 200mm2) 
*Adapted from Speight et al (2018). 
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Table 1.4 Promising prognostic biomarkers for malignant transformation in OPMD. 
Marker RR HR OR 95% CI P value Relevant 
studies 
LOH 3p +/- 
9p 
3.92 NA NA 1.50 -
10.25 
0.006 (Rosin et al., 
2000; Zhou et 
al., 2005) 
DNA ploidy 3.90 NA NA 1.30 -
11.62 
0.01 (Torres-
Rendon et al., 
2009) 
Survivin 30.00 NA NA 4.25 -
197.73 
  < 0.001 (Lo Muzio et 
al., 2003) 
MMP9 
mRNA 
19.00 NA NA 1.56 – 
209.38 
0.02 (Jordan, 2004) 
Podoplanin NA 3.09 NA 1.53 -
6.23 
0.02 (Kawaguchi et 
al., 2008) 
ΔNp63 NA 3.31 NA 1.66 -
6.58 
0.0007 (Saintigny et 
al., 2009) 
EGFR copy 
number 
NA 3.62 NA 1.44 -
9.10 
0.006 (Taoudi 
Benchekroun 
et al., 2010) 
*Adapted from Smith et al (2009) and Nankivell and Mehanna (2011).  
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Figure 1.1 The hallmarks of cancer comprising six capabilities acquired by neoplastic 
cells during carcinogenesis.  
Two new emerging hallmarks; deregulating cellular energetics and avoiding immune 
destruction are also included. Genomic instability & mutation and tumour-promoting 
inflammation are two factors which have been considered as enabling characteristics 
for cancer development. Adapted from Hanahan & Weinberg (2011) (Hanahan and 
Weinberg, 2000; Hanahan and Weinberg, 2011). 
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Figure 1.2 Multistep genetic progression model for oral carcinogenesis.  
LOH: Loss of heterozygosity. Adapted from Califano et al (1996) and Forastiere et al 
(2001). 
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Chapter 2. Materials and Methods 
 
2.1 Case Selection 
Suitable patients for the “training cohort” were identified from a pre-existing oral 
potentially malignant disorder (OPMD) database. All the patients were diagnosed 
with OPMD between 1st August 1996 and 31st December 2015, had a diagnostic 
biopsy, were seen at a specialist clinic and have been followed-up for at least 12 
months. Demographic and clinico-pathologic features as well as outcome data were 
recorded.  
Patients for the “validation cohort” were identified through a systematic search of the 
Royal Victoria Infirmary Cellular Pathology Database for OPMD cases originating 
from Sunderland Royal Hospital diagnosed between 1st January 2001 and 31st 
December 2015. The search was performed using the Systematised Nomenclature 
of Medicine-Clinical Terms (SNOMED CT) codes. Demographic and clinico-
pathologic features as well as outcome data were obtained from the Oral and 
Maxillofacial Surgery Department at Sunderland Royal Hospital. 
2.1.1 Inclusion and exclusion criteria  
The following inclusion and exclusion criteria were applied to the cases found from 
the initial search: 
• Inclusion criteria: 
o Clinical diagnosis of OPMD 
o Clinical follow-up for at least 12 months after initial diagnosis of 
OPMD 
o FFPE tissue available for analysis 
• Exclusion criteria: 
o Previous history of head and neck cancer 
o Less than six months between index biopsy for OPMD and 
diagnosis of OSCC (the initial biopsy may be a false negative) 
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o Patients with hereditary/acquired conditions that are linked to an 
increased risk of head and neck SCC (such as ataxia 
telangiectasia, xeroderma pigmentosum, Fanconi anaemia etc) 
o Patients that were diagnosed as having chronic hyperplastic 
candidosis/chronic candidosis. Such cases were excluded as the 
literature is divided as to whether these lesions are truly OPMDs 
(El-Naggar et al., 2017; Speight et al., 2018) 
o Patients with clinical follow up of less than 12 months 
o Cases with incomplete/inconsistent records 
o Cases with inadequate/damaged/unavailable FFPE tissue for 
analysis 
 
2.1.2 Clinical outcomes  
The cases were categorized into one of two clinical outcomes: 
• Malignant transformation (MT) or 
• No malignant transformation (NT) 
A case was classified as having undergone MT when there was progression from an 
OPMD to oral squamous cell carcinoma (OSCC) after a period of six months or more 
from the time of the initial diagnosis of OPMD. Those patients with OPMD who were 
recorded as not having developed OSCC at their last known follow-up appointment 
were classified as NT cases with the caveat that the patients were followed up for at 
least 12 months.  
2.1.3 Data management  
For each selected case, the following data points were collected and entered into a 
Microsoft Excel spreadsheet:  
• age at first diagnosis of OPMD  
o continuous and 
o dichotomised into £  50 or > 50 years of age (Einhorn and Wersall, 1967; 
Speight et al., 2018) 
• sex 
• clinical diagnosis of lesion 
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• site of index OPMD 
• clinical management of OPMD 
• clinical outcome of OPMD 
• date of MT (diagnostic biopsy with OSCC) or last clinical follow-up. 
All data were coded, link anonymised and stored in password protected computer files. 
2.2 Ethical Approval 
This project has favourable ethical opinion (“Evaluation of the prognostic potential 
and functional significance of biomarkers in oral cancer”; NRES Committee Northeast 
– Sunderland 11/NE/0118). 
2.3 Histopathological Specimens  
Archived haematoxylin and eosin (H&E) stained sections of the cases identified from 
the OPMD database were retrieved and assessed to choose suitable FFPE blocks 
from each case. Subsequently, selected FFPE blocks were retrieved from the Royal 
Victoria Infirmary Department of Cellular Pathology archives. Blocks with adequate 
material for the planned experiments were then selected. In case a FFPE block for a 
specific case was unavailable or had inadequate tissue, an alternative FFPE block 
from the case was chosen if available. Serial 4µm sections were taken from the 
selected FFPE blocks using a Leica RM 2135 microtome (Leica Microsystems, 
Germany) and individual sections were mounted onto microscope slides (Superfrost 
Plus, Thermo Fisher Scientific, UK). 
All histopathological assessments (oral epithelial dysplasia grading; OPMD 
associated leukocytic infiltrate scoring; high-risk HPV assessment) were performed 
using a 3-tiered assessment protocol involving three oral and maxillofacial 
pathologists; Dr Max Robinson (MR), Hans Sathasivam (HS) and Professor Philip 
Sloan (PS). The pathologists were blinded to clinical outcome of OPMD patients 
during the assessment and grading exercise.  
2.3.1 Oral epithelial dysplasia (OED) assessment and grading 
Following FFPE block selection, 4µm sections were taken from each block and 
individual sections were mounted onto microscope slides. Haematoxylin & eosin 
(H&E) staining was performed on the DAKO CoverStainer (Agilent Technologies, 
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USA). The slides for each of the cases were reviewed, assessed and graded following 
a modified three-tier system adapted from the work published by Speight et. al. (2015). 
Briefly, the slides were first graded independently by two oral and maxillofacial 
pathologists (MR & HS). Following which, if there was discordance in the grade 
between the two pathologists, the cases were sent to a third pathologist (PS), who 
assumed the role of an adjudicator and independently graded the case. The majority 
diagnosis (agreement by two out of three pathologists) was accepted as the final 
grading. For cases where the grading of the adjudicator was different from both 
pathologists, a consensus meeting was convened to derive a final grade. The workflow 
for this process is outlined in Figure 2.1. 
The cases were graded using two different grading systems: 
I. Three-tiered (mild, moderate or severe) World Health Organization (WHO) 
2017 classification (El-Naggar et al., 2017)  
II. Binary (low-grade or high-grade) classification (Kujan et al., 2006; El-Naggar et 
al., 2017) 
 
2.3.2 Assessment of oral potentially malignant disorders (OPMD) associated 
leukocytes (OPAL) 
Subepithelial leukocytic inflammatory infiltrate was assessed and scored for each 
case in a binary manner depending on whether there was a high or low level of 
leukocytic infiltrate. An OPMD associated leukocytes (OPAL) score (or OPALS) was 
given for each case. When there was presence of a well-defined leukocytic infiltrate 
in the lamina propria, the case was scored as being OPALS positive and if there was 
either no/very minimal leukocytic infiltrate in the lamina propria, it was scored as 
OPALS negative. All cases were assessed in a manner similar to the earlier 
mentioned 3-tiered OED grading method (Figure 2.1).  
2.3.3 Assessment for high-risk human papillomavirus (HR-HPV) 
Cases chosen for molecular and gene expression experiments were all assessed for 
the presence of HR-HPV due to the fact that HR-HPV positive cases may have a 
different aetiopathogenesis and gene expression profile compared to negative cases. 
A two-tiered testing method was employed: 
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• Initial screening with p16 staining via immunohistochemistry (IHC) 
• High-risk human papillomavirus DNA in situ hybridisation (HR-HPV ISH) 
for cases that were considered to be positive for p16 staining. 
Immunohistochemistry for p16 was performed on 3µm thick FFPE sections using a 
proprietary kit (CINtec Histology, Roche mtm laboratories AG, Germany) on a 
Ventana Benchmark Autostainer (Ventana Medical Systems Inc, USA). 
Oropharyngeal squamous cell carcinoma (OPSCC) tissue with high p16 expression 
was used as a positive control whilst histologically normal tonsillar tissue was used 
as a negative control. A case was considered as being p16 positive when there was 
strong and diffuse nuclear and cytoplasmic staining of OED involving more than 1/3 
of the thickness of the involved epithelium, excluding keratin (Singhi and Westra, 
2010; McCord et al., 2013; Woo et al., 2013).   
HR-HPV ISH was performed on 3µm thick FFPE sections using proprietary reagents 
(Inform HPV III Family 16 Probe (B), Ventana Medical Systems Inc, USA) on a 
Benchmark Autostainer (Ventana Medical Systems Inc, USA). The following control 
samples were used: FFPE CaSki cells (HPV-16 positive), HeLa cells (HPV-18 
positive) and C-33A (HPV negative; Ventana Medical Systems Inc, USA). The test 
was recorded as being positive if any blue reaction products were observed within 
the nucleus of epithelial cells (either punctate or homogenous pattern) (Thavaraj et 
al., 2011; McCord et al., 2013; Woo et al., 2013). All cases were assessed in a 
manner similar to the earlier mentioned 3-tiered OED grading method (Figure 2.1). 
Cases were only considered HR-HPV positive if there was positivity for both p16 IHC 
and HR-HPV ISH. 
2.4 Image-based Cytometry (IBC) DNA Ploidy Analysis 
All image-based cytometry (IBC) DNA ploidy analysis procedures were performed at 
Guy’s Hospital Head & Neck Pathology Laboratory London, in collaboration with 
Professor Edward Odell (EO). Cases with adequate tissue for analysis were selected 
from the OPMD cohort. Sample preparation was performed by HS with the kind 
assistance of Mrs. Deepa Nayar, Senior Biomedical Scientist at the Guy’s Hospital 
Head & Neck Pathology Laboratory. 
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2.4.1 Sample preparation  
The relevant H&E stained slides were reviewed to delineate suitable areas for DNA 
ploidy analysis (areas with worst OED). Whole sections were taken for small tissue 
samples whilst larger samples were macrodissected to obtain the areas of interest. 
The relevant areas for macrodissection were marked on the H&E slides. The 
preliminary decision as to whether ploidy analysis could be performed for each 
specimen was dependent largely on visual inspection of the amount of tissue in each 
FFPE block. Samples were prepared and analysed according to the steps outlined by 
Diwakar et al (2005). 
Macrodissection was performed on large samples by outlining/scoring the 
corresponding areas (previously marked on the H&E slides) using a scalpel blade. 
The blocks were then cut into multiple 50µm sections (approximately 4 – 7 sections 
depending on the length of area of interest; ideally 8mm epithelial length x 6 
sections) using a microtome (Jung RM2055, Leica) (Table 2.1). The sections were 
then placed into a 15ml labelled polypropylene centrifuge tube.  
For deparaffinisation, tissues were incubated twice for 30 minutes in 4ml of xylene. 
Following this, rehydration in a series of aqueous ethanol solutions of decreasing 
concentrations was performed: two washes of 5 minutes in 4ml absolute ethanol and 
sequential immersion in 96%, 85%, 74% and 50% ethanol for 10 minutes each. The 
supernatant was then removed and replaced with 4ml of ice-cold PBS and left 
standing for 5 minutes. The supernatant was subsequently removed, and enzymatic 
digestion was performed by incubating samples with 2ml 0.05% protease (Sigma 
Protease type XXIV [Proteinase]) in a shaking (250 rpm) water bath (37°C) for 90 
minutes. After which, the tubes were placed on ice and 2ml of ice-cold PBS was 
added and tissue pellets were re-suspended using a 1ml pastette.   
The suspension was then filtered through a 60µm Nylon mesh filter into labelled 5ml 
Falcon tubes. The tubes were then centrifuged at 3300 rpm (Immufuge II, Dade 
Behring, USA) for 10 minutes, following which the supernatant was removed using a 
1ml Gilson pipette and 0.5 – 2 ml (depending on size of pellet) of PBS was added to 
re-suspend the pellet. For dispersion of a monolayer of nuclei onto a glass 
microscope slide, 200µl of the cell suspension was spun for 5 minutes at 600 rpm 
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using a cytospin cytocentrifuge (Thermo Shandon Cytospin 4, Thermo Fisher 
Scientific, UK).   
A light microscope was used to determine the nuclear concentration. A monolayer 
containing between 10 and 20 nuclei per x40 magnification field was considered to 
be suitable for analysis. If the monolayer was deemed to be inadequate for analysis, 
a new monolayer was made from the remaining suspension. The monolayer was 
then fixed in 4% buffered formalin overnight in a fume cupboard.  
The next day, the slides with the fixed monolayers were washed in distilled water for 
2 minutes before being placed in 5N HCl for one hour at room temperature to remove 
the purine bases of DNA. They were then washed in distilled water for two minutes 
and stained in Schiff’s reagent (in the dark) for two hours. This was then followed by 
placing the slides in three changes of sodium bisulphite for 30 minutes (10 minute 
per change). The slides were then gently rinsed three times in tap water and three 
times in distilled water, following which the slides were dehydrated through a series 
of graded ethanols (96%, 85%, 74% and 50% ethanol) and transferred to xylene (5 
minutes each immersion). The slides were then mounted with DPX mounting medium 
and coverslips were placed. The slides were then dried flat in an oven at 60°C for 10 
minutes. 
2.4.2 Measurement and analysis of DNA content 
The Ploidy Work Station (PWS) Grabber system (Room4, Sussex UK) was used for 
scanning and capturing the images of the monolayer slides. The system was 
composed of an automated scanning microscope with a 546nm green barrier filter 
(Zeiss Axioplan II, Zeiss, Oberkochen, Germany), a black and white digital camera 
that provided a resolution of 162nm per pixel using a 40x lens (AxioCam MRm, Zeiss, 
Oberkochen, Germany) and a computer work-station.   
Nuclear area and optical density of each nucleus was measured and corrected to the 
background optical density. By integrating the measured optical density of each pixel 
across the area of each nucleus, the software is able to provide the integrated optical 
density (IOD) value. The software automatically sorts the nuclei into separate 
galleries (epithelial nuclei, small lymphocyte nuclei, large lymphocyte nuclei, 
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fibroblast nuclei and unclassified objects) for analysis using the PWS Classifier 
software (Room4, Sussex, UK). 
Using the PWS Classifier, the contents of each gallery were manually edited and 
refined to ensure the contents were accurate. For each case, at least 300 epithelial 
nuclei were assessed to arrive at ploidy status. Samples with < 300 nuclei of interest 
were repeated if there was adequate remaining material or excluded from further 
analysis. The software was then used to create DNA ploidy histograms from the 
integrated optical density (IOD) of the nuclei; the lymphocyte and fibroblast nuclei 
were used as the internal control/reference nuclei (diploid nuclei) by the software.  
Classification of the histograms were performed according to a published set of 
criteria (Haroske et al., 2001; Sperandio et al., 2013): 
• A sample was classified as being diploid if; 
o the epithelial nuclei formed only one 2c peak (G0/G1),  
o the 4c peak (G2) has £ 10% of the total number of epithelial nuclei  
o the percentage of epithelial nuclei with DNA content of more than 
5c was £ 1%. 
• A sample was considered as tetraploid if; 
o A 4c peak with > 10% of the total number of epithelial nuclei was 
present with no other abnormal values 
• A sample was classified as being aneuploid if; 
o there were one or more peak/s containing > 10% of the total 
epithelial nuclei outside the range of the diploid or tetraploid 
peaks or 
o number of epithelial nuclei with a DNA content of 5c and above 
was > 1% of the total number of epithelial nuclei 
The ratio of standard deviation to mean DNA content for nuclei in the diploid peak (in 
percentage) was obtained through the software. This ratio, known as the coefficient 
of variation (CV), provides a measure of the detection limit or resolution for the 
analysis; peaks that are narrower (low CV with a low degree of scatter) are easier to 
assess and discriminate compared to peaks that are broad (high CV with a high 
degree of scatter) (Haroske et al., 2001; Danielsen et al., 2016). In best case 
scenarios a 1% change (corresponding to a CV of 1%) of DNA content is detectable 
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(Haroske et al., 2001; Danielsen et al., 2016). For the current study, cases with a CV 
that was > 5% for the diploid peak were excluded. The cut-off of 5% was chosen 
based on previously published studies and guidelines on DNA ploidy analysis 
(Haroske et al., 2001; Sperandio et al., 2013; Sperandio et al., 2016). All image 
galleries were edited, and histograms were diagnosed by HS and Professor Edward 
Odell (EO). 
2.5 Loss of Heterozygosity (LOH) Analysis 
Sample preparation from FFPE tissue for LOH analysis was performed at the 
Institute for Genetic Medicine, Newcastle University, whilst the molecular analysis 
portion for LOH analysis was performed by medical scientists at an ISO 15189:2012 
accredited molecular diagnostics laboratory, NewGene Limited (Centre for Life, 
Newcastle upon Tyne). Patient samples in the form of FFPE material were selected 
from the OPMD cohort identified earlier. The entire oral epithelium was selected as 
the “test” sample whilst the underlying connective tissue component was used as a 
comparator (“control”) to judge loss of heterozygosity in the overlying oral epithelium. 
Two different methods were assessed to determine the most suitable method for 
sample preparation: 
• LASER capture microdissection (LCM) and  
• manual microdissection  
The two methods were assessed using six cases. The more pragmatic method, 
manual microdissection, was then used for the remaining samples.  
The number of 4µm thick sections per sample was dependent on the size of the 
tissue; 12 - 14 sections for small sized samples, 8 – 12 sections for medium sized 
samples, 6 – 8 sections for large sized samples and 3 – 6 sections for very large 
sized samples (Table 2.1). To facilitate microdissection, the sections were stained 
with haematoxylin and eosin (H&E) on a DAKO CoverStainer (Agilent Technologies, 
USA) without coverslips. All sample collection tubes were labelled with unique patient 
identifiers before the start of the procedure. The matched “test” and control tubes had 
the same identifier numbers with the exception of the addition of “C” as the last letter 
for tubes used for controls. The oral epithelium was collected into the “test” sample 
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tubes whilst the matching underlying connective tissue for each case was collected 
into the control sample tubes. 
2.5.1 Sample preparation using LASER capture microdissection (LCM) 
FFPE blocks were cut to produce 4µm thick sections using a Leica RM2135 
microtome (Leica Microsystems, Germany) and mounted onto special Polyethylene 
Naphthalate (PEN) membrane slides (MembraneSlide) (Carl Zeiss, Munich, 
Germany). LASER capture microdissection (LCM) was performed using the PALM 
MicroBeam LASER capture microdissection system (Zeiss, Germany). As the LCM 
procedure is a non-contact procedure, a specialised collection device with an 
adhesive material filled microcentrifuge tube cover known as AdhesiveCap (Zeiss, 
Munich, Germany) was used as the collection device for the procedure.  
2.5.2 Sample preparation by manual microdissection 
The manual microdissection method was adapted from the methodology described 
by Mao et al (1996). FFPE blocks were cut to produce 4µm thick sections using a 
Leica RM2135 microtome (Leica Microsystems, Germany) and mounted onto glass 
microscope slides. The relevant areas for microdissection were annotated and 
subsequently microdissected manually using sterile 25-gauge needles and sterile 
scalpel blades. The laboratory bench and microscope were wiped clean with 70% 
ethanol before starting microdissection for each new case and new disposable 
gloves, needles and scalpel blades were used for each case. Dissected samples 
were placed in labelled sterile collection tubes.  
2.5.3 Microsatellite markers  
A panel of microsatellite markers located on chromosomes 3p, 9p, and 17p were 
chosen based on relevant studies which have shown that LOH involving these 
regions were useful as early predictors of malignant change in OPMDs (Partridge et 
al., 1998; Zhang and Rosin, 2001; Bremmer et al., 2008; Bremmer et al., 2009). LOH 
at 3p14 (FHIT), 9p21 (p16/CDKN2A) and 17p13 (TP53) has been shown by some 
studies to be a useful adjunct to predict malignant transformation of OPMD (Califano 
et al., 1996; Mao et al., 1996; Partridge et al., 1998; Partridge et al., 2000; Rosin et 
al., 2000; Zhang and Rosin, 2001; Bremmer et al., 2008; Zhang et al., 2012). The 
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chosen markers also have been shown to have a high percentage of LOH in head & 
neck SCC (Lippman and Hong, 2001; Tabor et al., 2001; Braakhuis et al., 2003). 
The nine microsatellite markers are listed in Table 2.2. The microsatellite markers 
were initially assessed in 24 paired samples (test & control) to evaluate the 
performance of each of the microsatellite. Based on the results from the 24 paired 
samples, the best performing microsatellite marker for each chromosomal region was 
chosen for the remaining samples.  
2.5.4 DNA extraction  
DNA extraction was performed at an ISO 15189:2012 accredited molecular 
diagnostics laboratory (NewGene Limited, Centre for Life, Newcastle upon Tyne). 
Automated DNA extraction was performed using the Promega Maxwell MDx 
(Promega Corporation, Wisconsin, USA) extraction robot and the Promega FFPE 
DNA extraction kit AS1135 (Promega Corporation, Wisconsin, USA).  
Briefly, following an overnight digestion in incubation buffer with proteinase K at 70°C 
(provided in the kit), lysis buffer was added to the sample and it was then loaded onto 
the DNA extraction robot. For samples obtained via LCM, prior to addition of 
proteinase K, 15µl of lysis buffer was added to the microdissected sample in the 
AdhesiveCap and the tubes were centrifuged at 10000xg for 5 minutes. DNA was 
extracted using magnetic beads. The quantity and quality of the DNA in each sample 
was determined using a NanoDrop Spectrophotometer (ThermoFisher Scientific, 
United Kingdom). 
2.5.5 Polymerase chain reaction (PCR)  
Polymerase chain reaction (PCR) was performed using the HotStarTaq DNA 
polymerase Master Mix Kit (QIAGEN, Germany). Sample DNA was diluted to 10ng/µl 
to dilute any contaminants from the FFPE tissue that may inhibit PCR. PCR was 
performed using specific primers labelled with either fluorescein (FAM) or 
hexachlorofluorescein (HEX) depending on the specific microsatellite marker. The 
PCR cycling protocol is shown in Table 2.3. 
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2.5.6 Loss of heterozygosity (LOH) analysis 
PCR products from the samples were subjected to capillary electrophoresis using the 
ABI 3130xl genetic analyser (Applied Biosystems, Thermo Fisher Scientific, UK). 
Analysis of the outputs were performed using the GeneMarker software 
(SoftGenetics, LLC, State College, USA). Electropherograms produced by the 
GeneMarker software were assessed for LOH in the test sample using the control 
sample as the comparator and final results were verified by an appropriately qualified 
staff member of NewGene Limited, Centre for Life, Newcastle upon Tyne. LOH was 
defined as a 50% decrease in the peak height of the test sample compared to the 
peak height of the relevant control sample. 
2.6 Cell Culture Techniques  
All the cell culture work for the project was performed at the Craniofacial & Molecular 
Biology Research Laboratory at the Faculty of Dentistry, University of Malaya, 
Malaysia. The OED cell lines were cultured in keratinocyte serum-free medium 
(KSFM) supplemented with 25ug/ml bovine pituitary extract, 0.2ng/ml EGF and 
0.3mM calcium chloride (CaCl2). Cells were cultured in a CO2 incubator (5%; Binder 
Inc, NY, USA) at 37°C. All the cell culture media and reagents were obtained from 
Gibco (Thermo Fisher Scientific, UK). 
2.6.1 Characteristics of oral epithelial dysplasia (OED) cell lines 
Four OED cell lines (D4, D19, D20 and D35) were used in this study. The 
characteristics of cell lines grown are shown in Table 2.4. The characterisation and 
maintenance of these cell lines have been previously described (McGregor et al., 
1997; McGregor et al., 2002). Cryopreserved cells were revived by quickly thawing 
them at 37°C. The thawed cells were then re-suspended in 5ml of culture medium 
and centrifuged using Rotofix 32A (Hettich Instruments, Tuttlingen, Germany) at 
13,000xg for 10 minutes before growing them in 25 cm3 flasks containing 5ml of 
medium.  
2.6.2 Subculture and cell number determination 
The cells were subcultured at approximately 60 - 70% confluence. Cells were 
washed with phosphate buffered saline (PBS) followed by incubation with 4ml 
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trypsin/EDTA (Thermo Fisher Scientific, USA) for 20 minutes at 37°C. Trypsinised 
cells were then resuspended in 4ml of medium in a universal tube and centrifuged at 
13,000xg using Rotofix 32A (Hettich Instruments, Tuttlingen, Germany) for 10 
minutes. Cell pellets were re-suspended in fresh medium and the number of cells 
was determined. To assess the number of dead cells, cell suspensions were mixed 
1:1 with Trypan Blue (Sigma-Aldrich, UK) and 10μl of the mixture was pipetted onto 
the Luna cell counting slide (Logos Biosystem Inc., South Korea). The Luna 
Automated Cell Counter (Logos Biosystem, South Korea) was then used to 
determine the cell concentration from the glass slide. Cells were then seeded out at 
the required density. The necessary volume of cell suspension was added to the 
culture flask containing pre-warmed medium and the flask was then placed in an 
incubator at 37°C with 5% CO2. Cell lines were subcultured at least once before RNA 
extraction. 
2.6.3 Storage of cells  
Approximately 1x106 cells were resuspended in foetal bovine serum (FBS) with 10% 
dimethyl sulfoxide (DMSO) (Sigma-Aldrich, Gillingham, UK). Cells were then 
transferred to cryopreservation tubes (Nunc® Cryo Tubes®; Sigma-Aldrich, UK) and 
cooled overnight to -80°C in a cryo-container (Nalgene® Mr. Frosty; Sigma-Aldrich, 
Gillingham, UK). Following which, the cells were stored in liquid nitrogen.  
2.6.4 Total RNA extraction from cell lines  
RNA extraction was performed using the QIAGEN RNeasy® Mini kit following the 
manufacturer's protocol (QIAGEN, Manchester, UK). Adherent cells were collected 
by trypsinisation (as described in Section 2.6.2), washed once with ice-cold PBS, 
transferred to a polypropylene centrifuge tube and centrifuged at 300xg for 5 
minutes. The recommended volume of RLT buffer supplemented with β-
mercaptoethanol was added prior to vortexing for one minute to homogenise 
samples. Alcohol (70%) was added to the cell lysates and then transferred to the 
RNeasy Mini spin column for centrifugation. Subsequently, on-column 
deoxyribonuclease (DNase) digestion was performed as per the manufacturer’s 
instructions using the ribonuclease (RNase) Free DNase Set (QIAGEN, Manchester, 
UK). Following multiple washes with the supplied buffers, RNA was eluted from the 
columns using 40μl of RNase-free water pipetted directly onto the membrane. The 
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concentration and the quality of the isolated RNA were measured using a NanoDrop 
2000 Spectrophotometer (Thermo Fisher Scientific, UK). RNA with a 260/280 ratio of 
1.7 - 2.3 as well as a 260/230 ratio in the range of 1.8 -2.3 were considered to be of 
acceptable quality for downstream assays (NanoString, 2016).  
2.7 Differential Gene Expression Experiments  
Differential gene expression (DGE) experiments were performed using RNA 
extracted from FFPE and cell line material. Two different gene expression profiling 
platforms were used to determine differential gene expression profiles between 
OPMD that underwent malignant transformation (MT) and those that had not 
undergone malignant transformation (NT): 
• whole transcriptome sequencing using Illumina’s Next Generation Sequencing 
RNASeq platform (Illumina, USA) 
• targeted transcriptome profiling using the NanoString nCounter platform 
(NanoString Technologies, Seattle, USA) 
RNA extraction and purification from FFPE tissue for differential gene expression 
analysis was performed at the Institute for Genetic Medicine, Newcastle University. 
The RNA sequencing was performed by biomedical scientists at the Genome Centre, 
Queen Mary University of London. NanoString sample processing was performed 
with the kind assistance of Ms. Anastasia Resteu from the Human Dendritic Cell 
Laboratory, Institute of Cellular Medicine, Newcastle University. 
2.7.1 Total RNA extraction from formalin-fixed paraffin-embedded (FFPE) tissue 
After trimming excess paraffin off the sample block, 10μm sections were cut from the 
FFPE blocks and placed in 2ml microcentrifuge tubes after discarding the first two 
sections. Whole sections that included both epithelium and underlying connective 
tissue were used. The number of sections per sample was dependent on the size of 
the tissue; 4 sections for small sized samples, 3 - 4 sections for medium sized 
samples, 2 - 3 sections for large sized samples and 1 – 2 sections for very large 
sized samples (Table 2.1). RNA extraction and purification were performed using the 
QIAGEN RNeasy FFPE kit following the manufacturer's protocol (QIAGEN, 
Manchester, UK). A brief outline of the protocol is listed in Appendix C. Following 
RNA extraction, the concentration and the quality of the isolated RNA were 
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measured using a NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific, 
UK). The samples were then stored in a -80°C freezer prior to utilisation in 
downstream experiments. 
2.7.2 Whole transcriptome sequencing - RNA sequencing (RNASeq)  
Total RNA sequencing (RNASeq) was performed using RNA extracted from 20 FFPE 
samples (10 MT vs 10 NT). RNA samples were assessed for quantity and integrity 
using the NanoDrop 8000 spectrophotometer V2.0 (Thermo Fisher Scientific, USA) 
and Agilent 2100 Bioanalyser (Agilent Technologies, Waldbronn, Germany). From 
each sample, 100ng of total RNA was used to prepare RNA libraries using the KAPA 
Stranded RNASeq Kit with RiboErase (KAPA Biosystems, Massachusetts, USA). 
Prior to first strand cDNA synthesis, fragmentation was carried out using incubation 
conditions recommended by the manufacturer for degraded samples (65°C for 1 
minute), and 14 cycles of PCR were performed for final library amplification. The 
libraries produced were quantified using the Qubit 2.0 spectrophotometer (Life 
Technologies, California, USA) and assessment of the average fragment size was 
performed using the Agilent 2200 Tapestation (Agilent Technologies, Waldbronn, 
Germany). The Illumina NextSeq®500 (Illumina Inc., Cambridge, UK) was used to 
generate 75bp paired-end reads for each library.  
2.7.3 Bioinformatic analysis of RNASeq data 
Bioinformatic analysis was performed by Mr. John Casement from the Bioinformatics 
Support Unit of Newcastle University. FastQ files generated from the sequencing 
runs were downloaded from the Illumina server using BaseMount, the command line 
interface for Illumina BaseSpace. Read quality of the FastQ files generated from the 
sequencing run were assessed using FastQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc) and MultiQC 
(http://multiqc.info) was used to obtain summary statistics for quality control tests on 
the read quality. Reads were quantified against transcripts using “Kallisto” (Bray et 
al., 2016). Kallisto is a program for quantifying abundances of transcripts from 
RNASeq data, which determines the compatibility of reads with targets without the 
need for alignment. The summarised Kallisto workflow is as follows: 
• (1) Build index file using the “kallisto index” command. The index was built from 
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Gencode transcript FASTA files (Gencode version 24: 
http://www.gencodegenes.org/releases/24.html)   
• (2) Run the quantification algorithm “kallisto quant” for each pair of forward (R1) 
and reverse (R2) FastQ files against the index. 
Kallisto was used to quantify reads against transcripts. To obtain gene-level counts, a 
package from the R statistical programming language (R Foundation for Statistical 
Computing, Vienna, Austria), “tximport” was used. Gene annotation was obtained 
from Ensembl transcript IDs using the R package “biomaRt” (Durinck et al., 2005). 
The R package DESeq2 was used for normalisation and testing for differential gene 
expression by use of negative binomial generalised linear models (Love et al., 2014). 
Genes were considered to be significantly differentially expressed when the False 
Discovery Rate (FDR) using the Benjamini-Hochberg method corrected p-value was 
less than 0.05.  
2.7.4 NanoString experiments 
The NanoString nCounter system (NanoString Technologies, Seattle, USA) uses 
hybridisation of short length probes (35- to 50- base sequence) that are subsequently 
fixed to a biotin-coated cartridge which is then digitally imaged and counted to 
quantify mRNA expression. In-depth details regarding NanoString technology can be 
obtained from Geiss et. al. (2008). NanoString sample processing was carried out at 
the Human Dendritic Cell Laboratory, Institute of Cellular Medicine, Newcastle 
University using the nCounter MAX/FLEX system (NanoString Technologies, Seattle, 
USA) with the kind assistance of Ms. Anastasia Resteu. The experiment involved two 
stages: 
• Stage 1: Differential gene expression experiment using the PanCancer 
Pathways Panel Plus of target genes  
• Stage 2: Differential gene expression experiment using a customised list of 
target genes  
Experiments were performed using previously extracted RNA from selected FFPE 
blocks as described in section 2.7.1. Each assay comes with engineered External 
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RNA Controls Consortium (ERCC) synthetic internal negative and positive control 
probes. 
For the PanCancer Pathways Panel Plus, an additional ten probes targeting specific 
mRNA (Appendix D) were added to the pre-existing 770 gene list available in the 
PanCancer Pathways Panel. The additional targets were chosen from statistically 
significant differentially expressed genes from the earlier RNASeq experiment (FDR 
< 0.05 and fold change greater than 2). The selection of these additional candidate 
genes was based upon biological relevance and review of the relevant literature. This 
was discussed with and finalised through consensus by members of the Newcastle 
University Oral Cancer Research Group (OCRG). This experiment was performed 
using RNA extracted from 48 FFPE samples (25 NT and 23 MT cases). RNA 
samples were assessed for quantity and quality using the NanoDrop 2000 
Spectrophotometer (Thermo Fisher Scientific, UK). Samples were considered 
suitable for the NanoString experiment if the A260/A280 ratio was between 1.7 – 2.3 
and the A260/A230 ratio was between 1.8 – 2.3 (NanoString, 2016). RNA content for 
all samples was normalised to 30ng/μl and 5 μl (150ng of total RNA) per sample was 
used for the experiment [Dr Jim White, Senior Field Application Specialist, 
NanoString Technologies; personal communication]. The summarised laboratory 
workflow for the NanoString nCounter assay using the PanCancer Pathways Panel 
Plus according to the manufacturer's protocol is listed in Appendix E (NanoString, 
2016).  
For the Customised CodeSet Panel experiment, a list of target genes was compiled 
based on the results from the RNASeq experiment, NanoString PanCancer 
Pathways Panel Plus experiment and review of relevant scientific literature. The 
selection of candidate genes for this customised panel was discussed and finalised 
through consensus by members of the Newcastle University Oral Cancer Research 
Group (OCRG) and the gene list is shown in Appendix F. This experiment was 
performed using RNA extracted from 44 FFPE samples (24 NT and 20 MT) and four 
OED cell lines. RNA samples were assessed for quantity and quality using the 
NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific, UK). Samples were 
considered suitable for the NanoString experiment if the A260/A280 ratio was 
between 1.7 – 2.3 and the A260/A230 ratio was between 1.8 – 2.3 (NanoString, 
2016). RNA content for all samples was normalised to 30ng/μl and 5 μl (150ng of 
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total RNA) per sample was used for the experiment. The summarised laboratory 
workflow for the Customised CodeSet Panel gene expression assay according to the 
manufacturer's protocol is listed in Appendix G (NanoString, 2016). 
Output from the nCounter Platform was quality assured using the quality control (QC) 
function in the nSolver analysis software 3.0 (NanoString Technologies, Seattle, 
USA). The following parameters were assessed during the QC function for each 
sample: 
• Imaging QC:  measure of the percentage of requested fields of view 
successfully scanned in each cartridge lane (75% cut-off) 
• Binding Density QC: measure of reporter probe density on the cartridge 
surface within each sample lane (range between 0.05 – 2.25) 
• Positive Control Linearity QC: measure of correlation between the counts 
observed for the ERCC synthetic positive control probes and the 
concentrations of the spike-in synthetic target nucleic acids (0.95 cut-off) 
• Positive Control Limit of Detection QC:  measures the limit of detection by 
comparing results from positive control probes and negative control probes 
(0.5fM positive control probe should produce raw counts of > 2 standard 
deviations higher than the mean of the negative control probes) 
2.7.5 Differential gene expression analysis of NanoString data 
Differential gene expression data analysis between MT and NT groups was 
performed using the nSolver Analysis Software 3.0 (NanoString Technologies, 
Seattle, USA). Prior to the DGE analysis, the raw data were normalised in a two-step 
manner. Firstly, the raw counts were background subtracted using the geometric 
mean of the internal negative controls followed by technical normalisation using the 
geometric mean of the internal positive controls. Subsequently, the data were then 
normalised using the geNorm algorithm that chooses only the most stable 
housekeeping genes in the analysed dataset (Vandesompele et al., 2002). 
For the PanCancer Pathways Panel Plus experiment, genes were considered to be 
significantly differentially expressed when the False Discovery Rate (FDR) using the 
Benjamini-Hochberg method corrected p-value was < 0.1.  A False Discovery Rate 
(FDR) of < 0.1 was chosen to be significant for this experiment as this was an 
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exploratory experiment to find genes with altered expression between OPMD that 
undergo MT and those that do not. Setting the FDR rate too stringently could exclude 
key genes that may have been statistically significant if the cohort was larger. A 
hypergeometric test was carried out to identify Kyoto Encyclopaedia of Genes and 
Genomes (KEGG) pathways in which differentially expressed genes were over-
represented. KEGG pathways were rendered using Pathview (Luo and Brouwer, 
2013). 
For the Customised CodeSet Panel experiment, genes were considered to be 
significantly differentially expressed when the False Discovery Rate (FDR) using the 
Benjamini-Hochberg method corrected p-value was < 0.05. Raw and log2 normalised 
counts of significant differentially expressed genes were then exported in a CSV file 
to be used for statistical analysis and model building. Log2 normalised counts of the 
significant differentially expressed genes between MT and NT cases were then 
dichotomised using the respective medians into low-expression and high-expression 
sub-groups for further analysis [Dr Kim Pearce and Dr Syed Haider; personal 
communication]. 
2.7.6 Development of gene-signature for clinical outcome in OPMD 
Development of a gene-signature was performed by fitting the dichotomised (low-
expression; high-expression) log2 normalised gene expression of significant 
differentially expressed genes between MT and NT cases from the Customised 
CodeSet experiment into a Cox regression (proportional hazards regression) model 
using a stepwise method. The b-coefficients from the gene-signature model were 
used to obtain risk scores and the resultant risk scores were then dichotomised into 
risk groups (low-risk and high-risk) using the median of the risk scores [Dr Kim 
Pearce and Dr Syed Haider; personal communication].  
2.8 Statistical Analysis and Prognostic Model Building 
Statistical analysis and prognostic model building were performed using IBM SPSS 
for Windows (version 24, IBM-SPSS Inc., Chicago, Illinois, USA) and the R 
Environment for Statistical Computing version 3.2 (R Foundation for Statistical 
Computing, Vienna, Austria). The selection and interpretation of specific tests was 
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informed by discussions with Dr Kim Pearce from Newcastle University and Dr Syed 
Haider from the Institute of Cancer Research, London. 
A variety of methods were used to assess and analyse the data. Continuous data 
was always assessed for normality of distribution prior to choosing appropriate 
statistical tests. Parametric and non-parametric tests were used for initial analysis of 
demographic, clinical, pathological and molecular variables. For continuous data, 
descriptive results were appropriately expressed as either median with interquartile 
range (IQR) or mean with standard deviation (SD). For crosstabulations and chi-
squared tests, exact p-values were calculated where possible. Cohen’s kappa 
coefficient statistics was used to measure the level of agreement for OED grading 
between Pathologist A and Pathologist B (Cohen, 1960; Cohen, 1968). The kappa 
scores were interpreted based on the study by Landis and Koch (1977) (Landis and 
Koch, 1977). 
Differential gene expression data analyses between MT and NT groups were carried 
out and genes were considered to be significantly differentially expressed where the 
False Discovery Rate (FDR) using the Benjamini-Hochberg method corrected p-value 
was < 0.05 except for the PanCancer Pathways Panel Plus experiment, where the 
FDR value was set at the 10% level (< 0.10). Principal component analysis (PCA), an 
unsupervised method to summarise complex data that has high dimensionality into 
fewer dimensions whilst attempting to find patterns without knowing the clinical 
outcome of the samples was also performed. 
Univariate analysis and multivariate analysis were performed using Cox regression 
(proportional hazards regression) analysis. The proportional hazard assumption for 
each variable was also assessed prior to Cox regression analysis. Multivariate 
analysis was performed using variables that were considered to be clinically relevant 
and/or statistically significant from preliminary statistical analyses. Multivariate 
analysis was performed to determine the variables that independently contributed to 
clinical outcome as well as to formulate a suitable prognostic model composed of 
different variables (clinical, pathological or molecular variables). During multivariate 
regression analysis, covariates were selected using a stepwise procedure. Statistical 
significance was defined at the 5% level. The concordance index (Harrel’s c-index) 
for each model was also calculated (Harrell et al., 1996). Confidence intervals (CI) at 
the 95% confidence level were reported where relevant. Statistically significant 
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variables from the regression analysis were then used to build a prognostic model for 
patients with OPMD. Assessment of biomarkers was performed guided by the 20-
point recommendations made in the “Reporting Recommendations for Tumour 
Marker Prognostic Studies (REMARK)” checklist (Appendix A) (McShane et al., 
2005). 
Only complete-case analysis was performed for multivariate analysis; cases with 
missing data-points were excluded from statistical model building. Multivariate 
prognostic statistical model construction and validation were performed guided by the 
recommendations in the “Transparent Reporting of a multivariable prediction model 
for Individual Prognosis or Diagnosis (TRIPOD) Statement” checklist (Collins et al., 
2015; Moons et al., 2015). The TRIPOD statement is composed of a 22-item 
checklist (Appendix B) that covers a minimum set of recommendations focusing on 
how the study was designed, performed, analysed and interpreted (Collins et al., 
2015; Moons et al., 2015).  
Receiver operating characteristic (ROC) curves were generated by plotting the 
cumulative frequency distribution of a variable/model score for predicting MT. ROC 
curves plot sensitivity (true positive rate) against 1 – specificity (false positive rate) 
and provide a graphical representation of the performance of a prognostic 
variable/model in a binary outcome situation.  
Area under the curve (AUC) from the ROC curves generated from different 
independent variables and statistical models were used to assess the 
performance/efficacy of the variables or models. Time to event analysis was also 
performed and Kaplan-Meier curves were generated to assess the influence of 
independent variables as well as prognostic models on time to event (MT) using the 
Log Rank test. All statistical tests were two-sided, and results were considered 
statistically significant at p < 0.05 value unless stated otherwise; the Exact method 
was used for calculating p-values where relevant. 
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Table 2.1 Amount of formalin-fixed paraffin-embedded tissue used for molecular 
experiments according to sample size  
Sample size DNA ploidy 
analysis 
Loss of 
heterozygosity 
(LOH) 
analysis 
Differential 
gene 
expression 
(DGE) 
experiments 
Small sized 
samples  
 
 
 
50µm x  
(4 to 7) 
sections* 
4µm x  
(12 to 14) 
sections 
10µm x 
4 sections 
Medium sized 
samples 
4µm x  
(8 to12) 
sections 
10µm x 
(3 to 4) 
sections 
Large sized 
samples 
4µm x  
(6 to 8) 
sections 
10µm x  
(2 to 3) 
sections 
Very large sized 
samples 
4µm x  
(3 to 6) 
sections 
10µm x  
(1 to 2) 
sections 
* Ideally 8mm epithelial length x 6 sections 
 
Table 2.2 Microsatellite markers for LOH analysis 
Marker Loci Position on chromosome 
D3S1766 3p14.2 58956715-58956927 
D3S1029 3p21.33 44110861-44111030 
D3S1293 3p24.3 21902207-21902338 
D9S171 9p21 24524210-24524384 
D9S162 9p22.1 19669807-19669992 
D9S157 9p22.2 17618382-17618526 
CHRNB1 17p13.1 7290301-7290466 
TP53 17p13.1 7558143-7558252 
D17S1866 17p13.3 82571-82745 
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Table 2.3 Optimised PCR cycling protocol 
Step Temperature Time Cycle(s) 
Initial activation  95°C 15 minutes 1 
Denaturation 95°C 1 minute  
35 Annealing 60°C 1 minute 
Extension 72°C 1 minute 
Final extension 72°C 10 minutes 1 
 
Table 2.4 Characteristics of OED cell lines cultured. 
Cell 
line 
Age 
(years) 
Sex Smoker Site Lesion OED grade  
D4 51 M Yes FOM/VT Leukoplakia Severe  
D19 53 M Yes LT Erythroleukoplakia Severe  
D20 50 M No LT Leukoplakia Moderate  
D35 68 M Yes FOM/VT Erythroleukoplakia Severe  
* M = Male; FOM = floor of mouth; VT = ventral tongue; LT = lateral tongue; OED = 
oral epithelial dysplasia;  
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Figure 2.1 Workflow of the histopathological assessment process.  
MR: Dr Max Robinson; HS: Hans Sathasivam; PS: Professor Phil Sloan. Adapted from 
Speight et al (2015). 
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Chapter 3. Clinical and Histopathological Parameters  
 
3.1 Introduction 
Risk stratification and management strategies for patients with OPMD at most 
centres are based on the demographic and clinico-pathological features of the patient 
such as age, sex, smoking history, type of OPMD and OED grading (van der Waal, 
2009; Awadallah et al., 2018; Speight et al., 2018). However, such methods are not 
very accurate as some patients stratified as being low-risk using such parameters still 
experience malignant transformation (Holmstrup et al., 2006; van der Waal, 2009; 
Warnakulasuriya et al., 2011; Sperandio et al., 2013; Dost et al., 2014; van der Waal, 
2014). This chapter examines the relationship between demographic as well clinico-
pathological parameters of the study cohort and clinical outcome.  
3.1.1 Demographic and clinical parameters 
A few demographic and clinical factors have been found to be correlated to increased 
risk of malignant transformation (MT) in OPMDs (Table 1.4) (Speight, 2007; van der 
Waal, 2009; Warnakulasuriya et al., 2011; El-Naggar et al., 2017; Speight et al., 
2018). However, many of these factors are not particularly good as prognostic 
indicators especially when used individually. Combining the demographic and clinical 
parameters for risk stratification of OPMD patients though imperfect is commonplace. 
Clinical parameters are usually augmented by histopathological findings from 
incisional biopsies to guide patient management (Epstein et al., 2012; Forman et al., 
2015; National Institute for Health and Care Excellence, 2015a). Data of several 
demographic and clinical parameters were obtained and analysed to ascertain 
correlation with clinical outcome. Unfortunately, it was not possible to obtain 
complete information regarding risk habits (tobacco usage, alcohol consumption etc) 
for all patients and as such these parameters were excluded from further analysis. 
3.1.2 Oral epithelial dysplasia (OED) 
There have been several classification systems that have been proposed over the 
years for oral epithelial dysplasia (OED) grading (Warnakulasuriya et al., 2008) with 
the recently published WHO reference text on head and neck tumours elaborating on 
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two systems; the three-tiered WHO grading system and the binary grading system 
(El-Naggar et al., 2017). Grading systems developed thus far attempt to mirror the 
perceived spectrum of histologic changes in oral epithelium undergoing oral 
carcinogenesis from normal to severe OED to cancer. However, oral carcinogenesis 
is not likely to be a simple stepwise linear progression model. There is no established 
evidence of it following a simple progressive model of changes from normal 
epithelium to OED followed by oral squamous cell carcinoma (OSCC). This is proven 
by studies that show that OSCC can arise in oral mucosa that is histologically non-
dysplastic/mildly-dysplastic and conversely, severely dysplastic oral epithelium may 
regress or remain unchanged (Gupta et al., 1980; Silverman et al., 1984; Holmstrup 
et al., 2006; Arduino et al., 2009; Dost et al., 2014; Goodson et al., 2015; Kuribayashi 
et al., 2015). For this study, both the WHO 2017 and binary OED grading systems 
were used to grade OED. Data were then analysed to ascertain the relationship 
between OED grading and clinical outcome. 
3.1.3 Oral potentially malignant disorder (OPMD) associated leukocytes score 
(OPALS) 
A prominent sub-epithelial leukocytic infiltrate is not an infrequent finding in 
conjunction with OPMD or oral epithelial dysplasia (OED) and its presence can at 
times mimic inflammatory conditions affecting the oral cavity such as oral lichen 
planus histologically (Eisenberg and Krutchkoff, 1992; Eisen, 2002; Muller, 2011). 
Previously the term “lichenoid dysplasia” was introduced by Krutchkoff and Eisenberg 
(1985) to describe dysplastic oral lesions with lichenoid features (Krutchkoff and 
Eisenberg, 1985). This term however is quite misleading and such lesions are now 
more commonly described as either oral epithelial dysplasia with lichenoid 
inflammation/lichenoid features/lichenoid mucositis/interface mucositis. Fitzpatrick et 
al (2014) in a recent study showed that up to 39% of mild to moderate dysplasia and 
16% of severe dysplasia specimens in their study had a positive overall score for 
focal lichenoid features ( ³ 3 lichenoid features) (Fitzpatrick et al., 2014b). The most 
frequently encountered lichenoid feature in their study was the presence of a band-
like inflammatory infiltrate (Fitzpatrick et al., 2014b). This is suggestive that a 
prominent sub-epithelial inflammatory infiltrate is not specific for oral lichen planus 
and may arise in conjunction with OED. It is hoped that through the assessment of 
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OPMD associated leukocytes (OPAL) in this cohort of patients, a clearer picture 
regarding the prognostic significance of OPAL in OPMD patients can be obtained. 
3.1.4 High-risk human papillomavirus (HR-HPV) infection 
The association between high-risk human papillomavirus (HR-HPV) infection and 
oropharyngeal squamous cell carcinoma (OPSCC) has been well established and in 
recent years several groups have managed to identify and characterise HPV-
associated oral epithelial dysplasia (OED) (McCord et al., 2013; Woo et al., 2013). 
HPV-associated OED is defined by specific histopathological features together with 
the demonstration of HR-HPV by molecular methods such as DNA/RNA in situ 
hybridisation (ISH) (McCord et al., 2013; El-Naggar et al., 2017). Strong and diffuse 
nuclear and cytoplasmic expression of p16 by immunohistochemistry is consistently 
observed in HPV-related cervical intraepithelial neoplasia and OPSCC, as such, it is 
a useful surrogate marker for HR-HPV in HPV-associated OED but secondary testing 
for HR-HPV using molecular methods is currently recommended to diagnose HPV-
associated OED (McCord et al., 2013; El-Naggar et al., 2017). The influence and role 
of HR-HPV infection on development and clinical outcome of OPMD is still unclear as 
there are no studies with long-term follow up data (Angiero et al., 2010; Lopes et al., 
2011; Lingen et al., 2013; McCord et al., 2014; Nankivell et al., 2014; El-Naggar et 
al., 2017; Lerman et al., 2017; Muller, 2018; Speight et al., 2018). HPV-related oral 
squamous cell carcinoma may actually be a completely different disease from 
traditional non-HPV related OSCC. As such, identifying HPV-associated OED and 
performing sub-group analysis for clinical studies on OPMD/OED is desirable. All the 
cases chosen for the molecular arm of this study were assessed for HR-HPV 
infection using both p16 immunohistochemistry (IHC) and HR-HPV DNA in-situ 
hybridisation (DNA ISH).  
3.2 Aims 
The aims of this chapter are:  
1) To summarise the case selection process of OPMD patients that were suitable for 
this study as well as selection of the cohort to be assessed using molecular methods 
(training cohort) described in Chapters 4, 5 and 6. 
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2) To describe the demographic and clinical features of the overall OPMD cohort as 
well as the sub-groups. 
3) To assess and correlate demographic and clinical features as prognostic 
parameters for OPMD patients. 
4) To assess and correlate oral epithelial dysplasia (OED) grading as a prognostic 
instrument for OPMD as well as to compare the efficacy of two different OED grading 
systems in prognosticating clinical outcome in patients with OPMDs. 
5) To describe and assess the relationship between OPAL and clinical outcome in 
OPMDs. 
6) To describe and assess the prevalence and association between high-risk human 
papillomavirus (HR-HPV) infection and clinical outcome in OPMDs. 
 
3.3 Results 
3.3.1 Case selection 
OPMD cases for the training cohort were obtained from a clinical database. Briefly, 
301 cases were assessed for eligibility and 135 cases were excluded. Ninety-eight 
cases were excluded as they did not meet the inclusion criteria and a further 37 
cases were excluded as the FFPE tissue blocks could not be obtained from the 
archives. There were 166 cases that were suitable for this study. Sixty-five cases 
were selected for downstream molecular experiments based on the amount of FFPE 
tissue available. A balanced number of malignant transforming and non-transforming 
cases were selected for the molecular experiments; 30 malignant transforming (MT) 
vs 35 non-transforming (NT). The flow chart displayed in Figure 3.1 summarises the 
case selection process for this study. 
3.3.2 Demographic and clinical parameters 
The demographic and clinical features of the 166 cases that were found suitable for 
this study are shown in Table 3.1. Mean patient age at diagnosis of the index lesion 
was 58.79 (SD ±12.81) years of age. There was a male predominance in this cohort 
(62.7%). Leukoplakia was the most frequently encountered OPMD (85.5%) and the 
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tongue was the most frequent site for the index lesions (34.3%). Only time to 
malignant transformation/last-follow-up was significantly different between the MT 
and NT cases (p = 0.015; Mann-Whitney U test), with the median time to MT being 
41 months (range: 7 – 128 months) and for NT cases the median follow-up time was 
61 months (range: 12 – 215 months). No other clinical variable was significantly 
associated with clinical outcome when analysis was performed using the 166-patient 
cohort (p > 0.05).  
Table 3.2 shows the demographic and clinical characteristics of the 65 cases chosen 
for the molecular experiments in this study. There were 30 MT cases in the selected 
cohort versus 35 NT cases. The mean age at diagnosis of OPMD was 60.00 years 
(SD = 13.29) and the majority were males (n = 44; 67.7%). The cohort of patients 
with OPMD that underwent MT was older with a male preponderance although these 
findings were not statistically significant (Table 3.2 and Figure 3.2). When cases were 
divided according to those aged £ 50 and > 50, there was a statistically significant 
relationship between age at diagnosis and clinical outcome (p = 0.046; c2= 4.74; df = 
1). The non-transforming (NT) cases were followed-up for a median of more than 10 
years whilst the median of MT cases occurred within 3 years of diagnosis. 
There was a statistically significant relationship between site of index OPMD and 
clinical outcome (p = 0.028; c2= 10.18; df = 4). The tongue was the most commonly 
involved site that underwent MT, however, when analysis was performed after re-
categorising site into tongue versus at all other sites, site of index OPMD was not 
statistically significant (p = 0.065). Most of the cases that underwent MT were 
clinically diagnosed as leukoplakia, but this was not statistically significant (p = 
0.650).  
3.3.3 Oral epithelial dysplasia (OED) 
Results from the oral epithelial dysplasia (OED) grading assessment are shown in 
Tables 3.3 to 3.5. OED for each case was graded according to the worst area in the 
specimen.  
There were five cases that had no obvious OED in the overall cohort, one of which 
underwent MT. The one non-dysplastic case that underwent MT only transformed to 
cancer after more than 10 years of being diagnosed with an OPMD. When analysis 
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was performed on all 166 cases (Table 3.3; including non-dysplastic cases), only the 
binary grading system was significantly correlated with clinical outcome (p = 0.016; 
c2= 8.41; df = 2). Inter-rater agreement between the two pathologists (MR and HS) 
using weighted kappa scoring was 0.822 (p < 0.001; Cohen’s k) for the WHO 2017 
OED grading system and 0.833 (p-value of < 0.001; Cohen’s k) for the binary OED 
grading system. The binary OED grading was found to outperform the WHO 2017 
grading system when it comes to prognosticating clinical outcome for OPMD and this 
finding was statistically significant (Figure 3.3). Time to event analysis on the cohort 
of patients with OED (n = 161) showed that binary grading system was statistically 
significant (Figure 3.4; Log rank test; p = 0.003;  c2= 9.05; df = 1). 
Analysis of the grading systems showed that there were statistically significant 
associations between OED grading (binary and WHO 2017 systems) and site of 
index OPMD as well as type of OPMD (Tables 3.4 and 3.5). The association between 
“tongue” as the site of index OPMD and OED grading systems was statistically 
significant after sub-analysis was performed by combining the other oral sub-sites 
(Tables 3.4 and 3.5).  
Results of the OED grading exercise on the 65 cases selected for downstream 
assays are shown in Table 3.6. Inter-rater agreement between the two pathologists 
(MR and HS) for the WHO 2017 OED grading system was 0.709 (p < 0.001; 
weighted Cohen’s k) and 0.814 (p-value of < 0.001; weighted Cohen’s k) for the 
binary OED grading system. There was statistically significant correlation between 
the binary OED grading system and clinical outcome (p = 0.026;  c2= 5.464; df = 1). 
The WHO 2017 grading system however was not statistically significant (p > 0.05). 
Time to event analysis on this cohort of patients (Figure 3.5) again showed that the 
binary grading system was statistically significant (Log rank test; p = 0.012;  c2= 6.34; 
df = 1). The binary grading system was shown to have good negative predictive 
values for clinical outcome (Table 3.7).  
3.3.4 Oral potentially malignant disorder (OPMD) associated leukocyte score 
(OPALS) 
The summarised results of OPALS from the 166 and 65 patient cohorts is shown in 
Table 3.8 and Table 3.9 respectively. There was a statistically significant relationship 
between OPALS and both the WHO 2017 grading system (p = 0.001;  c2= 15.841; df 
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= 3) and binary grading system (p = 0.004;  c2= 10.384; df = 2) in the 166-patient 
cohort. Higher grades of OED were found to be more frequently OPALS positive 
(Table 3.8). Clinical features were not statistically significantly associated with 
OPALS in the 166-patient cohort (p > 0.05). Time to event analysis showed that there 
was no statistically significant relationship between OPALS and clinical outcome in 
the 166-patient cohort (Figure 3.6). 
However, when analysis was performed using the 65-patient cohort, only the 
association between clinical outcome and OPALS was statistically significant (p = 
0.026;  c2= 5.251; df = 1) and other clinico-pathological features such as type of 
OPMD, site of index OPMD and OED grading were found to have no statistically 
significant association with OPALS (p > 0.05).  
3.3.5 High-risk human papillomavirus (HR-HPV) infection 
Assessment for high-risk human papillomavirus (HR-HPV) infection was performed in 
a two-tiered manner as described in Section 2.3.3. All 65 cases selected for the 
molecular arm of the study were tested for p16 using IHC. Only seven cases showed 
p16 staining. These cases were then tested for HR-HPV using DNA ISH and only 
three cases (4.6 %) were positive, two from the NT and one from the MT sub-groups. 
HR-HPV infection was not correlated to clinical outcome in this cohort of 65 patients 
(p = 1.000).  
3.4 Discussion 
Overall, from the 166 cases that were found to be suitable for the study, 32 cases 
(19.3%) had undergone MT. This figure however does not represent the true 
incidence or prevalence rate of MT in OPMD patients as not all patients with OPMD 
from the centre were included in the study. Previous studies on a cohort of OPMD 
patients seen at a single institution in Newcastle upon Tyne have reported the 
incidence of MT in OPMD patients to be around 4.8% (Thomson et al., 2017a; 
Thomson et al., 2017b). However, this figure would not be a true representation of 
the population and may be an overestimation due to referral bias as this is a referral 
centre based (hospital-based) cohort.  
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3.4.1 Demographic and clinical parameters 
In this study, the majority of patients were aged above 50 years at time of diagnosis 
with OPMD, however the age range of the cohort was rather wide; 23 to 93 years. It 
would appear that patients with non-transforming (NT) OPMD were younger than 
those that underwent malignant transformation (MT), with those older than 50 years 
of age at diagnosis being more likely to have MT, however the findings were not 
statistically significant for this study. This finding has been documented by several 
earlier studies and a recent review has mentioned that a moderate association with 
risk to malignant transformation in OPMD is found in patients aged more than 50 
years old (Einhorn and Wersall, 1967; Banoczy and Sugar, 1972; Mehta et al., 1972; 
Gupta et al., 1980; Schepman et al., 1998; Napier and Speight, 2008; 
Warnakulasuriya et al., 2011; Speight et al., 2018). 
As OPMDs are chronic disorders, it is to be expected that the number of cases 
undergoing MT will increase over time in a given cohort, however, many studies have 
reported that the majority of cases that undergo MT do so within a span of 5 years 
from the date of initial presentation (Silverman et al., 1984; Lind, 1987; Schepman et 
al., 1998; Mehanna et al., 2009). This was also the case for our study, with 71.9% of 
MT occurring within 5 years from date of initial presentation/diagnosis with the 
median time to MT being 41 months. There was one case in the molecular 
experiment cohort that developed OSCC after more than 10 years (128 months) of 
being diagnosed with an OPMD. This emphasizes the fact that though the risk of MT 
may diminish after 5 years, it does not disappear completely. 
Although there were more male patients with OPMD, there was no statistically 
significant association between sex and clinical outcome in this cohort.  Historically, 
females have been considered to have a higher risk for MT (Silverman et al., 1984; 
Schepman et al., 1998; Cowan et al., 2001; Amagasa et al., 2006; Speight, 2007; 
Napier and Speight, 2008; Speight et al., 2018) however numerous studies have 
shown either a male predilection or no obvious difference between the sexes when it 
comes to MT (Einhorn and Wersall, 1967; Gupta et al., 1980; Hsue et al., 2007; 
Arduino et al., 2009; Warnakulasuriya et al., 2011; Ho et al., 2012; Goodson et al., 
2015; Bates et al., 2016). 
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The majority of OPMDs in this study were leukoplakias (85.5%), and due to the small 
numbers of other types of OPMD in this cohort, no statistically significant association 
between clinical outcome and type of OPMD was found. Although the literature is 
suggestive that erythroplakia has the highest risk of MT amongst OPMDs (Reichart 
and Philipsen, 2005; El-Naggar et al., 2017), due to the relative rarity of 
erythroplakia, the true rate of MT is yet unknown.  
There was a statistically significant association between site of index OPMD and 
clinical outcome for this cohort with MT being more frequently seen with lesions from 
the tongue, though on further sub-analysis (by combining sub-categories) this 
significance was not apparent. Association between OPMD on the tongue and 
increased malignant transformation is consistent with the findings of a recent meta-
analysis on follow-up of oral dysplasia by Mehanna et al (2009) as well as a 
systematic review of malignant transformation in oral leukoplakia by Warnakulasuriya 
and Ariyawardana (2016) (Mehanna et al., 2009; Kuribayashi et al., 2015; 
Warnakulasuriya and Ariyawardana, 2016). All the tongue lesions in this cohort 
involved either the lateral or ventral or latero-ventral surfaces of the tongue.  
Although the tongue and floor of mouth regions have been described as being “high-
risk” areas for the development of OSCC because of prolonged exposure to 
carcinogens due to saliva pooling (Reibel, 2003; El-Naggar et al., 2017), the location 
and subsequent progression to cancer of an OPMD may be related to the aetiologic 
factors that contributed to its development in the first instance. This is best illustrated 
by risk factor habits such as reverse smoking and betel-quid chewing; where betel-
quid chewers will have an increased tendency to have lesions on the buccal mucosa 
whilst reverse smokers tend to have lesions on the palate (Gupta et al., 1980; 
Warnakulasuriya and Ariyawardana, 2016; Speight et al., 2018). As such, site of 
OPMD may be a prognostic indicator for clinical outcome, however due consideration 
should be given to risk factor habits and geographical variation. Unfortunately, risk 
factor habits such as tobacco usage and alcohol consumption could not be assessed 
in this cohort of patients due to incomplete medical records regarding these features.  
3.4.2 Oral epithelial dysplasia (OED) 
Presence and severity of OED in biopsy specimens is one of the most frequently 
used prognostic method to direct treatment and management of OPMDs worldwide 
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(Warnakulasuriya et al., 2008; van der Waal, 2009; El-Naggar et al., 2017; Speight et 
al., 2018). Even though demographic and clinical parameters may be useful for 
clinical risk assessment, diagnostic biopsies and histopathological assessment are 
considered paramount to rule out malignancy and other pathologies that may mimic 
OPMDs as well as to provide a measure of cytological atypia and architectural 
changes that have occurred in the tissue to help with risk assessment. The measure 
most commonly used to communicate the level of cytological atypia and architectural 
disruption in oral epithelia is dysplasia grading. However, not all OED will undergo 
malignant change as shown by two recent systematic reviews on the topic of MT in 
OED, with MT observed in only around 10 – 12% of patients with OED (Mehanna et 
al., 2009; Shariff and Zavras, 2015). 
Intra- and inter-rater agreement has been shown to be a major issue associated with 
currently used OED grading systems (Abbey et al., 1995; Fischer et al., 2004; 
Warnakulasuriya et al., 2008; Dost et al., 2014). Some authors have suggested using 
a binary grading system to reduce intra- and inter-rater variation and improve 
prognostic strength (Kujan et al., 2006; Kujan et al., 2007; Nankivell et al., 2013). The 
present study confirms the improvement of the inter-rater agreement when using the 
binary grading system using weighted kappa scoring, however the scores for both 
systems were similar in value in the larger cohort; with a high level of agreement 
between the pathologists (Landis and Koch, 1977). A reason as to why there was an 
improvement in the inter-rater agreement for the WHO 2017 OED grading system as 
compared to previous studies is possibly because of the reduced number of levels in 
the new WHO 2017 system compared to the previous WHO 2005 system (Kujan et 
al., 2006; Kujan et al., 2007; Nankivell et al., 2013; El-Naggar et al., 2017). One way 
to improve the prognostic ability of OED grading and reproducibility is through 
consensus grading exercises especially for cases that are difficult to classify as being 
either low- or high-grade (Kujan et al., 2007; Warnakulasuriya et al., 2008; Speight et 
al., 2015; El-Naggar et al., 2017). 
Although the binary grading system was statistically significant as a prognostic 
indicator, the sensitivity and specificity levels for predicting which OPMD would 
undergo MT were found to be lacking with very low positive predictive values as well. 
One of the reasons why OED grading will almost always be found to be lacking is the 
fact that the grading is a snapshot of a supposedly “representative” portion of the oral 
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lesion. An incisional biopsy may not actually be representative of the true overall 
pathology due to poor or inadequate sampling. This is well illustrated by studies in 
which the authors describe “unexpected” OSCC in excision specimens of lesions 
where the incisional biopsies were diagnosed with either OED or non-dysplastic 
lesions (Giunta et al., 1969; Pentenero et al., 2003; Holmstrup et al., 2007; Lee et al., 
2007; Thomson et al., 2017a; Thomson et al., 2017b). Such incidences where the 
results from the index biopsy is perceived to have “under-diagnosed” the case are 
most likely the result of non-representative sampling during the incisional/index 
diagnostic biopsies (Holmstrup et al., 2007; Lee et al., 2007; Chen et al., 2016). 
Another possibility could be that the malignant transformation occurred during the 
period between incisional biopsy and surgical excision.  
To overcome this problem, some clinicians advocate “field-mapping” or multiple 
incisional biopsies, whereby small samples are obtained from various regions of the 
lesional area (Lee et al., 2007; Thomson and Hamadah, 2007; van der Waal, 2009). 
Although this may reduce the probability of inadequate or non-representative 
sampling it does not eliminate the possibility of missing the lesion that has the 
highest risk of MT. Other attempts have also been made in developing tools and 
methods to improve screening and detection of OPMDs such as using toluidine blue 
dye, brush biopsy sampling, fluorescence-based methods and also light 
reflectance/absorption methods (Lingen et al., 2008; Rashid and Warnakulasuriya, 
2015; Spivakovsky and Gerber, 2015; Lingen et al., 2017; Yang et al., 2018). 
However, none of these adjunct methods have been conclusively proven to improve 
detection of OPMDs or increase accuracy of biopsy sampling (Lingen et al., 2008; 
van der Waal, 2009; Brocklehurst et al., 2013; Macey et al., 2015; Spivakovsky and 
Gerber, 2015; Lingen et al., 2017; Yang et al., 2018)  
Lack of prognostic ability is also compounded by “field-change” in OPMD patients. 
The concept of “field-change” in OPMDs is well established and is possibly one of the 
reasons why not all OSCCs arise from the site of index OPMD. As such, an OED 
grade based on a biopsy at one site is not truly representative of the whole oral 
mucosa (Holmstrup et al., 2007; van der Waal, 2009; Thomson et al., 2017a). The 
chronicity of OPMDs is another factor that possibly reduces the prognostic utility of 
OED grading; lesions that have been diagnosed as having mild or low-grade 
dysplasia on index biopsies maybe considered as having a lower risk of transforming 
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at that particular point in time, but that does not mean that the lesion is static in 
nature, with some lesions regressing and others becoming more dysplastic or 
progressing to cancer.  
Clinicians directly involved with patient management may view the binary grading 
system as being more “user-friendly” compared to the multi-tiered grading systems 
used traditionally. This is because of the difficulty faced by clinicians and pathologists 
in ascertaining the risk of malignant transformation related to those graded as being 
moderately dysplastic. The question always asked of the pathologist is whether these 
moderately dysplastic lesions should be observed or excised, a question that has no 
simple answer as was previously mentioned, even lesions with mild/low-grade OED 
can undergo MT; again, highlighting the shortcomings of OED grading in general. 
Although far from being perfect, due to the lack of any other established prognostic 
factors for clinical outcome in OPMDs, OED grading in conjunction with demographic 
and clinical findings is still the most utilised method to direct clinical management of 
OPMD patients (Napier and Speight, 2008; Warnakulasuriya et al., 2008; van der 
Waal, 2009; Macey et al., 2015; El-Naggar et al., 2017; Speight et al., 2018). 
However, using a histo-morphological method such as OED grading is bound to be 
inadequate to predict malignant change in OPMDs due to the complexity of oral 
carcinogenesis. This underlies the importance of discovering additional methods and 
biomarkers to augment the prognostic power of OED grading through multivariate 
prognostic models. 
3.4.3 Oral potentially malignant disorders (OPMD) associated leukocytes score 
(OPALS) 
Although in this study there was no statistically significant relationship between 
OPALS and clinical outcome (n = 166), the true clinical significance of OPMD 
associated leukocytes (OPAL) is as yet unconfirmed; whether the leukocytic infiltrate 
influences malignant transformation in OPMDs or is a response to the atypical 
epithelium and is somewhat protective is still unclear.  
Fitzpatrick et al (2014) in their study discovered that specimens with mild and 
moderate OED as well as OSCC specimens had more lichenoid features than cases 
with severe OED (Fitzpatrick et al., 2014b). However, in our study, high-grade and 
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severe OED were more frequently associated with OPAL. This difference may be due 
to the fact that the current study only looked at one lichenoid-type feature, sub-
epithelial inflammatory infiltrate, whilst Fitzpatrick et al (2014) looked at all lichenoid 
features (Fitzpatrick et al., 2014b). Additionally, it was not clear whether there were 
differences that could act as confounding factors (such as site of OED) between the 
OED and OSCC sub-groups in the study by Fitzpatrick et al (2014); sub-groups that 
have differing clinico-demographic features may have an impact on the presence and 
intensity of lichenoid features (Fitzpatrick et al., 2014b).  
The recently published review on the hallmarks of cancer by Hanahan & Weinberg 
(2011) highlights the importance of inflammation as an enabling factor for 
carcinogenesis (Hanahan and Weinberg, 2011). The relationship between chronic 
inflammation and cancer is rather complex; with some studies showing that long-
standing inflammatory conditions predisposes one to carcinogenic change as seen in 
colon cancer whilst other studies have suggested that inflammatory and immune 
responses may inhibit carcinogenesis (Balkwill and Mantovani, 2001; O'Byrne and 
Dalgleish, 2001; Mignogna et al., 2004; Mantovani et al., 2008; Colotta et al., 2009). 
The role of inflammatory infiltrates in OPMD and OED is even more poorly 
understood. Results from our study would suggest that in oral carcinogenesis, the 
presence of sub-epithelial inflammation may not be an enabling factor but more of a 
host response to eliminate atypical cells with the inflammatory response increasing in 
tandem with the grade of OED. This however needs to be investigated further using 
molecular techniques to precisely identify the population of inflammatory cells in 
OPAL and assess their possible roles in either promotion or antagonism of oral 
carcinogenesis. There is possibly complex interplay between different inflammatory 
cells within the stroma and tumour micro-environment which may also be influenced 
temporally (Allavena et al., 2008; Mantovani et al., 2008; Hanahan and Weinberg, 
2011; Feller et al., 2013; Ferris, 2015). 
3.4.4 High-risk human papillomavirus (HR-HPV) infection 
There have been many studies that have attempted to evaluate the association 
between HPV and oral precursor lesions with a recent systematic review suggesting 
that there may be a causal association between HPV and OPMDs (Syrjanen et al., 
2011). However, many of the studies included in this systematic review had a high 
risk of bias with all of them being case-control studies (Syrjanen et al., 2011).  
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There was a very low prevalence (4.6 %) of high-risk human papillomavirus (HR-
HPV) positivity in this cohort with only three cases fulfilling the criteria to be confirmed 
as HPV-associated OED. This prevalence rate is quite low compared to the 25.3% 
published in a recent meta-analysis on prevalence of HPV 16/18 in OED 
(Jayaprakash et al., 2011) and 37.1% published in a recent meta-analysis on 
detection of HPV in OPMDs (Syrjanen et al., 2011) but comparable to the prevalence 
of 3.5% for oral oncogenic HPV in healthy individuals published by Kreimer et al 
(2010) (Kreimer et al., 2010; Jayaprakash et al., 2011; Syrjanen et al., 2011).  
The high values for prevalence in OPMD based on previous studies could be due to 
the use of polymerase chain reaction (PCR) as the sole method to detect HPV DNA. 
Of the 19 studies included in the systematic review by Syrjanen et al (2011) to 
assess prevalence of HPV in OPMDs, most used PCR as the sole 
detection/diagnostic method (Syrjanen et al., 2011). PCR techniques though 
sensitive, lack specificity and may give a positive result even if the virus was not 
transcriptionally active (carrier/bystander) and should preferably be used in 
conjunction with other modalities (Smeets et al., 2007; Thavaraj et al., 2011). 
Transient infections as well as contamination could be another source of false 
positives seen when PCR techniques are employed. 
At this point in time, there is no convincing evidence related to the role of HPV 
infection in OPMD and malignant transformation (Yang et al., 2009; Lopes et al., 
2011; Lingen et al., 2013; Nankivell et al., 2014; El-Naggar et al., 2017). Results from 
current studies are still inconclusive and further studies involving larger cohorts need 
to be performed to better understand the natural history of HPV-associated OPMD 
and OSCC (Yang et al., 2009; Jayaprakash et al., 2011; Lopes et al., 2011; Lingen et 
al., 2013; Chung et al., 2014; Nankivell et al., 2014; El-Naggar et al., 2017; Fakhry et 
al., 2017; Lerman et al., 2017). 
3.5 Conclusions 
This chapter has highlighted the strengths and weaknesses of clinical and 
histopathological parameters as prognostic indicators for malignant transformation in 
OPMD. Clinical parameters were found to be mostly lacking as prognostic indicators 
for OPMD when larger cohorts were used for analysis. From the histopathological 
parameters, the binary OED grading system has shown some promise as a 
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prognostic instrument and is slightly superior to the traditional WHO 2017 three-tiered 
grading system, but it is still lacking in sensitivity and specificity. The relationship 
between OPAL and clinical outcome is as yet not very clear though it does appear 
that OPAL is more of a reaction to the severity of OED. Combining OED grading with 
clinical parameters may improve clinical prognostication and this will be discussed 
further in Chapter 7 of this thesis. HR-HPV associated OED is an infrequent finding in 
OPMDs and the association with MT is still unclear. By assessing and exploring the 
strengths and weaknesses of current methods (clinical and histological parameters) 
being employed in risk stratification and directing clinical management of OPMD 
patients, the findings from this chapter serve to illustrate the need for better 
prognostic indicators of clinical outcome in these patients. 
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Table 3.1 Demographic and clinical characteristics of cohort (n = 166) 
Characteristics Non-
transforming 
(NT) n = 134 
Malignant 
transforming 
(MT) n = 32 
p-value 
Age  
Mean [SD] 
(Range) 
 58.19 
[12.79] 
(23 – 93) 
61.31 
[12.74] 
(35 – 92) 
0.216 Ϯ 
Age at 
diagnosis 
£ 50 years  38 5 0.180* 
> 50 years 96 27 
Time to last follow-up/ 
malignant transformation in 
months  
Median [IQR] 
(Range) 
61.00 
[93.00] 
(12 – 215) 
41.00 
[59.75] 
(7 – 128) 
0.015α 
Sex Male 83 21 0.839* 
Female 51 11 
Type of 
OPMD 
Leukoplakia 117 25 0.332** 
Erythroplakia 3 2 
Erythroleukoplakia 14 5 
Site of 
index 
OPMD 
Tongue 42 15 0.455** 
 
 Floor of mouth 41 6 
Buccal mucosa 34 6 
Gingiva/Alveolar 
mucosa 
7 2 
Palate 10 3 
Site of 
index 
OPMD 
(binary) 
Tongue 42 15 0.103* 
Other sites 92 17 
Ϯ Independent t-test; α Mann-Whitney U test; *Fisher’s exact test; **Pearson’s chi-
square test (Exact method); SD = standard deviation; IQR = interquartile range 
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Table 3.2 Characteristics of cases chosen for molecular experiments (n = 65) 
Characteristics Non-
transforming 
(NT) 
 n = 35 
Malignant 
transformi
ng (MT) 
n = 30 
p-value 
Age  
[Mean (±SD)] 
(Range) 
 58.31 
[13.57] 
(34 – 89) 
61.97 
[12.90] 
(35 – 92) 
0.273 Ϯ 
Age  £ 50 years  13 4 0.046* 
> 50 years 22 26 
Time to last follow-up/ 
malignant transformation 
in months Median [IQR] 
(Range) 
124.00 
[112.00] 
(20 – 215) 
32.50 
[48.25] 
(7 – 128) 
< 0.001α 
Sex Male 23 21 0.794* 
Female 12 9 
Type of 
OPMD 
Leukoplakia 29 23 0.650** 
Erythroplakia 3 2 
Erythroleukoplakia 3 5 
Site of 
index 
OPMD 
Tongue 8 14 0.028** 
 
 Floor of mouth 20 6 
Buccal mucosa 5 5 
Gingiva/Alveolar 
mucosa 
1 2 
Palate 1 3 
Site of 
index 
OPMD 
(binary) 
Tongue 8 14 0.065* 
Other sites 27 16 
Ϯ Independent t-test; α Mann-Whitney U test; *Fisher’s exact test; **Pearson’s chi-
square test (Exact method); SD = standard deviation; IQR = interquartile range 
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Table 3.3 Oral epithelial dysplasia grading of OPMD cases (n = 166) 
Oral epithelial dysplasia 
(OED) 
grading system 
Non-
transforming 
(NT) 
n = 134 
Malignant 
transforming 
(MT) 
n = 32 
p-value 
WHO 2017 
OED 
grading  
No OED 4 1 0.064** 
Mild  
OED 
72 12 
Moderate 
OED 
33 6 
Severe 
OED 
25 13 
Binary OED 
grading 
No OED 4 1 0.016** 
Low-grade  87 12 
High-grade  43 19 
**Pearson’s chi-square test (Exact method) 
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Table 3.4 Association of clinico-pathological features with binary OED grading (n = 
166) 
Features No OED 
n = 5 
Low-
grade 
OED 
n = 99 
High-grade 
OED 
n = 62 
p-value 
Age 
(years) 
 £ 50 years 2 31 10 0.065* 
> 50 years 3 68 52 
Sex Male 2 60 42 0.378* 
Female 3 39 20 
Type of 
OPMD 
Leukoplakia 4 92 46 0.029** 
Erythroplakia 0 1 4 
Erythroleukoplakia 1 6 12 
Site of 
index 
OPMD 
Tongue 2 25 30  
0.033** 
Floor of mouth 0 29 18 
Buccal mucosa 2 31 7 
Gingiva/Alveolar 
mucosa 
1 5 3 
Palate 0 9 4 
Site of 
index 
OPMD 
(binary) 
Tongue 2 25 30 0.010* 
All other sites 3 74 32 
*Fisher’s exact test; **Pearson’s chi-square test (Exact method) 
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Table 3.5 Association of clinico-pathological features with WHO 2017 OED grading 
(n = 166) 
Features No 
OED 
n = 5 
Mild 
OED 
n = 84 
Moderate 
OED 
n = 39 
Severe 
OED  
n = 38 
p-value 
Age 
(years) 
 £ 50 years 2 28 7 6 0.095* 
> 50 years 3 56 32 32 
Sex Male 2 50 26 26 0.529* 
Female 3 34 13 12 
Type of 
OPMD 
Leukoplakia 4 78 34 26 0.017** 
Erythroplakia 0 1 0 4 
Erythroleukoplakia 1 5 5 8 
Site of 
index 
OPMD 
Tongue 2 18 19 18  
0.020** Floor of mouth 0 23 12 12 
Buccal mucosa 2 29 4 5 
Gingiva/alveolar 
mucosa 
1 5 1 2 
Palate 0 9 3 1 
Site of 
index 
OPMD 
(binary) 
Tongue 2 18 19 18 0.004* 
All other sites 3 66 20 20 
*Fisher’s exact test; **Pearson’s chi-square test (Exact/Monte Carlo method) 
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Table 3.6 Oral epithelial dysplasia grading of OPMD cases selected for downstream 
analysis (n = 65) 
Oral epithelial dysplasia 
(OED) grading system 
Non-
transforming 
(NT) 
n = 35 
Malignant 
transforming 
(MT) 
n = 30 
p-value 
WHO 2017 
OED 
grading 
Mild  
OED 
18 11 0.490** 
Moderate  
OED 
6 6 
Severe  
OED 
11 13 
Binary OED 
grading 
Low-grade  23 11 0.026* 
High-grade  12 19 
*Fisher’s exact test; **Pearson’s chi-square test (Exact method) 
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Table 3.7 Evaluation of binary OED grading as a prognostic instrument (only cases 
with OED; n =161) 
Statistic Value based on 
12.1% rate MT 
(Mehanna et al., 
2009) 
Value based on 
10.5% rate of 
MT (Shariff and 
Zavras, 2015) 
Value based on 
4.8% rate of MT 
(Thomson et al., 
2017a) 
Sensitivity 61.3% 
Specificity 66.9% 
Accuracy 65.8% 
Positive 
predictive value 
20.3% 17.8% 8.5% 
Negative 
predictive value 
92.9% 93.8% 97.3% 
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Table 3.8 Association of clinic-pathological features with OPALS (n = 166) 
Features OPALS 
negative 
    n = 77 
OPALS 
positive 
n = 89 
p-value 
Clinical 
outcome 
Malignant 
transformation 
18 14 0.240* 
No malignant 
transformation 
59 75 
Age (years) £ 50 years 18 25 0.595* 
> 50 years 59 64 
Sex Male 48 56 0.938* 
Female 29 33 
Type of OPMD Leukoplakia 65 77 0.316** 
Erythroplakia 4 1 
Erythroleukoplakia 8 11 
Site of index 
OPMD 
Tongue 30 27  
0.073** Floor of mouth 19 28 
Buccal mucosa 14 26 
Gingiva/alveolar 
mucosa 
4 5 
Palate 10 3 
WHO 2017 OED 
grading 
No OED 2 3 0.001** 
Mild OED 50 34 
Moderate OED 17 22 
Severe OED 8 30 
Binary OED 
grading 
No OED 2 3  0.004* 
Low-grade OED 56 43 
High-grade OED 19 43 
*Fisher’s exact test; **Pearson’s chi-square test (Exact method) 
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Table 3.9 Association of clinic-pathological features with OPALS (n = 65) 
Features OPALS 
negative 
n = 27 
OPALS 
positive 
n = 38 
 p-value 
Clinical 
outcome 
Malignant 
transformation 
17 13 0.026* 
No malignant 
transformation 
10 25 
Age 
(years) 
£ 50 years 7 10 1.000* 
> 50 years 20 28 
Sex Male 18 26 1.000* 
Female 9 12 
Type of 
OPMD 
Leukoplakia 20 32 0.233** 
Erythroplakia 4 1 
Erythroleukoplakia 3 5 
Site of 
index 
OPMD 
Tongue 8 14 0.724** 
Floor of mouth 11 15 
Buccal mucosa 4 6 
Gingiva/alveolar 
mucosa 
1 2 
Palate 3 1 
WHO 2017 
OED 
grading 
Mild OED 16 13 0.075** 
Moderate OED 5 7 
Severe OED 6 18 
Binary 
OED 
grading 
Low-grade OED 16 18 0.451* 
High-grade OED 11 
 
20 
HR-HPV 
status 
Negative 27 35 0.260* 
Positive 0 3 
*Fisher’s exact test; **Pearson’s chi-square test (Exact method) 
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Figure 3.1 Flow chart outlining case selection for study.  
Cases were chosen for molecular experiments based on the amount of FFPE tissue 
available. 
 
 
 
 
 
 
    
85 
 
Figure 3.2 Bar chart showing age distribution of OPMD patients selected for 
molecular studies (n=65).  
The patients with malignant transformation appear to be slightly older than the non-
transforming group of patients. 
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OED 
grading 
system 
Area 
under 
curve 
Standard 
error 
Asymptotic 
significance 
Asymptotic 95% 
Confidence Interval 
Lower  
Bound 
Upper 
Bound 
Binary 
OED 
grading 
0.633 0.055 0.019 0.526 0.741 
WHO 
2017 
OED 
grading 
0.610 0.059 0.053 0.495 0.726 
 
Figure 3.3 Receiver operating characteristics curves comparing efficacy of binary and 
WHO 2017 OED grading systems in prognosticating clinical outcome for the OPMD 
cohort (n = 166).  
Only the binary grading system was statistically significant for prognosticating 
malignant transformation in OPMD (p = 0.019). 
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Figure 3.4 Kaplan-Meier curve for time to event analysis comparing malignant 
transformation in the OPMD cohort with OED stratified according to binary OED 
grading (n = 161).  
There was statistically significant correlation between binary grading and clinical 
outcome with high-grade cases undergoing MT much more frequently and earlier 
than low-grade cases (Log rank test; p = 0.003;  c2= 9.05; df = 1); Low-grade OED = 
blue line; High-grade OED = red line. 
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Figure 3.5 Kaplan-Meier curve for time to event analysis comparing malignant 
transformation in the OPMD cohort chosen for molecular assays stratified according 
to binary OED grading (n = 65).  
There was statistically significant correlation between binary grading and clinical 
outcome with high-grade cases undergoing MT much more frequently and earlier 
than low-grade cases (Log rank test; p = 0.012;  c2= 6.34; df = 1); Low-grade OED = 
blue line; High-grade OED = red line. 
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Figure 3.6 Kaplan-Meier curve for time to event analysis comparing malignant 
transformation in the OPMD cohort stratified according to OPALS (n = 166).  
Although cases with a negative OPAL score appear to have poorer prognosis, the 
findings were not statistically significant (Log rank test; p = 0.084; c2= 2.99; df = 1); 
OPALS positive = blue line; OPALS negative = red line. 
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Chapter 4. DNA Ploidy Analysis 
 
4.1 Introduction 
It has been established that the majority of cancer cells exhibit abnormal genetic 
material and such variation in DNA content is also seen in some pre-malignant 
lesions (Grassel-Pietrusky et al., 1982; Sen, 2000; Pihan and Doxsey, 2003; 
Duesberg et al., 2004; Torres-Rendon et al., 2009b; Duijf and Benezra, 2013).  
Abnormal or irregular DNA chromosomal complement exhibiting a karyotype that is 
not in multiples of a haploid set of chromosomes is known as aneuploidy. Aneuploidy 
is a marker and possibly the result of genomic instability. Genomic instability is 
considered an enabling characteristic that facilitates and drives carcinogenesis 
(Hanahan and Weinberg, 2011). Aneuploidy is most likely due to chromosomal 
instability, whereby defects in chromosomal segregation during mitotic cell division 
lead to variation in chromosomal copy numbers as well as chromosomal structure 
(Danielsen et al., 2016). Ploidy analysis has been successfully used as a prognostic 
instrument for Barret’s oesophagus (Dunn et al., 2010), colorectal carcinoma (Hveem 
et al., 2014) and a host of other cancers that have been reviewed recently by 
Danielsen et al (2016). 
The utility and role of DNA ploidy status in OPMD and OED has been studied with 
great interest in recent years (Pentenero et al., 2009; Torres-Rendon et al., 2009b; 
Bradley et al., 2010; Donadini et al., 2010; Bremmer et al., 2011; van Zyl et al., 2012; 
Siebers et al., 2013; Sperandio et al., 2013). DNA ploidy analysis measures the total 
DNA content in nuclei and is not synonymous with conventional chromosomal ploidy 
analysis that measures chromosome numbers (Haroske et al., 2001; Danielsen et al., 
2016). A recent meta-analysis suggested that aneuploidy may be of value as a 
biomarker for malignant transformation in OPMD, however this was a meta-analysis 
of only five retrospective studies (Alaizari et al., 2018). DNA ploidy status has also 
been shown to be associated with the presence and severity of OED, with dysplastic 
lesions being more frequently aneuploid than non-dysplastic lesions and increasing 
severity of dysplasia being more frequently associated with an aneuploid status 
(Grassel-Pietrusky et al., 1982; Saito et al., 1995; Pentenero et al., 2009; van Zyl et 
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al., 2012). A study by Islam et al (2010) found that lesions from the tongue have the 
highest frequency of aneuploidy compared to other oral sub-sites (Islam et al., 2010).  
DNA ploidy assessment for clinical specimens is most often performed using either 
image-based cytometry (IBC) or flow cytometry (Haroske et al., 2001; Danielsen et 
al., 2016). Flow cytometry requires fresh tissue samples (nuclei in suspensions) 
whilst IBC can be performed even using formalin-fixed paraffin-embedded (FFPE) 
material (Brouns et al., 2012; Danielsen et al., 2016). DNA ploidy status 
determination is based on DNA content measured using Feulgen-Schiff staining 
(stoichiometrically binds to DNA) in IBC or fluorescent dyes in flow cytometry 
(Caspersson, 1987; Carey, 1994; Biesterfeld et al., 2011). Aside from the obvious 
advantage of being able to use FFPE material, IBC also allows users to specifically 
select areas of interest in the tissue prior to processing and smaller tissue samples 
can also be analysed (Danielsen et al., 2016). IBC also allows users to sub-classify 
nuclei into different cell types based on morphology, allows quantitative 
measurement of nuclear morphology and has been shown to have better 
discriminatory value than flow-based cytometry (Bol et al., 2003; Belien et al., 2009; 
Dunn et al., 2010; Danielsen et al., 2016).  In recent years, fluorescence in situ 
hybridisation (FISH) based methods using centromere probes to detect aneuploidies 
of specific chromosomes have been used as well (Rygiel et al., 2007; Schramm et 
al., 2011; Danielsen et al., 2016). 
In IBC, the amount of DNA within a cell is obtained by assessing the staining density 
of a dye (such as Feulgen’s stain) that binds with DNA in a stoichiometric way 
(Caspersson, 1987; Carey, 1994; Biesterfeld et al., 2011). Nuclear DNA content is 
thus expressed as integrated optical density (IOD) (Caspersson, 1987; Haroske et 
al., 2001; Danielsen et al., 2016). The amount of nuclear DNA from the target cells is 
compared to nuclear content in control/reference cells and scaled in units/multiples of 
‘c’. A value of ‘2c’ is representative of the DNA content of diploid cells in the G0/G1 
phases of cell cycle. The 2c value is usually established using control/reference cells 
such as lymphocytes or fibroblasts (depending on the target tissue) (Caspersson, 
1987; Haroske et al., 2001; Danielsen et al., 2016). It must be emphasised that this is 
a scaling to represent DNA content and not chromosomal ploidy status. 
DNA ploidy analysis output is usually in the form of a DNA content histogram that 
describes the frequency of nuclei containing differing amounts of DNA reflective of 
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the cell-cycle of diploid cells (Caspersson, 1987; Ross et al., 2003; Darzynkiewicz, 
2010; Biesterfeld et al., 2011; Danielsen et al., 2016). The resulting DNA ploidy 
histogram is interpreted as being either ‘diploid’, ‘tetraploid’ or ‘aneuploid’ depending 
on the distribution of the cells according to DNA content. A DNA ploidy histogram is 
interpreted as being diploid when a major peak is present at point 2c (IOD that 
corresponds to the DNA content of 46 chromosomes) whilst the corresponding peaks 
for G2/M and S phases of cell cycle (up to point 4c on the histogram) are minor and 
account for between 10 - 15% of the cells (Haroske et al., 2001; Sperandio et al., 
2013; Danielsen et al., 2016). A histogram may be interpreted as being tetraploid if 
there is a large/distinct peak at 4c (G2/M) together with a smaller population of cells 
at 8c or if ³ 10% of target nuclei have DNA content of 4c. This would indicate that the 
specimen has a higher than usual number of cells with double the normal DNA 
content. The presence of a prominent separate peak differing from 2c and which 
cannot be accounted for by a 4c (G2) peak, is defined as an aneuploid peak 
(Haroske et al., 2001; Danielsen et al., 2016). 
Scattering or spreading of DNA content around peaks in the histogram is due to 
variation in staining, instrumental errors and presence of debris (Haroske et al., 2001; 
Danielsen et al., 2016). This variation is expressed using the coefficient of variation 
(CV) and is measured on the 2c peak (Rabinovitch, 1994). Too large a CV would 
mean reduced resolution and an inability to detect abnormal peaks (Haroske et al., 
2001; Danielsen et al., 2016). The ratio of the modal DNA content of target cell nuclei 
to reference nuclei (diploid) is known as the DNA index (DI); for normal tissue, DI for 
cells in G0/G1 would be 1.0, cells in G2/M would be 2.0 and for cells in S phase it 
would be between 1.0 and 2.0 (Shankey et al., 1993; Haroske et al., 2001; Danielsen 
et al., 2016). Researchers would need to take into consideration all the mentioned 
factors when attempting to accurately interpret DNA ploidy histograms. 
4.2 Aims 
The aims of this chapter are: 
1) To assess association between DNA ploidy status and clinical outcome in 
OPMD. 
2) To assess association between DNA ploidy status and oral epithelial 
dysplasia. 
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4.3 Results 
Of the 65 cases that were suitable for the study, ploidy analysis could not be carried 
out for 22 cases due to lack of FFPE material. Of the remaining cases, eight cases 
failed DNA ploidy analysis due to inadequate nuclei from the available material. DNA 
ploidy analysis was successfully performed on 35 cases. 
4.3.1 Patient characteristics 
Mean patient age at diagnosis of index lesion was 59.97 (SD ±13.00) with 80.0% of 
patients being more than 50 years of age at diagnosis. There was a male 
predominance in this cohort (65.7%). Leukoplakia was the most frequently 
encountered OPMD (80.0%) and the tongue was the most frequent site for index 
lesions (40.0%). There were 18 cases that underwent malignant transformation (MT) 
in this cohort versus 17 cases that did not undergo malignant change (NT). Patients 
aged > 50 years at age of diagnosis with OPMD were more likely to undergo MT (p = 
0.041; c2= 4.83; df = 1). The cohort of patients with OPMD that underwent malignant 
transformation (MT) had a male preponderance although this finding was not 
statistically significant (Table 4.1). The tongue was the most commonly involved site 
that underwent MT, although not statistically significant for this cohort (p > 0.05) 
(Table 4.1). The non-transforming (NT) cases were followed-up for a median of more 
than 10 years whilst MT cases occurred within a median of 28.5 months of OPMD 
diagnosis in this cohort (Table 4.1). OPALS and the WHO 2017 OED grading system 
were not significantly associated with clinical outcome in this cohort of patients whilst 
the binary grading system was significantly associated with clinical outcome (p = 
0.006; c2= 8.58; df = 1) (Table 4.1). 
4.3.2 DNA ploidy and clinico-pathologic features 
From the successfully analysed cases, 26 (74.3%) were diploid and 9 (25.7%) were 
aneuploid; there were no tetraploid cases. Examples of DNA ploidy histograms from 
this study are shown in Figure 4.1. The mean coefficient of variation (CV) of the 
diploid peaks for the samples in this study was 1.63 (SD ± 0.30; range 1.15 to 2.17). 
Of the 18 cases that underwent MT, 14 were scored as being diploid (77.8%) and 
four (22.2%) as aneuploid (Table 4.1 and Table 4.2). DNA ploidy status and clinical 
outcome were found to have no statistically significant relationship (p > 0.05) in this 
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cohort of patients (Table 4.1 and Table 4.2). There was no statistically significant 
association between any of the clinico-pathologic features and DNA ploidy status 
(Table 4.2). The OED grading and clinical outcome of these 35 patients according to 
DNA ploidy status are shown in Table 4.2. 
Statistical analysis was repeated after excluding the two HR-HPV positive cases and 
the results showed that DNA ploidy status was not significantly associated with 
clinical outcome or OED grading (Table 4.3). Time to event analysis on this cohort of 
patients showed that DNA ploidy status was not significantly associated with clinical 
outcome for this cohort of patients (Figure 4.2; Log rank test; p = 0.610;  c2= 0.26; df 
= 1). Sensitivity and specificity analysis of DNA ploidy in relation to clinical outcome 
showed that the sensitivity, positive predictive value and negative predictive value of 
this method were not as good as the binary OED grading system (Table 4.4).  
4.4 Discussion 
4.4.1 Patient characteristics 
The age distribution of patients according to clinical outcome in this cohort was 
similar to other studies on DNA ploidy analysis of OPMD cases, with the group of 
patients that underwent MT having a mean age at diagnosis with OPMD that was 
higher than the mean age of NT cases (Torres-Rendon et al., 2009b; Bradley et al., 
2010; Siebers et al., 2013). However, the age difference between the two sub-groups 
(MT vs NT) was only statistically significant when patients were categorised as being 
either £ 50 years or > 50 years at age of diagnosis with OPMD. This finding is similar 
to previous studies that have looked at the clinical and demographic characteristics 
of OPMD patients that underwent MT (Einhorn and Wersall, 1967; Banoczy and 
Sugar, 1972; Mehta et al., 1972; Gupta et al., 1980; Schepman et al., 1998; Napier 
and Speight, 2008; Warnakulasuriya et al., 2011; Speight et al., 2018). 
The male predominance of this cohort is reflective of most studies on OPMD and 
OSCC, but sex was not significantly associated with clinical outcome in this cohort. At 
this point in time there is no consensus regarding the influence sex on clinical 
outcome in OPMD patients with some studies reporting that females having higher 
risk of MT, others reporting that males are more likely to undergo MT and others still 
reporting that there is no statistically significant difference (Einhorn and Wersall, 
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1967; Gupta et al., 1980; Silverman et al., 1984; Schepman et al., 1998; Cowan et 
al., 2001; Amagasa et al., 2006; Hsue et al., 2007; Arduino et al., 2009; 
Warnakulasuriya et al., 2011; Ho et al., 2012; Goodson et al., 2015; Bates et al., 
2016). 
A number of studies on DNA ploidy and OPMD have reported some association 
between DNA ploidy status and OED grade with the majority of aneuploidy being 
seen in cases having severe OED (Saito et al., 1995; Pentenero et al., 2009; Bradley 
et al., 2010; van Zyl et al., 2012; Sperandio et al., 2013). This trend was not present 
in our study, with no statistically significant association seen between OED grade and 
ploidy status.  
The mean CV of the diploid peaks for the samples in this study was 1.63 (SD ± 0.30; 
range 1.15 to 2.17) which is well below the 5% diagnostic criteria cut-off. The low CV 
value meant a higher resolution and ability to discern minor aneuploid peaks 
(Rabinovitch, 1994; Danielsen et al., 2016). DNA ploidy analysis for this study was 
performed at an established laboratory that provides DNA ploidy analysis as part of 
routine diagnostic pathology services and has been involved in published research 
on DNA ploidy analysis in OPMD (Sperandio et al., 2013; Sperandio et al., 2016). 
The ploidy histograms obtained were validated by an experienced pathologist, 
Professor Edward Odell (EWO), thus ensuring the quality of the experiment. The 
diagnostic criteria used for our study were the same as published previously 
(Haroske et al., 2001; Sperandio et al., 2013; Sperandio et al., 2016). 
4.4.2 DNA ploidy and clinical outcome 
The relationship between DNA ploidy status and clinical outcome in OPMD patients 
has been studied with renewed interest in recent years (Grassel-Pietrusky et al., 
1982; Saito et al., 1995; Pentenero et al., 2009; Torres-Rendon et al., 2009b; Bradley 
et al., 2010; Donadini et al., 2010; Bremmer et al., 2011; van Zyl et al., 2012; Siebers 
et al., 2013; Sperandio et al., 2013). Many of the studies on clinical outcome of 
OPMD have shown that DNA ploidy status has some value as a prognostic 
biomarker in such cases although most of the studies were retrospective in nature 
and involved cohorts from single centres (Torres-Rendon et al., 2009b; Bradley et al., 
2010; Bremmer et al., 2011; Siebers et al., 2013; Sperandio et al., 2013). A recently 
published meta-analysis by Alaizari et al (2018) assessing the utility of DNA ploidy as 
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a biomarker in OPMD cases concluded that aneuploidy was a good predictor of 
malignant change in OPMD (Alaizari et al., 2018). However, the meta-analysis only 
included five retrospective studies, highlighting the limited availability of scientific 
evidence regarding the role of DNA ploidy analysis in prognosticating clinical 
outcome for OPMD patients (Alaizari et al., 2018).  
The current study failed to show any statistically significant correlation between DNA 
ploidy status and clinical outcome in OPMD. An important point to note is that not all 
lesions classified as being aneuploid underwent MT and conversely some lesions 
classified as being diploid did undergo MT; this is similar in some ways to OED 
grading whereby non-dysplastic or lesions with low-grade dysplasia may undergo MT 
whilst some lesions with high-grade OED will not undergo MT. However, it was 
demonstrated that IBC-DNA ploidy analysis was inferior to the binary OED grading 
system with regard to predicting malignant transformation in OPMD in this cohort. 
Sperandio et al (2013) using a relatively large cohort of patients showed that DNA 
ploidy analysis was at least as good as the WHO OED grading as a prognostic 
marker of malignant change in OED (Sperandio et al., 2013). The discrepancy 
between our study and the previous study could be due to the limiting factor of the 
small sample size in our study. However, even though the study by Sperandio et al 
(2013) had larger overall numbers, it had only 15 patients in whom MT occurred 
more than 6 months after index biopsy with the majority of lesions undergoing MT 
being diploid (53.3%) reflecting the inherently poor prognostic ability of DNA ploidy 
analysis (Sperandio et al., 2013).  
Previous studies assessing the efficacy of DNA ploidy in predicting MT in either OED 
or OPMD usually compared their findings with the traditional method of OED grading, 
the multi-tiered WHO system (hyperplasia, mild OED, moderate OED, severe OED 
and carcinoma in-situ) (Torres-Rendon et al., 2009b; Bradley et al., 2010; Bremmer 
et al., 2011; Siebers et al., 2013; Sperandio et al., 2013). From Table 4.4, it becomes 
clear that the results for DNA ploidy (past and present studies) and the WHO 2017 
grading system are comparable and not as good as the results from the current study 
using the binary OED grading system (Torres-Rendon et al., 2009b; Bradley et al., 
2010; Bremmer et al., 2011; Siebers et al., 2013; Sperandio et al., 2013). Results 
from Section 3.3.3 of this thesis as well as Table 4.4 clearly show that for this cohort 
the binary OED grading system performed better than the WHO 2017 OED grading 
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system as a prognostic instrument for OPMD patients. As such, it could be 
hypothesized that DNA ploidy analysis may be equivalent to the WHO 2005 OED 
grading system (Barnes et al., 2005) but is inferior to the binary OED grading system 
for prognosticating clinical outcome in OPMD patients.  
A sub-analysis after excluding HR-HPV positive cases was performed as active viral 
infections can change nuclear DNA content that is detectable by image-based 
cytometry (Haroske et al., 2001). After excluding the HR-HPV positive cases, the 
association between DNA ploidy status and clinical outcome was still not statistically 
significant. The influence of HPV-associated OED has not been considered or raised 
in previous studies reporting on DNA ploidy assessment of oral lesions (Torres-
Rendon et al., 2009b; Bradley et al., 2010; Bremmer et al., 2011; Siebers et al., 
2013; Sperandio et al., 2013). Other studies have indicated a rather high prevalence 
of HPV in the oral cavity with a recent meta-analysis arriving at a prevalence rate of 
25.3% for HPV 16/18 presence in OED (Jayaprakash et al., 2011) and another meta-
analysis on detection of HPV in OPMD concluding that 37.1% of OPMD have 
detectable HPV (Syrjanen et al., 2011). The natural history of HPV-associated OED 
is as yet not fully understood but it is imperative that future studies on OED/OPMD 
consider including assessment of HR-HPV infection as part of their study design to 
ensure clarity of any results obtained. Studies that have not assessed the influence 
of HPV infection on DNA ploidy analysis should then be read with caution. 
A major limitation of this technique is the requirement for large amounts of epithelial 
tissue required to produce viable results unlike OED grading or 
immunohistochemistry-based biomarkers that require at most a few sections of FFPE 
tissue. From our cohort, IBC DNA ploidy analysis could not be performed on almost 
half the cases (46.2%) due to insufficient amounts of tissue available. Access to large 
amounts of tissue would be feasible for excision specimens, however, though most 
OPMDs would undergo incisional biopsies as part of the diagnostic process, surgical 
excisions are currently not the standard of care for all OPMDs (van der Waal, 2009; 
Balasundaram et al., 2014; Lodi et al., 2016). One of the main reasons why many of 
the samples in this study failed DNA ploidy analysis could be because they were 
small incisional biopsy specimens. As such, DNA ploidy analysis may not be a 
feasible biomarker for small incisional biopsies that are routinely available for most 
OPMD cases. 
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Another aspect of IBC-based DNA ploidy analysis that is not discussed frequently in 
the literature is the presence and influence of intra- and inter-observer variation in 
cell selection for IBC and interpretation of DNA ploidy histograms. The presence of 
such variability is similar to OED grading and its’ influence cannot be under-
estimated. It would be highly valuable for fellow researchers if studies could assess 
and report intra- and inter-observer variation using conventional methods. 
It is also obvious that both DNA ploidy analysis as well as OED grading are not very 
good at prognosticating malignant transformation (poor positive predictive value) but 
are good at prognosticating lesions that are unlikely to undergo malignant change 
(good negative predictive values) (Sperandio et al., 2013). There is some merit in 
suggestions that combining DNA ploidy analysis and OED grading will improve 
predictive values, but it would appear that the degree of improvement conferred 
would be minimal at best (Sperandio et al., 2013). Though one may argue that some 
improvement is better than none, it would be best to investigate the benefit of doing 
additional DNA ploidy testing in augmenting the prognostic power of OED grading on 
larger cohorts of OPMD patients with known clinical outcomes before recommending 
it for routine clinical practice. It is acknowledged that the results from the current 
study should be interpreted with caution as the number of cases analysed were 
small.  
4.5 Conclusions 
Although previous studies have shown that DNA ploidy is a useful prognostic method 
for patients with OPMDs, similar results were not obtained from this study. However, 
the consistent finding of DNA ploidy analysis having low positive predictive values 
leaves much to be desired. The amount of tissue required for analysis is also a major 
limitation for clinical utility in OPMD patients availing only incisional biopsy samples. 
DNA ploidy analysis at this point in time does not seem to be much better than OED 
grading for predicting clinical outcome in OPMD patients and cannot be advocated 
for sole use in risk-stratification of patients with OPMD. Larger multicentre or 
prospective studies that include assessment of HR-HPV infection as part of the study 
design will be required before the true utility of this method as a prognostic biomarker 
for OPMD can be fully assessed. 
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Table 4.1 Characteristics of cases according to clinical outcome (n = 35) 
Characteristics  Non-
transforming 
(NT) 
n = 17 
Malignant 
transforming 
(MT) 
n = 18 
p-value 
Age (years) 
Mean [SD] 
(Range) 
56.41 
[11.23]  
(34 -74) 
63.33  
[13.95] 
(35 – 92) 
0.117Ϯ 
Age  £ 50 years  6 1 0.041* 
> 50 years 11 17 
Time to last follow-up/malignant 
transformation in months  
Median [IQR]  
(Range) 
175.00  
[40.00] 
(91 – 215) 
28.50 
[67.50] 
(7 – 128) 
< 0.001α 
Sex Male 10 13 0.489* 
Female 7 5 
Type of 
OPMD 
Leukoplakia 14 14 0.692** 
Erythroplakia 2 1 
Erythroleukoplakia 1 3 
Site of 
OPMD 
Tongue 4 10 0.105** 
Floor of mouth 9 2 
Buccal mucosa 2 2 
Gingiva/Alveolar 
mucosa 
1 2 
Palate 1 2 
Site of 
OPMD 
(binary) 
Tongue 4 10 0.086* 
Others 13 8 
OPALS OPALS negative 5 8 0.489* 
OPALS positive 12 10 
WHO 
2017 OED 
grading  
Mild 10 6 0.165** 
Moderate 4 3 
Severe 3 9 
Binary 
OED 
grading 
Low-grade 14 6 0.006* 
High-grade 3 12 
HR-HPV 
status 
Negative 16 17 1.000* 
Positive 1 1 
DNA 
ploidy 
status 
Diploid 12 14 0.711* 
Aneuploid 5 4 
Ϯ Independent t-test; α Mann-Whitney U test; *Fisher’s exact test; **Pearson’s chi-
square test (Exact method); IQR = interquartile range; SD = standard deviation 
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Table 4.2 Characteristics of cases according to DNA ploidy status (n = 35) 
Characteristics Diploid 
n = 26 
Aneuploid 
n = 9 
p-
value 
Age (years) 
Mean [SD] 
(Range) 
56.00 
[14.34]  
(34 -92) 
62.78  
[8.00] 
(52 – 77) 
0.461Ϯ 
Age  £ 50 years  7 0 0.153* 
> 50 years 19 9 
Time to last follow-up/malignant 
transformation in months  
Median [IQR]  
(Range) 
100.00 
[159.00] 
(7 – 187) 
95.00 
[105.50] 
(8-215) 
0.806α 
Sex Male 17 6 1.000* 
Female 9 3 
Type of 
OPMD 
Leukoplakia 22 6 0.623** 
Erythroplakia 2 1 
Erythroleukoplakia 2 2 
Site of OPMD Tongue 10 4 0.941** 
Floor of mouth 8 3 
Buccal mucosa 3 1 
Gingiva/Alveolar 
mucosa 
2 1 
Palate 3 0 
Site of OPMD 
(binary) 
Tongue 10 4 0.086* 
Others 16 5 
OPALS OPALS negative 11 3 0.431* 
OPALS positive 15 7 
WHO 2017 
OED grading  
Mild 14 2 0.311** 
Moderate 4 3 
Severe 8 4 
Binary OED 
grading 
Low-grade 16 4 0.451* 
High-grade 10 5 
HR-HPV 
status 
Negative 24 9 1.000* 
Positive 2 0 
Clinical 
outcome 
Non-transforming (NT) 12 5 0.711* 
Malignant transforming 
(MT) 
14 4 
Ϯ Independent t-test; α Mann-Whitney U test; *Fisher’s exact test; **Pearson’s chi-
square test (Exact method); IQR = interquartile range; SD = standard deviation 
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Table 4.3 Selected characteristics of HR-HPV negative cases according to DNA 
ploidy status (n = 33) 
 
Characteristics Diploid 
n = 24 
Aneuploid 
n = 9 
p-value 
Clinical 
outcome 
Non-transforming (NT) 11 5 0.708* 
Malignant 
transforming (MT) 
13 4 
WHO 2017 
OED grading  
Mild 14 2 0.151** 
Moderate 3 3 
Severe 7 4 
Binary OED 
grading 
Low-grade 15 4 0.442* 
High-grade 9 5 
*Fisher’s exact test; **Pearson’s chi-square test (Exact method) 
 
 
 
 
 
Table 4.4 Evaluation of DNA ploidy status (previous and current studies) as a 
prognostic instrument in OPMD (n = 35) 
Statistic Sperandio 
et al 
(2013) 
(MT > 6 
months 
after 
index 
biopsy) ** 
IBC-
DNA 
Ploidy 
WHO 
2017 
grading 
(mild & 
moderate 
vs 
severe 
OED) 
 
Binary 
grading 
Sensitivity 46.7% 22.2% 50.0% 66.7% 
Specificity 83.8% 70.6% 82.5% 82.4% 
Accuracy 81.6% 45.7% 65.7% 74.3% 
*Positive 
predictive 
value 
25.3% 8.1% 25.1% 30.8% 
*Negative 
predictive 
value 
93.1% 88.6% 93.4% 95.5% 
*Value based on 10.5% prevalence rate of MT in OED as all cases in this cohort had 
some level of OED (Shariff and Zavras, 2015). **Diploid and tetraploid results were 
combined. 
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Figure 4.1 Example of IBC DNA ploidy histogram of a diploid case from this study.  
X axes show integrated optical density (IOD) whilst Y axes show number of nuclei. 
Green: Epithelial cell nuclei; Blue: Internal control/reference nuclei (diploid nuclei). 
Summary: One 2c peak with 1971 nuclei and one 4c peak <10% of nuclei. No 
obvious 5c peak.  
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Figure 4.2 Example of IBC DNA ploidy histogram of an aneuploid case from this 
study.  
X axes show integrated optical density (IOD) whilst Y axes show number of nuclei. 
Green: Epithelial cell nuclei; Blue & Red: Internal control/reference nuclei (diploid 
nuclei). Summary: Large aneuploid peak (A1) with 1708 nuclei (67.1% of total nuclei) 
and 5c peak composed of more than 1% of total nuclei.  
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Figure 4.3 Kaplan-Meier curve for time to event analysis comparing malignant 
transformation in the OPMD cohort stratified according to the DNA ploidy status (n = 
35).  
The analysis shows that DNA ploidy status did not have an obvious influence on 
clinical outcome for this cohort of patients. patients (Log rank test; c2 = 0.260, df =1, 
p= 0.610); Diploid = blue line; Aneuploid = red line. 
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Chapter 5 . Loss of Heterozygosity Analysis 
 
5.1 Introduction 
Oral carcinogenesis is believed to be the result of a multi-step process of 
accumulated genetic alterations (Balmain et al., 1993; Califano et al., 1996; 
Forastiere et al., 2001; Hanahan and Weinberg, 2011; Kasamatsu et al., 2011; 
Leemans et al., 2011; Leemans et al., 2018) (Figure 1.2). The cancer-related genes 
can be altered via deletions, amplifications, rearrangements, translocations, and 
mutations (Scully et al., 2000a; Kasamatsu et al., 2011; Leemans et al., 2011; 
Leemans et al., 2018). Tumour suppressor genes and oncogenes are the two most 
widely studied cancer-related genes (Field, 1992; Scully, 1993; Ha et al., 2009; 
Leemans et al., 2011). Activation of oncogenes via alteration of proto-oncogenes 
may lead to uninhibited cellular proliferation and conversely, loss of function in 
tumour suppressor genes that are involved in negative regulation of cellular growth 
can also lead to uncontrolled cellular proliferation and growth (Scully, 1993; Scully et 
al., 2000a; Hanahan and Weinberg, 2011; Leemans et al., 2011).  
Several studies have shown that allelic loss at chromosomal regions 3p, 4q, 8p, 8q, 
9p, 11q, 13q and 17p occurs frequently in OSCCs with most studies placing a high 
degree of emphasis on chromosomal regions 3p, 9p and 17p (Hollstein et al., 1991; 
Maestro et al., 1993; Ah-See et al., 1994; Nawroz et al., 1994; van der Riet et al., 
1994; Wu et al., 1994; Field et al., 1995; Califano et al., 1996; Reed et al., 1996; 
Scully et al., 2000a; Forastiere et al., 2001; Beder et al., 2003; Leemans et al., 2011). 
Loss of genetic material at a tumour suppressor gene (TSG) chromosomal region is 
one way in which the activity of the relevant TSG could be altered and can be used 
as a proxy marker of TSG inactivation (Scully, 1993; Scully et al., 2000a; Hunt, 2009; 
Kasamatsu et al., 2011). Such TSG-associated deletions can be assessed using loss 
of heterozygosity analysis. 
Loss of heterozygosity (LOH) can be defined as allelic loss from one chromosomal 
locus in a chromosomal pair and can be identified by assessing DNA polymorphism 
patterns between normal and abnormal tissue (Scully et al., 2000a; Beder et al., 
2003; Kasamatsu et al., 2011). Polymorphic DNA microsatellite markers are the most 
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frequently used method to identify allelic loss (Mao et al., 1996; Zhang et al., 1997; 
Tabor et al., 2001; Zhang et al., 2001; Bremmer et al., 2008; Bremmer et al., 2009; 
Hunt, 2009; Accurso et al., 2011; Graveland et al., 2013; William et al., 2016).  
Traditionally, LOH assessment was performed through gel electrophoresis where the 
intensity of the normal and abnormal bands is compared and by convention, LOH is 
said to have occurred when one band is less than 50% as intense as the other band 
(Mao et al., 1996; Zhang et al., 1997; Rosin et al., 2000; Zhang et al., 2001; Zhang et 
al., 2012). However, currently most LOH analysis is performed using capillary 
electrophoresis, in which the relative amounts of PCR products for the two alleles is 
obtained from the respective peak heights in the electropherograms generated 
(Cawkwell et al., 1993; Cawkwell et al., 1994; Tabor et al., 2001; Farrand et al., 2002; 
Bremmer et al., 2008; Bremmer et al., 2009; Accurso et al., 2011; William et al., 
2016). The ratio of peak heights in the normal tissue is compared to the ratio from 
tumour/dysplastic tissue to ascertain whether LOH has occurred. Similarly, the cut-off 
value by convention is 50% although some studies have used different cut-off values 
(Cawkwell et al., 1993; Cawkwell et al., 1994; Farrand et al., 2002; Tabor et al., 2002; 
Accurso et al., 2011). A 50% cut-off allows for the presence of some normal cells in 
the test samples as there is a high probability that not all cells in the sample would 
harbour LOH (Tabor et al., 2001; Farrand et al., 2002; Tabor et al., 2002).  
Samples for LOH analysis are usually microdissected as contamination from normal 
tissue samples can mask allelic loss in the tumour/dysplasia tissue (Hunt, 2009). 
Although manual microdissection has been the conventional method for sample 
enrichment, LASER capture microdissection (LCM) which enables minimal physical 
manipulation of the tissue samples during microdissection has become more popular 
in recent years (Shumway et al., 2008; Accurso et al., 2011; Mallery et al., 2014).  
Deletion of several regions in chromosomal region 3p (3p13-p21.1, 3p21.3-p23 and 
3p25) has been shown to occur frequently in OSCC, however the region of focus for 
most studies has been the 3p14.2 locus which contains the fragile histidine triad 
(FHIT) gene (Maestro et al., 1993; Wu et al., 1994; Virgilio et al., 1996; Uzawa et al., 
1998; Scully et al., 2000a; Forastiere et al., 2001; Leemans et al., 2011; Nikitakis et 
al., 2018). Allelic loss at chromosomal region 9p is also frequently associated with 
OSCC specifically at locus 9p21 which is the site for the cyclin-dependent kinase 
inhibitor 2A (CDKN2A) gene (van der Riet et al., 1994; Califano et al., 1996; Reed et 
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al., 1996; Scully et al., 2000a; Forastiere et al., 2001; Leemans et al., 2011). The 
CDKN2A gene is known to encode for two tumour suppressor proteins, p16INK4a and 
p14ARF that are involved in cell-cycle regulation (Scully et al., 2000a; Forastiere et al., 
2001; Leemans et al., 2011). The region of interest on chromosome 17p that is 
studied most frequently is the region associated with the TP53 gene that encodes for 
the p53 tumour suppressor protein that is involved with cell-cycle regulation (Hollstein 
et al., 1991; Somers et al., 1992; Scully et al., 2000a; Forastiere et al., 2001; 
Leemans et al., 2011). LOH involving this locus has been reportedly seen in about 50 
– 60% of head and neck cancers (Hollstein et al., 1991; Somers et al., 1992; Burns et 
al., 1993; Nawroz et al., 1994; Forastiere et al., 2001; Leemans et al., 2011).  
Many of the chromosomal aberrations observed in OSCCs such as LOH at 3p, 9p 
and 17p, have also been seen in OPMDs albeit in differing magnitudes (Califano et 
al., 1996; Mao et al., 1996; Zhang et al., 1997; Califano et al., 2000; Rosin et al., 
2000; Forastiere et al., 2001; Zhang and Rosin, 2001; Braakhuis et al., 2003; 
Braakhuis et al., 2004a; Mithani et al., 2007; Bremmer et al., 2008; Bremmer et al., 
2009; Zhang et al., 2012). Studies have reported the frequent occurrence of LOH at 
3p14 and 9p21 in OPMDs, especially those that undergo malignant change (Mao et 
al., 1996; Rosin et al., 2000; Zhang et al., 2012). Recent studies have shown that 
LOH analysis at these chromosomal regions can be used as prognostic biomarkers 
for clinical outcome of OPMDs (Rosin et al., 2000; Zhang and Rosin, 2001; Zhang et 
al., 2012; William et al., 2016).  
A recently concluded clinical trial that used LOH status for stratification of patients 
into different treatment arms also appears to have validated the ability of LOH as a 
prognostic biomarker for malignant transformation in OPMDs (William et al., 2016). 
The findings of this study however have to be interpreted with caution as the clinical 
outcome for this study is biased due to the inclusion of patients with a previous 
history of oral cancer (58%) into the LOH positive group and conversely, the LOH 
“negative” group may have had some patient with LOH at 3p14 &/or 9p21 (William et 
al., 2016). Furthermore, active intervention in the form of Erlotinib was administered 
to the patients in the treatment arm of LOH positive cases which may have 
influenced clinical outcome (William et al., 2016). As such, although LOH has been 
proven to have some utility as a prognostic marker for malignant transformation in 
OPMD, adequate clinical validation is still pending.  
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5.2 Aims 
The aims of this chapter are: 
1) To compare two microdissection methods for LOH sample preparation.  
2) To assess association between LOH and clinico-pathological features of 
OPMD patients. 
3) To assess association between LOH and clinical outcome in OPMD. 
5.3 Results 
From the 65 cases that were suitable for this study, analysis could not be carried out 
for 15 cases due to lack of FFPE material and of the remaining cases, two failed LOH 
analysis. Thus, LOH analysis was successfully performed on 48 cases. For this 
section of the thesis, LOH refers to loss of heterozygosity at either one or more of the 
target loci (3p &/or 9p &/or 17p), whilst LOH (3p &/or 9p) refers to loss of 
heterozygosity at 3p and 9p either in isolation or in combination. 
5.3.1 Patient characteristics 
For the 48 cases analysed, mean patient age at diagnosis of index lesion was 61.25 
(SD ±13.10) with 77.1% of patients being more than 50 years of age at diagnosis. 
There was a male predominance in this cohort (62.5%). Leukoplakia was the most 
frequently encountered OPMD (79.2%) and the tongue was the most frequent site for 
index lesions (35.4%). There were 23 cases that underwent malignant transformation 
(MT) versus 25 cases that did not undergo malignant change in this cohort. Patients 
aged > 50 years at age of diagnosis with OPMD were more likely to undergo MT (p = 
0.039; c2= 5.06; df = 1). The cohort of patients with OPMD that underwent malignant 
transformation (MT) had a male preponderance although this finding was not 
statistically significant (Table 5.1). The tongue was the most commonly involved site 
that underwent MT, and this was statistically significant (p = 0.034; c2= 5.42; df = 1) 
(Table 5.1). Binary OED grading was statistically significant with regard to clinical 
outcome (p = 0.007; c2= 6.75; df = 1), whereas the WHO 2017 grading was not (p = 
0.152) (Table 5.1). The non-transforming (NT) cases were followed-up for a median 
of more than 10 years whilst MT cases occurred within a median of 39 months from 
OPMD diagnosis (Table 5.1). 
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5.3.2 Comparison between LASER capture microdissection (LCM) and manual 
microdissection methods for sample preparation 
There were six cases included in the comparison; three non-transforming (NT) cases 
and three malignant transforming (MT) cases. There was no difference detected 
between the two methods in terms of the final LOH classification. The summarised 
results are displayed in table 5.2. The remainder of the samples were manually 
microdissected prior to LOH analysis. 
5.3.3 Assessment of microsatellite markers for loss of heterozygosity (LOH) 
analysis 
Twenty-four samples were initially assessed for LOH using nine microsatellite 
markers; three each per target loci. Three microsatellite markers performed relatively 
well with low failure rates, D3S1766 (8.3%), D9S171(16.7%) and TP53 (6.3%). There 
were relatively high failure rates with the other markers. D9S157 and D9S162 failed 
in all samples whilst four other microsatellites had high failure rates; D3S1293 
(25.0%), D3S1029 (31.3%), CHRNB1 (22.9%) and D17S1866 (22.9%). The best 
microsatellite marker for each loci was chosen for the remaining samples; D3S1766, 
D9S171 and TP53. As such, all 48 samples were assessed for LOH using these 
three microsatellite markers. 
5.3.4 Loss of heterozygosity (LOH) and clinical outcome 
From the 48 analysed cases, 37 (77.1%) did not have loss of heterozygosity (LOH) at 
any of the loci tested whilst 11 (22.9%) had LOH at one or more loci. From the cases 
with LOH, eight (72.7%) had LOH at 3p &/or 9p. The summarised results are shown 
in Table 5.3. LOH at 3p &/or 9p &/or 17p (in combination or isolation) was found to be 
associated with clinical outcome in OPMDs and this was found to statistically 
significant when all 48 cases were analysed (p = 0.016; c2= 6.57; df = 1). Sub-group 
analysis on the HR-HPV negative cases showed that LOH status (at 3p &/or 9p &/or 
17p) was still significantly associated with clinical outcome (p = 0.015; c2= 6.70; df = 
1) (Table 5.4).  
When statistical analysis was performed after excluding results from locus 17p, LOH 
(3p &/or 9p) status was significantly associated with clinical outcome (p = 0.009; c2= 
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7.45; df = 1) (Table 5.3). Sub-group analysis on the HR-HPV negative cases showed 
that LOH (3p &/or 9p) status was still significantly associated with clinical outcome (p 
= 0.015; c2= 6.70; df = 1) (Table 5.4). Electropherograms of two exemplary cases are 
displayed in Figure 5.1. The two cases that had LOH but did not undergo MT were 
followed up for more than 10 years. 
Sensitivity and specificity analysis of LOH results in relation to clinical outcome 
showed that LOH has better specificity and positive predictive value than both OED 
grading systems in this 48-patient cohort (Table 5.5). Multivariate analysis was 
performed separately for LOH(3p/9p/17p) and LOH (3p &/or 9p), each time with 
inclusion of age at diagnosis, sex and binary OED grading. Cox proportional-hazards 
regression analysis (CRA) showed that both LOH(3p/9p/17p) and LOH (3p &/or 9p) 
were significantly associated with malignant transformation after adjustment for age 
at diagnosis, sex and binary OED grading (Table 5.6 and Table 5.7). Interestingly, 
binary OED grading was also significant in the multivariate model and its associated 
hazard ratios (HR) were equivalent to those of LOH status (Table 5.6 and Table 5.7). 
Time to event analysis showed that patients with LOH underwent MT more rapidly 
than those with no LOH (Figure 5.2 and Figure 5.3). 
5.4 Discussion  
It has been more than 20 years since the seminal study by Mao et al (1996) on the 
value of LOH analysis at 3p14 and 9p21 in cancer risk assessment of OPMDs (Mao 
et al., 1996). Since then, several research groups have shown that LOH has promise 
as a prognostic biomarker for OPMDs (Zhang et al., 1997; Rosin et al., 2000; 
Bremmer et al., 2009; Zhang et al., 2012; Graveland et al., 2013; William et al., 2016) 
prompting its inclusion in the latest edition of the WHO reference text on head and 
neck tumours (El-Naggar et al., 2017). The current study has also found a statistically 
significant association between LOH and clinical outcome in OPMD patients and 
supports this notion. 
5.4.1 Patient characteristics 
The overall clinical characteristics of this sub-cohort of patients for LOH analysis did 
not deviate much from the main cohort of patients for this study and have been 
described in Chapter 3. Age of patient (> 50 years), site of index OPMD (tongue) and 
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binary OED grading (high-grade) were the only clinico-pathologic features that were 
significantly associated with malignant transformation in this sub-cohort.  
5.4.2 Sample preparation methods 
The method employed for sample preparation in this study is an adaptation of the 
method described by one of the earliest studies on LOH in OPMDs by Mao et al 
(1996). Sample selection and preparation in OPMD samples is complicated by the 
amount of epithelial tissue in most biopsy samples which at times can be miniscule 
and also due to the close proximity of the epithelium to the underlying connective 
tissue.  To overcome this problem, microdissection methods have been employed to 
obtain the relevant tissues of interest (Mao et al., 1996; Zhang et al., 1997; Partridge 
et al., 1998; Partridge et al., 2000; Rosin et al., 2000; Zhang et al., 2012).  
Several recent studies on OPMD that involved LOH assessment have utilised LCM 
for sample preparation (Shumway et al., 2008; Accurso et al., 2011; Mallery et al., 
2014). Our experiment showed that for LOH analysis purposes, both LCM and 
manual microdissection produced similar results at each target locus suggesting that 
the manual microdissection method can be reliably used for sample preparation in 
LOH studies. This lack of difference is not surprising as the materials used for LOH 
analysis are not single cells but tissue and as such can be microdissected out 
manually without too much difficulty. The use of LCM for sample preparation is 
attractive due to its “non-contact” tissue manipulation technique that minimises 
contamination from tissues that are not of interest. However, LCM is also not without 
its disadvantages as it requires the availability of specialised hardware that is usually 
only available at research laboratories and not readily available at most diagnostic 
pathology laboratories. Although our results suggest that manual microdissection is 
just as good as LCM for LOH analysis, this would need to be verified using a much 
larger cohort. 
5.4.3 Loss of heterozygosity and clinical outcome 
The findings from this study were in agreement with most of the published literature, 
confirming that LOH is an acceptable prognostic biomarker for clinical outcome in 
OPMD (Mao et al., 1996; Rosin et al., 2000; Bremmer et al., 2009; Graveland et al., 
2013; William et al., 2016). Only 22.9% of the cases in this cohort showed LOH 
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compared to previous studies that have shown LOH in the majority of their patient 
cohorts (Rosin et al., 2000; Zhang et al., 2012). This was possibly due to the fact that 
only one microsatellite marker per target region was employed for all the samples in 
this study which could have reduced the detection of allelic loss that may have 
occurred in those cases that underwent malignant transformation (MT). However, it is 
conceivable that this approach may have reduced the number of false positives that 
could have occurred. In the past, most studies have used multiple markers that flank 
known polymorphisms that are near a gene of interest (Zhang et al., 1997; Rosin et 
al., 2000; Bremmer et al., 2009; Zhang et al., 2012; Graveland et al., 2013; William et 
al., 2016).  
Although the usage of multiple markers was attempted in this study, the majority of 
markers that were flanking the genes of interest underperformed when compared to 
the markers that were specific for the three genes of interest (FHIT, CDKN2A and 
TP53). Although this may have reduced the sensitivity of the assay, by reducing the 
number of microsatellites that were acting as surrogate markers for a specific gene 
(flanking the region), true allelic loss of the relevant genes was able to be identified. 
This in turn, reduced the number of false positives that may have occurred in cases 
where there may have been LOH at the region around the gene but did not truly 
affect the gene itself; resulting in increased specificity of the assay (92%). This is 
best exemplified by results from a previous study by Zhang et al (2012) that had 
numerous false positive results, with only 22 cases undergoing MT from 252 showing 
LOH at their target loci (specificity of 13.2%) (Zhang et al., 2012). However, the same 
study showed 100% sensitivity with all cases that underwent malignant change 
having LOH at one or more of the target loci (Zhang et al., 2012).  
Two recent studies have shown that LOH solely at 9p had a strong association with 
malignant change in OED/OPMD (Zhang et al., 2012; Graveland et al., 2013). Zhang 
et al (2012) in their prospective study suggested that allelic loss at 3p could be a 
bystander/passenger change instead of being an active participant in malignant 
change of OPMDs (Zhang et al., 2012). The authors also developed a new algorithm 
based on allelic loss at 9p and additional allelic loss at 4q and 17p which is yet to be 
validated (Zhang et al., 2012). However, other studies have shown that assessment 
of LOH at both 3p and 9p has some prognostic value, especially as a negative 
predictor in cases of retention at both regions (Mao et al., 1996; Roz et al., 1996; 
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Rosin et al., 2000; Zhang et al., 2012; William et al., 2016). This, together with the 
fact that allelic change at 3p and 9p has been shown to occur frequently in both 
OSCC and OPMD, suggests that it is rather premature to designate LOH at 
chromosome 3p as a “passenger alteration” (Zhang et al., 2012) and as such it would 
be best to include both loci with regard to risk-stratification of OPMD patients 
(Califano et al., 1996; Mao et al., 1996; Zhang et al., 1997; Califano et al., 2000; 
Rosin et al., 2000; Forastiere et al., 2001; Zhang and Rosin, 2001; Braakhuis et al., 
2003; Braakhuis et al., 2004a; Mithani et al., 2007; Bremmer et al., 2008; Bremmer et 
al., 2009; Zhang et al., 2012).  
Despite the pending validation of LOH as a prognostic biomarker for OPMDs, a 
recently completed clinical trial used LOH to stratify OED patients in a chemo-
prevention study (William et al., 2016). The authors concluded that although the 
intervention method (Erlotinib) did not reduce the cancer-free survival in high-risk 
patients, LOH analysis was validated as a biomarker for the development of OSCC 
(William et al., 2016). This statement by the authors is peculiar as it would appear 
that the authors acknowledge using an un-validated method to stratify patients in a 
clinical trial. Aside from that, as mentioned earlier in this chapter, the findings of this 
clinical trial should not be considered a true validation of LOH as a prognostic 
biomarker for OED due to active intervention (Erlotinib) in the treatment arm as well 
as the irregular patient stratification methods employed (William et al., 2016). 
Additionally, similar to our findings their study also showed that OED grading 
performed just as well as LOH status upon multivariate analysis (William et al., 2016). 
Both cases with HPV-associated OED in this study were shown to have retention of 
heterozygosity. A sub-group analysis after excluding these cases was performed as 
the natural history of HPV-associated oral epithelial dysplasia is still unclear (McCord 
et al., 2013; Woo et al., 2013; El-Naggar et al., 2017; Lerman et al., 2017). The 
results from the sub-group analysis confirmed that LOH had a statistically significant 
association with clinical outcome. In view of the possibility that HPV-associated OED 
may have a different carcinogenic pathway that traditional OED, it would be prudent 
to screen all cases of OED for high-risk HPV prior to including them in studies 
investigating prognostic or predictive biomarkers in OED/OPMD. Such cases may not 
contain allelic loss at the 3p, 9p or 17p sites during progression from OPMD to 
carcinoma as the pathogenesis may be entirely different. A study by Braakhuis et al 
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(2004) showed that LOH at chromosomal regions 3p, 9p and 17p is far less 
frequently observed in HPV-associated HNSCC compared to HPV negative HNSCC 
(Braakhuis et al., 2004b).  
Although LOH appears to be a prognostic biomarker for OPMD, a major drawback 
with this technique is the need for relatively large amounts of tissue to produce valid 
results compared to histopathological methods (OED grading). This requirement 
poses a major problem especially when analysis involves incisional biopsies from the 
oral cavity that tend to be rather small and tissue may need to be conserved for 
routine histopathological assessment and diagnosis.  
Overall, LOH analysis does appear to show promise as a prognostic biomarker for 
clinical outcome in OPMDs although further investigation and validation is required 
before clinical recommendations can be put forth. 
5.5 Conclusions 
The results from the current and previous studies have highlighted the advantages 
and shortcomings of LOH analysis as a prognostic biomarker of malignant 
transformation in OPMD. LOH at 3p &/or 9p appears to perform better than LOH at 
3p &/or 9p &/or 17p as a prognostic marker for OPMDs. Although LOH status 
appears to have good specificity, the sensitivity and positive predictive values are still 
lacking. However, LOH analysis does merit further investigation preferably in larger 
multicentre or prospective studies that include assessment of HR-HPV infection as 
part of the study design. At this point in time, it would be ill-advised to use LOH as a 
sole risk-stratification method for clinical practice or clinical trials; combined use with 
other clinico-pathological features would be more appropriate in such instances. 
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Table 5.1 Characteristics of cases according to clinical outcome (n = 48) 
Characteristics Non-
transforming 
n = 25 
Malignant 
transforming 
n = 23 
p-value 
Age (years) 
Mean [SD] 
(Range) 
59.36 
[13.19] 
(34 -89) 
63.30 
[12.98] 
(35 – 92) 
0.302Ϯ 
Age  £ 50 years  9 2 0.039* 
> 50 years 16 21 
Time to last follow-up/malignant 
transformation in months  
Median [IQR](Range) 
173.00 
[72.00] 
(60 – 215) 
39.00 
[55.00] 
(7 – 128) 
< 0.001α 
Sex Male 14 16 0.502* 
Female 11 7 
Type of 
OPMD 
Leukoplakia 20 18 0.886** 
Erythroplakia 3 2 
Erythroleukoplakia 2 3 
Site of 
OPMD 
Tongue 5 12 0.015** 
Floor of mouth 14 3 
Buccal mucosa 4 3 
Gingiva/Alveolar 
mucosa 
1 2 
Palate 1 3 
Site of 
OPMD 
(binary) 
Tongue 5 12 0.034* 
Other sites 20 11 
WHO 2017 
OED 
grading  
Mild 15 9 0.152** 
Moderate 5 3 
Severe 5 11 
Binary OED 
grading 
Low-grade 20 9 0.007* 
High-grade 5 14 
HR-HPV 
status 
Negative 24 22 1.000* 
Positive 1 1 
Ϯ Independent t-test; α Mann-Whitney U test; *Fisher’s exact test; **Pearson’s chi-
square test (Exact method); IQR = interquartile range; SD = standard deviation 
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Table 5.2 Results from loss of heterozygosity (LOH) analysis using different sample 
preparation methods 
Sample Targets 
3p  9p  17p 
LCM1 No LOH No LOH No LOH 
MMD1 No LOH No LOH No LOH 
LCM2 No LOH No LOH No LOH 
MMD2 No LOH No LOH No LOH 
LCM3 No LOH NI No LOH 
MMD3 No LOH NI No LOH 
LCM4 No LOH No LOH No LOH 
MMD4 No LOH No LOH No LOH 
LCM5 NI No LOH No LOH 
MMD5 NI No LOH No LOH 
LCM6 No LOH No LOH No LOH 
MMD6 No LOH No LOH No LOH 
* LCM = LASER capture microdissection samples; MMD = manual microdissection 
samples; NI = non-informative 
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Table 5.3 Association of loss of heterozygosity (LOH) and clinical outcome in all 
cases (n = 48) 
LOH Non-
transforming 
(NT) 
(n = 25) 
 
Malignant 
transforming 
(MT) 
(n = 23) 
p-value 
LOH (3p 
&/or 9p &/or 
17p) 
No LOH 23 14 0.016 * 
LOH 2 9 
LOH (3p 
&/or 9p) 
No LOH 24 15 0.009 * 
LOH 1 8 
*Fisher’s exact test 
 
 
Table 5.4 Association of loss of heterozygosity (LOH) and clinical outcome in HR-
HPV negative cases (n = 46) 
LOH Non-
transforming 
(NT) 
(n = 24) 
 
Malignant 
transforming 
(MT) 
(n = 22) 
p-value 
LOH (3p 
&/or 9p &/or 
17p) 
No LOH 22 13 0.015 * 
LOH 2 9 
LOH (3p 
&/or 9p) 
No LOH 23 14 0.009 * 
LOH 1 8 
*Fisher’s exact test 
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Table 5.5 Comparison and evaluation of LOH as a prognostic instrument in OPMD 
against OED grading (n = 48) 
Statistic LOH (3p 
&/or 9p 
&/or 17p) 
LOH (3p 
&/or 9p) 
WHO 2017 
grading 
(mild & 
moderate 
vs severe 
OED) 
 
Binary 
OED 
grading 
Zhang et 
al (2012)  
Sensitivity 39.1% 34.8% 47.8% 60.9% 100% 
Specificity 92.0% 96.0% 80.0% 80.0% 13.2% 
Accuracy 66.7% 66.7% 64.6% 69.0% 19.9% 
*Positive 
predictive 
value 
36.4% 50.5% 21.9% 26.3% 11.9% 
*Negative 
predictive 
value 
92.8% 92.6 92.9% 
 
 
94.6% 100% 
*Value based on 10.5% prevalence rate of MT in OED as all cases in this cohort had 
some level of OED (Shariff and Zavras, 2015) 
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Table 5.6 Cox proportional-hazards regression analysis (CRA) assessing association 
between malignant transformation and LOH (3p &/or 9p &/or 17p) status (n = 48) 
Variable Univariate Multivariate 
HR (95% 
CI) 
p -
value 
HR (95% 
CI) 
p -
value 
LOH (3p &/or 9p 
&/or 17p) 
No LOH 1.00  1.00  
LOH 2.88  
(1.24, 6.72) 
0.014 2.49  
(1.06, 5.89) 
0.037 
Binary OED grading Low-grade 1.00  1.00  
High-grade 3.31  
(1.40, 7.82) 
0.006 3.01 
(1.26, 7.21) 
0.013 
LOH = Loss of heterozygosity; HR = Hazard ratio; CI = Confidence interval. Variables 
included for multivariate analysis: age at diagnosis, sex, LOH and binary OED 
grading. 
 
 
Table 5.7 Cox proportional-hazards regression analysis (CRA) assessing association 
between malignant transformation and LOH (3p &/or 9p) status (n = 48) 
Variable Univariate Multivariate 
HR (95% 
CI) 
p -
value 
HR (95% 
CI) 
p -
value 
LOH (3p &/or 9p) No LOH 1.00  1.00  
LOH 3.51 
(1.46, 8.42) 
0.005 3.02  
(1.24, 7.33) 
0.015 
Binary OED 
grading 
Low-grade 1.00  1.00  
High-grade 3.31  
(1.40, 7.82) 
0.006 2.98 
(1.24, 7.13) 
0.014 
LOH = Loss of heterozygosity; HR = Hazard ratio; CI = Confidence interval. Variables 
included for multivariate analysis: age at diagnosis, sex, LOH and binary OED 
grading. 
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Figure 5.1 Exemplary electropherograms from LOH analysis.  
A case with LOH at the target site with only one peak in the test tissue (oral epithelial 
tissue) in contrast to two peaks in the control tissue (connective tissue). This case 
was confirmed to have undergone malignant transformation. 
A case without LOH at the target site with two peaks in both the test and control 
tissues. Although the second peak in the test tissue is slightly shorter than in the 
control, it is still above the 50% threshold for LOH. This case did not have malignant 
transformation (at census date). 
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Figure 5.2 Kaplan-Meier time to event analysis comparing malignant transformation 
in the OPMD cohort stratified according to LOH (3p &/or 9p &/or 17p) status.  
The analysis shows that patients with LOH underwent malignant change of OPMDs 
more rapidly than those with no LOH (Log rank test; c2 = 6.66, df =1, p = 0.010); No 
LOH = blue line; LOH = red line. 
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Figure 5.3 Kaplan-Meier time to event analysis comparing malignant transformation 
in the OPMD cohort stratified according to LOH (3p &/or 9p) status.  
The analysis shows that patients with LOH (3p &/or 9p) underwent malignant change 
of OPMDs more rapidly than those with no LOH (Log rank test; c2 = 9.11, df =1, p = 
0.003); No LOH (3p &/or 9p) = blue line; LOH (3p &/or 9p) = purple line 
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Chapter 6. Differential Gene Expression  
 
6.1 Introduction 
The previous chapters detailed the assessment of two different molecular methods 
(DNA ploidy and loss of heterozygosity analysis) in prognosticating the clinical 
outcome of patients with OPMD. This chapter will detail the differential gene 
expression (DGE) experiments between OPMD cases that underwent malignant 
transformation (MT) and those that did not. Two different gene expression profiling 
platforms were used for this purpose; RNA sequencing (RNASeq) and NanoString 
nCounter platform.  
6.1.1 Whole transcriptome sequencing 
Whole transcriptome sequencing is a major advancement in studying and 
understanding gene expression as it allows researchers to obtain a comprehensive 
view of the transcriptional profile at a given moment in time. A widely used method 
for profiling the whole transcriptome in a “snapshot” manner is RNASeq. As it 
captures the whole transcriptome, RNASeq is able to detect both known and novel 
transcripts and is suitable for assessing genes that are differentially expressed 
between different disease states. As such, RNASeq is suitable for preliminary DGE 
experiments prior to more targeted gene expression assays as well as being an 
excellent technique for discovering novel differentially expressed genes. In this study, 
RNASeq has been used as a discovery platform to identify both known and novel 
transcripts of genes that may be involved in the malignant transformation of OPMD. 
6.1.2 NanoString nCounter Platform 
FFPE tissue contains ample genetic material, however formalin fixation is known to 
adversely affect the quality of nucleic acids extracted hampering downstream 
applications such as gene expression microarrays (von Ahlfen et al., 2007). 
NanoString nCounter platform allows detection of up to 800 targets in a single 
reaction using probe-based technology to provide accurate gene expression analysis 
using total RNA from FFPE material without need for amplification (Geiss et al., 2008; 
Reis et al., 2011). Recent studies have shown that the performance of NanoString 
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technology using FFPE samples is comparable to qPCR and superior to microarray 
technology especially with regard to low-abundance transcripts (Geiss et al., 2008; 
Reis et al., 2011; Balko et al., 2012; Scott et al., 2013; Saba et al., 2015; Veldman-
Jones et al., 2015a; Veldman-Jones et al., 2015b). 
This technology also allows researchers to customise the panel of target genes to be 
studied. For the first part of the NanoString experiment the PanCancer Pathways 
Panel was used. This is a pre-designed panel containing 770 genes from 13 
canonical cancer pathways and internal reference genes. The following is the list of 
cancer pathways that are included in the panel: 
• NOTCH signalling pathway 
• WNT signalling pathway 
• Hedgehog signalling pathway 
• Chromatin modification 
• Transcriptional regulation 
• DNA damage control 
• Transforming growth factor beta (TGF-b) signalling pathway 
• Mitogen activated protein kinase (MAPK) signalling pathway 
• Janus kinase (JAK) – signal transducer and activation of transcription 
protein (STAT) signalling pathway 
• Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) signalling pathway 
• Ras signalling pathway 
• Cell Cycle 
• Apoptosis 
The second part of the NanoString experiment involved assessing differential gene 
expression between the two sub-groups (MT vs NT) using a customised panel of 
target genes (Customised CodeSet). Four OED cell line samples were also included 
to compare and contrast the gene expression profiles between cell line and FFPE 
tissue (clinical) samples. The design of the Customised CodeSet was based on the 
results from RNASeq analysis and NanoString PanCancer Pathways Panel Plus 
analysis as well as a systematic search through relevant scientific literature. 
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6.2 Aims 
The aims of this chapter are: 
1) To examine the differential gene expression profile between formalin-fixed 
paraffin-embedded clinical OPMD samples and OED cell line samples. 
2) To identify differentially expressed genes between OPMD that undergo 
malignant transformation and those that do not undergo malignant 
transformation. 
3) To discover a gene-signature that characterises OPMDs with a high risk of 
undergoing malignant transformation. 
6.3 Results 
6.3.1 Whole transcriptome sequencing 
Twenty cases (10 malignant transforming vs 10 non-transforming) from the cohort of 
65 patients were chosen for total RNA sequencing (RNASeq). The demographic, 
clinical and histopathological characteristics of the cases are shown in Table 6.1. 
None of the clinical or pathological features were significantly correlated with clinical 
outcome. The cohort was composed predominantly of males and patients aged more 
than 50 years at diagnosis.  
Results from the quality assessment of the reads from an exemplary sample (sample 
code: W1) are shown in Figure 6.1 and Figure 6.2. Figure 6.3 shows the summary of 
the quality assessment parameters for all the samples. All samples passed the 
quality control assessments to proceed for downstream analysis. During quality 
assessment, DNA base contents were found irregularly distributed in the first 13-14 
bp of reads, which in fact is commonly observed across next generation sequencing 
(NGS) datasets and originates from random hexamer priming (Figure 6.2) (Hansen et 
al., 2010).  
Bioinformatic analysis of RNASeq outputs revealed 41 genes that were significantly 
differentially expressed between MT and NT cases. The log2 fold change for the 
statistically significant differentially expressed genes ranged from -2.63 to 2.48, with 
27 genes being downregulated and 14 genes being upregulated in MT cases 
compared to NT (baseline) cases. The visual distribution of differentially expressed 
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genes is shown in Figure 6.4 and the list of statistically significant differentially 
expressed genes is shown in Table 6.2.  
6.3.2 NanoString nCounter platform 
These experiments involved two stages: 
• Stage 1: Differential gene expression experiment between MT and NT groups 
using the PanCancer Pathways Panel set of target genes. An additional ten 
customised probes (9 target genes and 1 housekeeping gene) targeting 
specific mRNA were supplemented to the 770 gene PanCancer Pathways 
Panel (Appendix D). The additional targets were chosen from significant 
differentially expressed genes from the RNASeq experiment as described in 
Section 2.7.4. The final panel was composed of 739 targets and 41 
housekeeping genes. This set of target probes will be referred to as the 
“PanCancer Pathways Panel Plus” for the remainder of the chapter. 
• Stage 2: Differential gene expression experiment between MT and NT group 
using a customised list of target genes (Appendix F) that will be referred to as 
the “Customised CodeSet Panel” for the remainder of the chapter  
Forty-eight cases (25 NT vs 23 MT) were analysed for DGE studies using the 
PanCancer Pathways Panel Plus. The demographic, clinical and histopathological 
characteristics of the cases are shown in Table 6.3. The cohort was composed 
predominantly of males and patients aged more than 50 years at diagnosis.  
All raw data passed the QC parameter measures. Prior to DGE analysis, the raw 
data were normalised using the geNorm algorithm that chooses only the most stable 
housekeeping genes in the analysed dataset (Vandesompele et al., 2002). Raw data 
normalisation and DGE analysis were performed twice: once with all cases (n = 48) 
and a second run with the two HR-HPV positive cases excluded (n = 46). Principal 
component analysis (PCA) was used to get an overall view of any obvious clustering 
in the data as well as outliers. The results are shown in Figure 6.5. PCA was unable 
to separate the malignant transforming and non-transforming OPMD cases. One 
sample (H5) was shown to be an outlier during this analysis. However, upon review 
of the case, it was decided that the sample should still be included for downstream 
analysis. 
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DGE analysis of all 48 cases revealed that 14 genes were significantly differentially 
expressed when the FDR value was set at the 5% level and 19 gene were 
differentially expressed when the FDR value was set at the 10%. DGE results from 
the experiment are shown in Table 6.4. When DGE analysis was repeated after 
excluding the two HR-HPV positive cases, seven genes were differentially expressed 
when the FDR value was set at the 5% level and 14 gene were differentially 
expressed when the FDR value was set at the 10%. DGE results are shown in Table 
6.5.  
The seven genes that were statistically significant at the 5% level were similar in both 
analyses (Tables 6.4 and 6.5). A False Discovery Rate (FDR) of < 0.1 was chosen 
for this part of the NanoString experiment as this was an exploratory experiment to 
find genes with altered expression between OPMD that undergo malignant 
transformation and those that do not. Additionally, unlike the RNASeq experiment 
that looked at the whole transcriptome, the PanCancer Pathways Panel only looked 
at 739 target genes. Setting the FDR rate too low can cause exclusion of key genes 
with biological relevance. A Kyoto Encyclopaedia of Genes and Genomes (KEGG) 
overview of all 13 pathways rendered using Pathview is shown in Figure 6.6. The 
most frequently encountered cancer-associated pathways were the PI3K/AKT, 
MAPK, RAS, JAK-STAT and Wnt signalling pathways (Tables 6.4 and 6.5). The top 
five KEGG pathways are shown in Appendix H. 
The Customised CodeSet Panel experiment was performed using RNA extracted 
from 44 FFPE samples (24 NT vs 20 MT) and four OED cell lines. The 44 cases were 
chosen from the earlier 48 cases that were used for the PanCancer Pathways Panel 
Plus. All cases were HR-HPV negative. The demographic, clinical and 
histopathological characteristics of the clinical cases are shown in Table 6.6. All raw 
data from the Customised CodeSet Panel experiment passed the QC measures. 
Principal component analysis (PCA) showed an obvious separation between the cell 
line samples and FFPE samples highlighting the different gene expression profile 
between the two sample types (Figure 6.7). PCA also showed considerable overlap 
between MT and NT cases (Figure 6.8). Raw data normalisation and DGE analysis 
were performed twice; once with all cases (OED cell lines and FFPE tissue samples; 
n = 48) and a second run with only the FFPE cases (n = 44).  
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DGE analysis between OED cell lines against clinical cases revealed a high number 
of statistically significant differentially expressed genes (Table 6.7). Sub-analysis 
between OED cell lines and clinical cases with differing outcomes (NT or MT) also 
showed a high number of statistically significant differentially expressed genes (Table 
6.8).  
There were five genes that were statistically significant differentially expressed 
between MT and NT cases (Table 6.9). The dichotomised log2 normalised gene 
expression of the five genes were then fitted into a Cox regression (proportional 
hazards regression) model to produce a gene-signature using the relevant 
coefficients from the regression model. The results of the analysis are shown in 
Table 6.10. Only three genes were retained after multivariate analysis; NOTCH1, 
cyclin E1 (CCNE1), and TP63. Gene-signature scores were then generated for each 
case. The concordance index (Harrell’s C-index) for the scores in relation to clinical 
outcome was 0.82 (CI: 0.69, 0.95) (Figure 6.9). The gene-signature scores were then 
dichotomised into low-risk and high-risk using the median of the scores. The 
dichotomised gene-signature score was significantly associated with clinical outcome 
of OPMD (p < 0.001; c2= 17.65; df = 1). Sensitivity and specificity analysis of the 
dichotomised gene-signature score in relation to clinical outcome showed that the 
gene-signature score had better sensitivity, specificity, negative predictive value and 
positive predictive values than the OED grading systems in this 44-patient cohort 
(Table 6.11). Time to event analysis showed that patients that were scored as high-
risk underwent MT more rapidly than those with low-risk scores (Figure 6.10).  
6.4 Discussion 
Archived FFPE tissues are an invaluable resource that can be successfully used for 
molecular-based assays despite the degradation that often accompanies fixation and 
embedding of tissues in paraffin wax (von Ahlfen et al., 2007; Geiss et al., 2008; 
Mittempergher et al., 2011; Reis et al., 2011; Eikrem et al., 2016; Wimmer et al., 
2018). The current study adds to the increasing body of work on utilisation of FFPE 
material for gene expression studies. Of note, compared to the previous molecular 
methods used in this study (DNA ploidy and LOH analysis), there was adequate RNA 
for the DGE experiment and none of the samples failed QC assessments. The 
amount of tissue required to obtain the necessary amount of RNA for the assays was 
also lower than that required for DNA ploidy and LOH analysis (Table 2.1). The 
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overall clinical characteristics of this sub-cohort of patients did not deviate much from 
the main cohort of patients for this study and have been described in Chapter 3. 
6.4.1 Whole transcriptome sequencing 
Gene expression analysis is based on the premise that valuable information 
regarding the function and activity of a cell can be gleaned from the expression levels 
and activity of genes. Assessment of RNA transcripts is believed to be representative 
of gene expression activity (Crick, 1970). RNASeq captures a “snapshot” of the 
whole transcriptome at a given point in time and has the advantage of detecting 
novel gene transcripts (Byron et al., 2016). The main disadvantage of RNASeq would 
be the complex data analysis involved (Byron et al., 2016). Collaborative work with 
bioinformaticians is routinely required for the data pre-processing and analysis to 
ensure results are quality-assured.  
For this study, RNASeq was used as a discovery platform to identify known and 
novel transcripts that were differentially expressed between MT and NT cases. The 
current study is the first to assess DGE between OPMDs with differing clinical 
outcomes using whole transcriptome profiling in the form of RNASeq as well as 
subsequent targeted transcriptome profiling. The one previous study that similarly 
assessed DGE in OPMD (MT vs NT) used microarray technology that assesses only 
known transcripts and does not capture the whole transcriptome (Saintigny et al., 
2011; Byron et al., 2016). Interestingly, the list of statistically significant genes from 
this study do not overlap with the gene list from the study by Saintigny et al (2011). 
This could possibly be due to one of three reasons: the molecular heterogeneity of 
OPMDs, the different gene expression analysis platforms employed and the fact that 
the patient cohort in the Saintigny et al (2011) study were enrolled in a chemo-
preventive trial for their leukoplakia (Saintigny et al., 2011). Their proposed gene-
expression based prognostic model for OPMD has yet to be replicated or validated 
by other groups (Saintigny et al., 2011). 
A recent study by Conway et al (2015) also employed RNASeq to assess DGE in 
“normal”, OED and OSCC tissues however all three tissue states (“normal”, OED and 
OSCC) were obtained from the same excision specimen (Conway et al., 2015). Due 
to the well-recognised theory of field change in OPMD patients, it is understood that 
histologically “normal” tissue may not be molecularly “normal” and free from 
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molecular change (Slaughter et al., 1953; Braakhuis et al., 2003) which introduces a 
confounder to the results obtained by Conway et al (2015). This confounding problem 
of normal epithelial tissue affects the majority of published gene expression studies 
involving OPMD and OSCC (Yu et al., 2008). Such studies may only provide an 
approximation of the molecular events that take place during malignant 
transformation of OPMD (Ha et al., 2003; Banerjee et al., 2005; Odani et al., 2006; 
Kondoh et al., 2007; Yu et al., 2008; Conway et al., 2015).  
One of the limitations of this part of the study is the relatively small number of cases 
included compared to the study by Saintigny et al (2011) that had an 86-patient 
cohort (Saintigny et al., 2011). Another limitation is that gene expression studies only 
allow a snapshot of the transcriptomic profile at that given point in time to be taken 
and as such is a very simplistic and static representation of a dynamic temporal 
process. Furthermore, an OPMD that was categorised as being a non-transforming 
case may eventually undergo MT. However, RNASeq analysis for this study was to 
serve only as an initial broad overview of the transcriptomic differences between 
OPMD cases that undergo MT and those that do not, which was successfully 
performed. 
6.4.2 NanoString nCounter platform 
The current study provides additional evidence to the clinical utility of the NanoString 
nCounter platform in providing robust gene expression outputs using RNA from 
FFPE tissue (Geiss et al., 2008; Reis et al., 2011; Scott et al., 2013; Saba et al., 
2015; Veldman-Jones et al., 2015a; Veldman-Jones et al., 2015b). Though relatively 
new, the NanoString nCounter assay has been shown by several studies to be 
sensitive and reproducible, with sensitivity and accuracy levels that are better than 
microarrays and similar to real-time PCR (qPCR) (Geiss et al., 2008; Reis et al., 
2011; Scott et al., 2013; Saba et al., 2015; Veldman-Jones et al., 2015a; Veldman-
Jones et al., 2015b). A recent study by Veldman-Jones et al (2015) that evaluated 
the robustness of the nCounter platform in analysing clinical samples showed that 
the platform has high sensitivity of target detection and good reproducibility even with 
low RNA amounts making it suitable for clinical utility (Veldman-Jones et al., 2015a). 
There are two main advantages of NanoString compared to conventional gene 
expression analysis methods such as qPCR and microarrays. In the nCounter 
platform, transcript levels are measured from un-amplified total RNA unlike other 
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platforms thus reducing errors/biases that may be introduced through increased 
sample manipulation and enzymatic reactions (Geiss et al., 2008; Reis et al., 2011). 
Another advantage of NanoString is that it can be multiplexed to measure up 800 
target genes in one sample unlike qPCR based methods that usually measures the 
expression of a single gene at a time (Geiss et al., 2008; Reis et al., 2011; Scott et 
al., 2013; Saba et al., 2015; Veldman-Jones et al., 2015a; Veldman-Jones et al., 
2015b). 
Results from the PanCancer Pathways Panel Plus showed that there was no single 
cancer pathway that was highly significant in the malignant transformation for this 
OPMD cohort. The most commonly implicated cancer-related pathways in this cohort 
appear to be the PI3K, RAS, MAPK, JAK-STAT and Wnt signalling pathways (Table 
6.4, Table 6.5 and Appendix H) which are also commonly implicated in head and 
neck SCC (HNSCC) (Kalyankrishna and Grandis, 2006; Molinolo et al., 2009; 
Rothenberg and Ellisen, 2012; Iglesias-Bartolome et al., 2013; Makarev et al., 2017).  
A recent pathway analysis study by Makarev et al (2017) showed that even though 
OSCCs may have a huge variety of distinct genetic alterations, these changes 
appear to involve only a few well-known pathways; Wnt, PI3K, RAS/MAPK, JAK-
STAT and TGF-b (Makarev et al., 2017). They also found that the usual cancer-
related pathways were not similarly affected in the majority of OPMDs, with many 
cancer-related pathways being downregulated and the pro-apoptotic pathways being 
slightly upregulated compare to normal tissue. This would fit in with the existing body 
of evidence that the majority (~ 90%) of OPMDs do not undergo MT (Mehanna et al., 
2009; Shariff and Zavras, 2015). Of note, they did find a sub-set of the OPMDs that 
had differentially activated pathways that were more similar to OSCCs. These 
findings suggest that although the majority of OPMD exhibit signalling pathway 
activity that is less aggressive than OSSC, a subset with dysregulation of these 
cancer-related pathways does exist. However, this also is suggestive that OSCC 
possibly arises from changes in different molecular pathways with no single 
prominent signalling pathway. The findings from our current study appears to be 
similar whereby the differentially expressed genes between MT and NT are 
implicated in those cancer-driving pathways. The pathway analysis performed on 
OPMD by Makarev et al (2017) however was based only on one gene expression 
dataset which was obtained from patients in a chemo-preventive clinical trial 
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(Saintigny et al., 2011), and as such the results need to be interpreted with caution 
(Saintigny et al., 2011; Makarev et al., 2017).  
The T-cell leukaemia homeobox 1 (TLX1) gene was the only gene that was 
significantly differentially expressed in both the RNASeq and PanCancer Pathways 
Panel Plus experiments. TLX1 belongs to the homeobox gene family of transcription 
factors involved in the early stages of embryonic development (McGinnis and 
Krumlauf, 1992; Garcia-Fernandez, 2005). TLX1 has been linked to splenic 
development, immortalisation of haematopoietic precursor cells and formation of 
neuronal circuity of central as well as peripheral nervous systems (Dear et al., 1995; 
Logan et al., 1998; Zhang et al., 1999). TLX1 has also been linked to the 
development of T-cell acute lymphoblastic leukaemia (Hatano et al., 1991). At this 
point in time, there have been no studies linking TLX1 to OPMD/OSCC. From this 
study, TLX1 appears to be downregulated in OPMD that undergo MT. None of the 
additional genes supplemented to the PanCancer Pathways Panel (Appendix D) 
were found to be statistically significant upon DGE analysis. 
From the Customised CodeSet Panel experiment, 22 genes were significantly 
differentially expressed between OED cell lines and FFPE tissue samples (clinical 
cases). This high number of differentially expressed genes in a targeted CodeSet 
made up of only 38 genes (excluding housekeeping genes) was to be expected due 
to two main reasons. Firstly, cell line RNA was obtained from fresh tissue and would 
not be as degraded as RNA from FFPE tissue (von Ahlfen et al., 2007). Secondly, 
OED cell lines are not as complex as human tissue samples and were composed of 
only epithelial tissue whilst the FFPE samples were composed of epithelium as well 
as underlying connective tissue. As such, although cell lines are invaluable for in-vitro 
experiments, the findings from the current study serve to remind us that OED cell 
lines are too simplistic and do not adequately represent the in-vivo environment of 
oral epithelial dysplasia. When comparing the list of differentially expressed genes 
separately between cell lines vs MT cases as well as cell line vs NT cases, the list of 
significant genes was similar, once again highlighting the vastly similar gene 
expression profile between NT and MT cases.  
After excluding the cell line samples, only five genes were significantly differentially 
expressed between the NT and MT cases using the Customised CodeSet Panel: 
NOTCH1, cyclin E1(CCNE1) and TLX1 were down-regulated whilst integrin subunit 
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beta 8 (ITGB8) and TP63 genes were up-regulated. NOTCH1 encodes for one of the 
proteins involved in the Notch signalling pathway and the association between 
NOTCH1 and oncogenesis was initially identified in T-cell acute lymphoblastic 
leukaemia (Ellisen et al., 1991). Since then, NOTCH1 has been implicated in several 
different types of cancer (Reedijk et al., 2005; Westhoff et al., 2009; Hanlon et al., 
2010; Ranganathan et al., 2011; Viatour et al., 2011; Yoshida et al., 2013; Yap et al., 
2015). Findings regarding the role of NOTCH1 in OSCC have been conflicting as 
some earlier studies have indicated that NOTCH1 is oncogenic whilst more recent 
studies tend to favour the hypothesis that NOTCH1 behaves as a tumour suppressor 
gene in OSCC (Leethanakul et al., 2000; Zeng et al., 2005; Agrawal et al., 2011; 
Stransky et al., 2011; Zhang et al., 2011; Lee et al., 2012; Sakamoto et al., 2012; 
Pickering et al., 2013; Yoshida et al., 2013; Song et al., 2014; Yap et al., 2015). 
Findings from this study show that expression of NOTCH1 is downregulated in 
OPMD that undergo MT, consistent with findings from studies suggesting that 
NOTCH1 has a tumour suppressive role in oral carcinogenesis (Agrawal et al., 2011; 
Sakamoto et al., 2012; Pickering et al., 2013; Song et al., 2014; Yap et al., 2015). 
Interestingly, both Notch1 and TLX1 have been implicated in the pathogenesis of T-
cell acute lymphoblastic leukaemia (Ellisen et al., 1991; Hatano et al., 1991; 
Rakowski et al., 2011). 
Expression of CCNE1 was found to be downregulated in this study. CCNE1 encodes 
cyclin E1, a protein that belongs to the cyclin family that function as regulators of 
cyclin-dependent kinases (CDKs). CCNE1 is particularly involved in the G1 to S 
phase transition in cells. CCNE1 has been implicated in several different types of 
cancers such as ovarian, breast, hepatocellular and oesophageal cancers (Kohzato 
et al., 2001; Sui et al., 2001; Moroy and Geisen, 2004; Scaltriti et al., 2011; Cancer 
Genome Atlas Research Network, 2017). At this point in time, there have been no 
studies linking CCNE1 to OPMD/OSCC. 
The ITGB8 gene is a member of the integrin family and encodes a membrane 
protein. In this study ITGB8 expression was upregulated in OPMD cases that 
underwent malignant transformation. Integrins are cell surface receptors involved 
with cellular adhesion and believed to mediate cell-to-cell as well as cell-to-
extracellular matrix interactions. ITGB8 has recently been implicated in several 
different types of cancers such as ovarian, hepatic, lung and laryngeal cancer (Ni et 
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al., 2012; Xu and Wu, 2012; Mertens-Walker et al., 2015; Wala et al., 2015; Wang et 
al., 2015; Cui et al., 2018). At this point in time, there have been no studies linking 
ITGB8 to OPMD/OSCC. 
The TP63 gene encodes for the p63 protein a member of the p53 family of 
transcription factors. An isoform of p63, ΔNp63 has been reported to be 
overexpressed in OPMDs that transformed to OSCC by several studies (Chen et al., 
2005; Saintigny et al., 2009; Matsubara et al., 2011; Varun et al., 2014). Findings 
from this study appear to support the notion that expression of TP63 is increased in 
cases of OPMD that undergo MT. However, the evidence is still inconclusive as to its 
role in oral carcinogenesis as well as being a prognostic biomarker for OPMDs 
(Smith et al., 2009; Lingen et al., 2011; Nankivell and Mehanna, 2011).  
A novel way to generate a prognostic gene-signature for OPMD patients utilising a 
tiered approach from whole transcriptome to targeted transcriptome assessment was 
performed in the current study. The gene-signature developed from this study 
appears to have good potential in discriminating OPMD that may undergo MT and 
those that do not, with very high specificity and negative predictive values. A major 
issue with developing gene-signatures is clinical validation (Koscielny, 2010; Brulard 
and Chibon, 2013; Chibon, 2013). An earlier prognostic gene-signature developed by 
Saintigny et al (2011) for oral leukoplakia, though initially promising, remains un-
validated and as such has not been translated into clinical practice (Saintigny et al., 
2011). The optimum method for validation of a new gene-signature would be for it to 
be validated by an independent research team on an independent patient cohort 
(Koscielny, 2010; Brulard and Chibon, 2013; Chibon, 2013). Lack of independence 
between the training and test/validation cohorts can lead to an over-estimation of the 
prognostic ability of a gene-signature. The lack of published validation for a gene-
signature may also not be due to a lack of trying, as some researchers may hesitate 
to publish findings that fail to validate the developed gene-signature.  
Another barrier for successful validation of a prognostic gene-signature is the 
presence of inter- and intra-tumour heterogeneity in OSCC as well as heterogeneity 
in OPMD (Hirsch et al., 1983; Perou et al., 2000; Chung et al., 2004; Diwakar et al., 
2005; Russnes et al., 2011; Marusyk et al., 2012; Fisher et al., 2013; De Cecco et al., 
2015; Gomes et al., 2015; Gay et al., 2016; Mroz and Rocco, 2016). As such, 
although promising, the newly developed gene-signature needs to be validated on a 
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separate larger cohort of patients to ascertain clinical utility as a prognostic indicator 
of clinical outcome in OPMD.  
6.5 Conclusions 
This chapter has highlighted the potential use of gene expression as a prognostic 
biomarker for OPMD. A stratified method to refine a suitable prognostic gene-
signature was detailed ranging from whole transcriptome sequencing to specifically 
targeted transcriptome assessment. The next generation sequencing platforms used 
in this experiment have shown good results using FFPE material with all samples 
being successfully analysed. Aside from developing a prognostic gene-signature, 
several new candidate genes with possible roles in oral carcinogenesis such as 
TLX1, CCNE1 and ITGB8 have been identified. Further investigation of these genes 
may provide more clarity to the natural history of OMPD as well as the 
aetiopathogenesis of OSCC. Importantly, the gene-signature that has been 
developed needs to be validated in an external cohort to ascertain its’ prognostic 
utility. 
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Table 6.1 Characteristics of cases selected for RNASeq experiment (n=20) 
Characteristic Non-
transforming 
(NT) 
n=10 
Malignant 
transforming 
(MT) 
n=10 
p-
value 
Age [Mean (± SD)] 55.7 
(±14.86) 
60.0 
(±12.41) 
0.491 Ϯ 
Time to last follow-up/malignant 
transformation in months [Median 
(IQR)] 
28.00 
(46.25) 
17.00 
(42.75) 
0.684α 
Sex Male 9 7 0.582* 
Female 1 3 
Site of OPMD Tongue 4 3 1.000* 
Other sites 6 7 
WHO 2017 OED 
grading 
Mild 3 3 0.635** 
Moderate 1 3 
Severe 6 4 
Binary OED 
grading 
Low-grade 3 3 1.000* 
High-grade 7 7 
Ϯ Independent t-test; α Mann-Whitney U test; *Fisher’s Exact test; **Pearson’s Chi- 
square test; SD = Standard deviation; IQR = Interquartile range 
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Table 6.2 Significant differentially expressed genes from RNASeq experiment (n=20) 
Ensembl gene ID HGNC   symbol Gene biotype Log2 fold 
Change 
FDR 
[BH p-
value] 
ENSG00000196805 SPRR2B Protein coding 2.48  0.015 
ENSG00000283029 NA Non-coding 2.44 0.015 
ENSG00000115844 DLX2 Protein coding 2.30 0.015 
ENSG00000229035 SPRR2C Unprocessed 
pseudogene 
2.28 0.015 
ENSG00000223802 CERS1 Protein coding 2.19 0.044 
ENSG00000166165 CKB Protein coding 2.11 0.015 
ENSG00000137869 CYP19A1 Protein coding 2.10 0.046 
ENSG00000235852 NA Antisense 2.00 0.019 
ENSG00000186648 LRRC16B Protein coding 1.79 0.030 
ENSG00000276368 HIST1H2AJ Protein coding 1.78 0.037 
ENSG00000123416 TUBA1B Protein coding 1.72 0.025 
ENSG00000137331 IER3 Protein coding 1.61 0.046 
ENSG00000066248 NGEF Protein coding 1.58 0.031 
ENSG00000127824 TUBA4A Protein coding 1.48 0.015 
ENSG00000162836 ACP6 Protein coding -1.05 0.031 
ENSG00000164808 SPIDR Protein coding -1.32 0.025 
ENSG00000117335 CD46 Protein coding -1.43 0.031 
ENSG00000111670 GNPTAB Protein coding -1.44 0.037 
ENSG00000135338 LCA5 Protein coding -1.45 0.035 
ENSG00000166432 ZMAT1 Protein coding -1.47 0.020 
ENSG00000181804 SLC9A9 Protein coding -1.67 0.026 
ENSG00000204789 ZNF204P Processed 
pseudogene 
-1.78 0.037 
ENSG00000165186 PTCHD1 Protein coding -1.79 0.036 
ENSG00000112773 FAM46A Protein coding -1.80 0.037 
ENSG00000139292 LGR5 Protein coding -1.82 0.046 
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Ensembl gene ID HGNC   symbol Gene biotype Log2 fold 
Change 
FDR 
[BH p-
value] 
ENSG00000185499 MUC1 Protein coding -1.83 0.026 
ENSG00000214290 COLCA2 Protein coding -1.83 0.016 
ENSG00000267395 DM1-AS Antisense -1.86 0.033 
ENSG00000196724 ZNF418 Protein coding -1.91 0.019 
ENSG00000177707 NECTIN3 Protein coding -2.01 0.026 
ENSG00000115648 MLPH Protein coding -2.03 0.019 
ENSG00000279387 NA NA -2.12 0.019 
ENSG00000180347 CCDC129 Protein coding -2.19 0.020 
ENSG00000235902 NA Antisense -2.21 0.024 
ENSG00000115112 TFCP2L1 Protein coding -2.22 0.015 
ENSG00000116039 ATP6V1B1 Protein coding -2.31 0.025 
ENSG00000177685 CRACR2B Protein coding -2.33 0.015 
ENSG00000134398 ERN2 Protein coding -2.41 0.015 
ENSG00000167165 UGT1A6 Protein coding -2.44 0.015 
ENSG00000107807 TLX1 Protein coding -2.46 0.016 
ENSG00000181143 MUC16 Protein coding -2.63 0.015 
*FDR = False discovery rate; BH = Benjamini-Hochberg. False Discovery Rate 
calculated using Benjamini-Hochberg method and significance set at the 5% level (p 
< 0.05). HGNC = Human Genome Organisation Gene Nomenclature Committee. NA 
= not available 
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Table 6.3 Characteristics of cases for PanCancer Pathways Panel Plus experiment 
(n=48) 
Characteristics Non-
transforming 
(NT) 
n = 25 
Malignant 
transforming 
(MT) 
n = 23 
p-value 
Age at diagnosis in years 
Mean [SD] 
(Range) 
59.36 
[13.19] 
(34 - 89) 
63.30 
[12.98] 
(35 - 92) 
0.302Ϯ 
Age at 
diagnosis 
£ 50 years  9 2 0.039* 
> 50 years 16 21 
Time to last follow-up/malignant 
transformation in months  
Median [IQR] 
(Range) 
173.00 
 
[72.00] 
(60 – 215) 
39.00 
 
[55.00] 
(7 – 128) 
< 0.001α 
Sex Male 
 
14 
 
16 0.502* 
Female 
 
11 7 
Type of 
OPMD 
Leukoplakia 20 18 0.886* 
Erythroplakia 3 2 
Erythroleukoplakia 2 3 
Site of 
OPMD 
(binary) 
Tongue 
 
5 12 0.034* 
Other sites 20 11 
OPALS OPALS negative 
 
7 10 0.367* 
OPALS positive 
 
18 13 
WHO 2017 
OED 
grading  
Mild 
 
15 9 0.152* 
Moderate 
 
5 3 
Severe 
 
5 11 
Binary OED 
grading 
Low-grade 
 
20 9 0.009* 
High-grade 
 
5 14 
HR-HPV 
status 
Negative 24 22 1.000* 
Positive 1 1 
Ϯ Independent t-test; α Mann-Whitney U test; *Pearson’s chi-square test (Exact 
method); IQR = interquartile range; SD = standard deviation  
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Table 6.4 Differentially expressed genes for PanCancer Pathways Panel Plus 
experiment (n =48) 
Gene Log2 
fold 
change 
p-value FDR 
[BH p-
value] 
Associated cancer 
pathway sets 
ITGB8 0.711 7.29E-06 0.005 PI3K 
IGF1R 0.401 2.24E-05 0.008 PI3K, Ras,  
NTRK2 0.886 3.71E-05 0.009 MAPK 
CCNE1 -0.936 4.91E-05 0.009 Cell Cycle - Apoptosis, 
PI3K 
IL22RA1 -0.896 6.87E-05 0.010 JAK-STAT 
FZD7 0.698 0.000117 0.014 Wnt 
GATA1 -0.969 0.000259 0.026 Driver gene 
ARID1B 0.224 0.000318 0.026 Driver gene 
PLCB1 0.782 0.000332 0.026 Wnt 
PLA2G4E -1.200 0.000348 0.026 MAPK, Ras 
PBX1  0.603    0.000387 0.026 Transcriptional 
misregulation 
MECOM 0.691 0.000546 0.034 MAPK 
SOX9 1.380 0.00081 0.046 Driver gene 
DUSP5 -1.040 0.000886 0.047 MAPK 
COL4A5 0.727 0.00107 0.053 PI3K 
AMH -0.844 0.00132 0.060 TGF-beta 
CACNA2D1 0.853 0.00137 0.060 MAPK 
TLX1 -1.970 0.00154 0.063 Transcriptional 
misregulation 
SMAD9 0.828 0.00249 0.097 TGF-beta 
* FDR = False discovery rate; BH = Benjamini-Hochberg. FDR calculated using 
Benjamini-Hochberg method and significance set at the 10% level (p < 0.10). ** 'Log2 
fold-change' estimates a gene's differential expression; a negative value would mean 
down-regulation and a positive value would mean up-regulation in MT cases versus a 
baseline of NT cases, holding all other variables in the analysis constant.   
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Table 6.5 Significant differentially expressed genes in HR-HPV negative cases for 
PanCancer Pathways Panel Plus experiment (n =46) 
Gene Log2 fold 
change 
P-value FDR 
[BH p-
value] 
Associated cancer pathway 
sets 
ITGB8 0.700 1.85E-05 0.012 PI3K 
IGF1R 0.406 3.72E-05 0.012 PI3K, Ras 
NTRK2 0.908 4.77E-05 0.012 MAPK 
CCNE1 -0.935 9.56E-05 0.018 Cell Cycle - Apoptosis, PI3K 
IL22RA1 -0.827 0.000224 0.031 JAK-STAT 
GATA1 -0.99 0.000252 0.031 Driver gene 
FZD7 0.678 0.000297 0.031 Wnt 
PBX1 0.6 0.000666 0.056 Transcriptional misregulation 
MECOM 0.7 0.000682 0.056 MAPK 
PLA2G4E -1.14 0.000788 0.058 MAPK, Ras 
PLCB1 0.74 0.000857 0.058 Wnt 
ARID1B 0.207 0.00102 0.063 Driver gene 
TLX1 -2.01 0.00134 0.077 Transcriptional misregulation 
COL4A5 0.717 0.00188 0.099 PI3K 
* FDR = False discovery rate; BH = Benjamini-Hochberg; FDR calculated using 
Benjamini-Hochberg method and significance set at the 10% level (p < 0.10). ** 'Log2 
fold-change' estimates a gene's differential expression; a negative value would mean 
down-regulation and a positive value would mean up-regulation in MT cases versus a 
baseline of NT cases, holding all other variables in the analysis constant. 
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Table 6.6 Characteristics of cases selected for NanoString Customised CodeSet 
Panel experiment (n = 44) 
Characteristic Non-
transforming  
(NT) 
n = 24 
Malignant 
transforming 
(MT) 
n = 20 
P-value 
Age at diagnosis in 
years 
Mean [SD] 
(Range) 
59.67  
[13.38] 
(34 - 89) 
61.30 
[12.58] 
(35 – 92) 
0.681Ϯ 
Age at 
diagnosis 
£ 50 years  9 2 0.078* 
> 50 years 15 18 
Time to last follow-up/ 
malignant trans-
formation in months 
Median [IQR] 
(Range) 
174.00  
[65.00] 
(66 – 215) 
28.50  
[47.75] 
(7 – 111) 
   < 0.001α 
 
Sex Male 14  13 0.760* 
 Female 10 7 
Site of 
OPMD 
Tongue 4 11 0.011* 
 Other sites 20 9 
WHO 2017 
OED 
grading  
Mild 15 8 0.140** 
 Moderate  5 3 
Severe 4 9 
Binary 
OED 
grading 
Low-grade 20 8 0.005* 
 High-grade 4 12 
Ϯ Independent t-test; α Mann-Whitney U test; *Fisher’s Exact test; **Pearson’s Chi-
square test; SD = Standard deviation; IQR = Interquartile range 
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Table 6.7 Significant differentially expressed genes between clinical cases and OED 
cell lines using Customised CodeSet Panel with OED cell lines being the baseline (n 
=48) 
Gene name Log2 fold change FDR 
[BH p-value] 
NTRK2 10.4 7.65E-27              
BCL2 5.19 1.49E-17 
CACNA2D1 8.36 1.49E-17 
PLA2G4E 8.56 5.90E-17 
Notch1 3.58 1.11E-12 
SPRR2B 8.55 4.08E-11 
LGR5 5.85 4.42E-11 
TP63 6.37 3.27E-10 
PAX9 4.52 1.37E-07 
FHIT 3.67 1.52E-07 
DUSP5 3.31 7.64E-07 
CTSL -1.97 9.84E-07 
DSPP 2.88 1.51E-06 
CERS1 3.24 2.06E-05 
TLX1 5.23 0.000156 
NECTIN3 -1.46 0.000156 
IBSP 1.9 0.000453 
BIRC5 -1.6 0.00321 
CDKN2A 2.36 0.00321 
TP53 1.06 0.00436 
CHEK2 -1.21 0.0056 
PDPN -1.33 0.00607 
*FDR = False discovery rate; BH = Benjamini-Hochberg; FDR calculated using 
Benjamini-Hochberg method and significance set at the 5% level (p < 0.05). ** 'Log2 
fold-change' estimates a gene's differential expression; a negative value would mean 
down-regulation and a positive value would mean up-regulation in MT cases versus a 
baseline of NT cases, holding all other variables in the analysis constant. 
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Table 6.8 Significant differentially expressed genes between OED cell lines and 
clinical cases with differing outcomes (MT & NT) using the Customised CodeSet 
Panel with OED cell lines being the baseline (n =48) 
NT vs Cell Lines MT vs Cell Lines 
Gene name Log2 
fold 
change 
FDR 
[BH p-
value] 
Gene name Log2 
fold 
change 
FDR 
[BH p-
value] 
NTRK2 10.2 2.80E-26 NTRK2 10.7 6.87E-27 
BCL2 5.22 5.98E-17 CACNA2D1 8.61 3.33E-17 
PLA2G4E 8.8 5.98E-17 BCL2 5.16 1.23E-16 
CACNA2D1 8.15 7.43E-17 PLA2G4E 8.26 7.37E-16 
NOTCH1 3.86 8.09E-15 NOTCH1 3.24 3.89E-12 
SPRR2B 8.41 1.83E-10 SPRR2B 8.73 9.42E-11 
TP63 6.08 1.91E-09 TP63 6.71 1.90E-10 
DUSP5 3.63 7.72E-08 PAX9 4.57 3.38E-07 
PAX9 4.49 3.27E-07 CTSL -2.1 6.69E-07 
CTSL -1.87 4.37E-06 DUSP5 2.92 7.03E-06 
NECTIN3 -1.29 0.000813 NECTIN3 -1.66 2.83E-05 
TP53 1.21 0.00177 BIRC5 -1.64 0.00439 
PDPN -1.51 0.00269 CHEK2 -1.3 0.00527 
BIRC5 -1.57 0.0054 TP53 0.886 0.0205 
CHEK2 -1.14 0.0111 PDPN -1.1 0.0269 
 
*FDR = False discovery rate; BH = Benjamini-Hochberg; FDR calculated using 
Benjamini-Hochberg method and significance set at the 5% level (p < 0.05). ** 'Log2 
fold-change' estimates a gene's differential expression; a negative value would mean 
down-regulation and a positive value would mean up-regulation in MT cases versus a 
baseline of NT cases, holding all other variables in the analysis constant. 
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Table 6.9 Significant differentially expressed genes using Customised CodeSet 
Panel (n = 44) 
Gene name Log2 fold 
change 
p-value FDR (BH p-
value) 
NOTCH1 -0.63 8.71 e-05 0.0027 
CCNE1 -0.824 
0.000813 
0.0065 
TLX1 -2.24 
0.000864 
 0.0059 
ITGB8 0.528 
0.00102 
0.0059 
TP63 0.621 0.00409 0.0188 
*FDR = False discovery rate; BH = Benjamini-Hochberg; FDR calculated using 
Benjamini-Hochberg method and significance set at the 5% level (p < 0.05). ** 'Log2 
fold-change' estimates a gene's differential expression; a negative value would mean 
down-regulation and a positive value would mean up-regulation in MT cases versus a 
baseline of NT cases, holding all other variables in the analysis constant. 
 
 
Table 6.10 Cox regression analysis (CRA) assessing association between malignant 
transformation and significant differentially expressed genes between MT and NT 
cases (n = 44) 
Variable HR (95% CI) p-value b-coefficient 
NOTCH1 0.27 (0.09, 0.81) 0.020 -1.317 
CCNE1 0.12 (0.04, 0.36) < 0.001  -2.158 
TP63 4.22 (1.44, 12.37) 0.009 1.441 
HR = Hazard ratio; CI = Confidence interval. Variables included for multivariate 
analysis: Dichotomised (low-expression; high-expression) log2 normalised gene 
expression for NOTCH1, CCNE1, TLX1, ITGB8 and TP63. 
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Table 6.11 Comparison and evaluation of dichotomised gene-signature score as a 
prognostic instrument in OPMD against OED grading (n = 44) 
Statistic Dichotomised 
gene-
signature 
score  
WHO 
2017 
grading 
(mild & 
moderate 
vs severe 
OED) 
 
Binary 
OED 
grading 
Sensitivity 70.0% 45.0% 60.0% 
Specificity 91.7% 83.3% 83.3% 
Accuracy 81.8% 65.9% 72.7% 
*Positive 
predictive 
value 
49.7% 24.1% 29.7% 
*Negative 
predictive 
value 
96.3% 92.8% 94.7% 
*Value based on 10.5% prevalence rate of MT in OED as all cases in this cohort had 
some level of OED (Shariff and Zavras, 2015) 
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Figure 6.1 Quality score distribution over all sequences with accuracy for sample W1 
measured by Phred quality score.  
Per sequence quality score shows that most reads for this sample have a high Phred 
score of > 30. 
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Figure 6.2 Percentage of bases in across all reads for sample W1.  
Non-normal distribution is observed on the first 12-13bp. This type of DNA base 
distribution is commonly seen in next-generation sequencing outputs and originates 
from the random hexamer priming (Hansen et al., 2010). 
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Figure 6.3 Summary of quality assessment of raw reads from all 20 samples for 
RNASeq experiment.  
Per sequence quality score shows that all samples have reads with a high Phred 
score of > 30. There were no low-quality reads from all samples. 
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Figure 6.4 Volcano plot showing log2 fold change and significance of all genes 
expressed.  
The red dots represent statistically significant differentially expressed genes between 
MT and NT sub-groups from the RNASeq experiment.  
 
 
Figure 6.5 Principal component analysis scatter plot showing first four principal 
components (n = 48) from the PanCancer Pathways Panel Plus.  
There appears to be no clear separation between MT and NT cases. MT = malignant 
transforming; NT = non-transforming. 
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Figure 6.6 Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway overview for all 13 cancer pathways.
Pathway nodes: white = no genes in the panel that map to them; grey = have corresponding genes in the panel, however no 
significant differential expression; green = downregulation in MT cases; red = upregulation in MT cases. 
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Figure 6.7 Principal component analysis scatter plot showing first four principal 
components for all cases (n = 48) from the Customised CodeSet Panel.  
There is obvious separation between the OED cell line samples and FFPE samples. 
Control = OED cell lines; MT = malignant transforming; NT = non-transforming. 
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Figure 6.8 Principal component analysis scatter plot showing first four principal 
components for FFPE cases (n = 44) from the Customised CodeSet Panel.  
There is considerable overlap between the MT and NT cases. MT = malignant 
transforming; NT = non-transforming. 
 
 
 
 
 
 
 
 
 
 
  
    
154 
 
Figure 6.9 Receiver operating characteristic (ROC) curve for the gene-signature 
derived scores in relation to prognosticating clinical outcome.  
The gene-signature has a concordance index of 0.82 (CI: 0.69, 0.95) and area under 
the curve of 0.893. 
Source of curve Area under 
curve 
Standard 
error 
Asymptotic 
significance 
Asymptotic 95% Confidence 
Interval 
Lower  
Bound 
Upper 
Bound 
Gene-signature 
derived scores 
0.893 0.047 < 0.001 0.800 0.985 
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Figure 6.10 Kaplan-Meier time to event analysis comparing malignant transformation 
in the OPMD cohort stratified according to the dichotomised gene-signature derived 
scores.  
The analysis shows that patients with a high-risk score underwent malignant change 
of OPMDs more rapidly than those with a low-risk score (Log rank test; c2 = 27.56, df 
=1, p < 0.001). Concordance index = 0.76 (CI: 0.66, 0.86). Low-risk score = blue line; 
High-risk score = red line 
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Chapter 7. Construction of Multivariate Prognostic Model   
 
7.1 Introduction 
Despite being extensively studied, a robust prognostic biomarker or model for OPMD 
patients has yet to be successfully developed and validated with most biomarkers 
having sensitivity and specificity that are not markedly better than OED grading 
(Smith et al., 2009; Nankivell and Mehanna, 2011; Nikitakis et al., 2018). Instead of 
relying on single biomarkers, prognostic models composed of several variables may 
prove to be more accurate in risk-stratifying OPMD patients (Moons et al., 2009; 
Royston et al., 2009; Collins et al., 2011; Steyerberg et al., 2013; Moons et al., 2015). 
Recently, Sperandio et al (2013) showed that combining OED grading with a 
molecular parameter (DNA ploidy analysis) may improve prognostication for OPMD 
patients, though not by very much (Sperandio et al., 2013). 
The prognostic ability of several factors (demographic, clinical, histopathology and 
molecular parameters) in OPMD patients were evaluated in the previous chapters. In 
this study, when used in isolation, the performance of most conventional methods 
such as clinical and histopathological findings did not show very good prognostic 
utility in identifying OPMD patients with a higher risk of undergoing MT (Chapter 3). In 
this chapter, the construction of prognostic models composed of two or more 
variables using data obtained from the 44-patient cohort that was analysed using the 
Customised CodeSet Panel will be described and discussed.  
7.2 Aims  
The aims of this chapter are: 
1) To develop novel prognostic models for patients with OPMD. 
2) To evaluate the prognostic utility of the models developed against a model 
based on conventional clinico-pathological parameters. 
3) To assess the performance of the best prognostic model on an external 
validation cohort of OPMD patients. 
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7.3 Results 
Prognostic model building was performed using the 44-patient cohort that had 
complete data for the statistically significant parameters from earlier assessments 
described in Chapters 3 to 6: 
• Age at diagnosis of OPMD ( £  50 vs > 50 years of age) 
• Site of index OPMD (tongue vs others) 
• Binary OED grading (low-grade vs high-grade) 
• LOH status 
o LOH at 3p &/or 9p &/or 17p 
o LOH at 3p &/or 9p 
• Gene-signature score (obtained from results of Customised CodeSet Panel 
experiment described in Chapter 6) 
7.3.1 Univariate analysis 
Preliminary assessment of the variables using either the Fisher’s exact test or 
Pearson’s chi squared test showed that all the above listed variables were 
statistically significant except for age at diagnosis (Tables 7.1 and 7.2). Time to event 
analysis using the log-rank test however showed that all the variables were 
statistically significant (Figures 7.1 to 7.6). Subsequent univariate analysis of the 
variables using Cox (proportional-hazards regression) analysis (CRA) showed that all 
the variables except age at diagnosis were statistically significant (Table 7.3). 
Univariate analysis of LOH results showed that results from LOH analysis assessing 
only two chromosomal regions (3p &/or 9p) outperformed analysis that included 
assessment of three chromosomal regions (3p &/or 9p &/or 17p) (Table 7.2 and 
Table 7.3). 
7.3.2 Multivariate analysis 
Several prognostic models were constructed using the earlier mentioned variables. A 
conventional model, Model 1, utilising only demographic, clinical, and 
histopathological parameters showed that only binary OED grading was statistically 
significant using CRA, with a concordance index of 0.63 (CI: 0.52, 0.74) in relation to 
clinical outcome (Table 7.4). A second prognostic model (Model 2) utilising four 
variables; age at diagnosis, site of OPMD, binary OED grading and LOH at 
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chromosomal regions 3p &/or 9p was then assessed using CRA. The analysis 
produced a prognostic model with a concordance index of 0.67 (CI: 0.56, 0.79) in 
relation to clinical outcome (Table 7.5). A comparison of the prognostic ability of 
Models 1 and 2 using the receiver operating characteristic (ROC) curve is shown in 
Figure 7.7. The performance of Model 2 appears to be slightly better than Model 1 
(Figure 7.7). 
A third prognostic model (Model 3) that included age at diagnosis, site of OPMD, 
binary OED grading, LOH (3p &/or 9p) and the dichotomised gene-signature based 
score was assessed using CRA. The results are shown in Table 7.6. The resultant 
prognostic model (Model 3) was composed of age at diagnosis, site of OPMD, binary 
OED grading and the dichotomised gene-signature based scores; LOH (3p &/or 9p) 
was not retained in the model. This model had a concordance index of 0.85 (CI: 0.72, 
0.98) in relation to clinical outcome; higher than the concordance index from the 
other two models. Assessment of the prognostic utility of Model 3 visualised using 
the ROC curve showed that Model 3 had a much better performance than both 
Models 1 and 2 with a much larger area under the curve (Figure 7.8).  
Model 3 derived scores were then dichotomised for further analysis. Time to event 
analysis showed cases that were categorised as being high-risk were more likely to 
have undergone malignant transformation (Figure 7.9). Sensitivity and specificity 
analysis comparing the dichotomised scores (low-risk vs high-risk for MT) of the three 
models showed that Model 3 performs better than Models 1 and 2 in prognosticating 
clinical outcome for the training cohort (Table 7.7). 
7.3.3 Validation of prognostic model on an external cohort of OPMD patients 
A validation cohort of similar size (23 NT vs 21 MT) to the training cohort was 
identified through a systematic search of the Royal Victoria Infirmary Cellular 
Pathology Database. The search identified 359 cases that fulfilled the inclusion and 
exclusion criteria of which 28 cases (7.8%) underwent MT. Subsequently, 44 cases 
(21 MT vs 23 NT) were selected as the validation cohort based upon completeness 
of medical records and availability of adequate FFPE tissue. For NT cases, the 
duration of follow-up was also taken into consideration, with patients having the 
longest follow-ups being preferentially selected. Binary OED grading, HR-HPV 
testing and the NanoString Customised CodeSet Panel experiment were carried out 
  
    
159 
as described in Chapter 2. The characteristics of the validation cohort are shown in 
Table 7.8. Age at diagnosis (binary), site of index OPMD, binary OED grade and 
gene-signature score were all statistically significant in this cohort (Table 7.8). There 
were no HR-HPV positive cases in the validation cohort. 
This cohort was used to validate the best prognostic model (Model 3). Model 3 had 
an area under the curve (AUC) of 0.902 and a concordance index of 0.76 (CI: 0.67, 
093) in relation to clinical outcome in the validation cohort. Assessment of the 
prognostic utility of Model 3 in this cohort visualised using the ROC curve is shown in 
Figure 7.10. Model 3 appears to have better prognostic ability than binary OED 
grading in this cohort of patients as well. Interestingly, the AUC for the binary OED 
grade in both the training and validation cohorts were quite similar (Figures 7.8 and 
7.10). The performance of Model 3 was almost similar in both the training and 
validation cohorts. 
7.4 Discussion 
The development, validation and reporting of multivariate prognostic models is a 
challenge due to the extensive work that is involved from inception to reporting. A 
major issue with reports on prognostic/predictive models is the lack of detail provided 
regarding all the different areas of model development and validation (Mallett et al., 
2010; Collins et al., 2011; Bouwmeester et al., 2012; Collins et al., 2013; Collins et 
al., 2014; Moons et al., 2014). Adequate review and assessment of such models can 
only be undertaken if reports are able to provide sufficient information on all aspects 
of the model construction and validation. The multivariate prognostic models 
constructed in this study were guided by the recommendations in the “Transparent 
Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis 
(TRIPOD) Statement” checklist that was developed and published recently in several 
medical journals (Collins et al., 2015; Moons et al., 2015).  
Currently, risk-stratification of OPMD patients in clinical practice is usually based on a 
combination of clinico-demographic and histopathological features (Reibel, 2003; 
Barnes et al., 2005; van der Waal, 2009; van der Waal, 2010; El-Naggar et al., 2017; 
Speight et al., 2018). However, the prognostic utility of these features has been found 
to be lacking and at times inconsistent (Mincer et al., 1972; Banoczy and Csiba, 
1976; Pindborg et al., 1977; Silverman et al., 1984; Lumerman et al., 1995; Lee et al., 
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2000; Cowan et al., 2001; Holmstrup et al., 2006; Mehanna et al., 2009; 
Warnakulasuriya et al., 2011; Sperandio et al., 2013; Dost et al., 2014). In this study, 
when considering clinico-pathological parameters, only three were found to be 
statistically significant using statistical analysis; age at diagnosis of OPMD (< 50 
years of age), site of index OPMD (tongue vs others) and OED grading using the 
binary system. These three variables have previously been shown to have an 
association with MT in OPMDs. 
An increased risk of MT amongst older patients has been reported by several studies 
and is possibly due to increasing cumulative genetic/molecular damage and longer 
period of exposure to risk factors that predispose to carcinogenesis (Banoczy and 
Sugar, 1972; Mehta et al., 1972; Schepman et al., 1998; Napier and Speight, 2008; 
Warnakulasuriya et al., 2011). Tongue lesions have been linked to a higher risk of 
MT compared to other oral sites in a recent meta-analysis by Mehanna et al (2009), 
however, several other studies have shown that oral sub-sites are not significantly 
associated with MT (Banoczy, 1977; Silverman et al., 1984; Schepman et al., 1998; 
Holmstrup et al., 2006; Mehanna et al., 2009; Liu et al., 2011; Brouns et al., 2014). 
Though imperfect, the presence and severity of OED has long been considered a 
prognostic indicator for clinical outcome in OPMD (Mincer et al., 1972; Banoczy and 
Csiba, 1976; Pindborg et al., 1977; Silverman et al., 1984; Lumerman et al., 1995; 
Lee et al., 2000; Cowan et al., 2001; Holmstrup et al., 2006; Mehanna et al., 2009; 
Warnakulasuriya et al., 2011; Sperandio et al., 2013; Dost et al., 2014).  
However, when these three variables were fitted together using a CRA model, only 
the binary OED grading of cases was found to be statistically significant. This 
suggests that of all the clinico-pathological parameters, OED grading is the most 
useful prognostic indicator for MT in OPMD. This is consistent with the findings of 
most studies that have indicated that OED grading is currently the “gold-standard” for 
prognosticating clinical outcome in OPMD cases (Warnakulasuriya, 2001; Barnes et 
al., 2005; Warnakulasuriya et al., 2008; van der Waal, 2009; van der Waal, 2010; 
Sperandio et al., 2013; El-Naggar et al., 2017; Speight et al., 2018). Interestingly, the 
prognostic ability of the binary OED grading appears to be rather consistent with the 
values for the area under the ROC curves being almost similar in both the training 
and validation cohorts highlighting the highly dependable nature of this grading 
system. 
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One limitation of the current study was the inability to assess the influence/prognostic 
utility of habit-related factors, specifically tobacco smoking history in this cohort of 
patients. Although the addition of data on habit-related factors may have improved 
the prognostic utility of the clinico-pathological prognostic model, such information 
was not available for this cohort of patients and as such the impact of smoking 
history could not be assessed. One point to consider with regard to smoking history 
is the fact that in most instances, smoking history related information is self-reported 
and the veracity of self-reported smoking history in HNSCC and OPMDs is 
ambiguous (Murray et al., 2002; Hald et al., 2003; Connor Gorber et al., 2009; 
Warren et al., 2012; Morales et al., 2013; Alberg et al., 2015; Khariwala et al., 2015). 
It is also worth noting that previous studies have shown that a non-smoking status is 
more often associated with MT in OPMDs suggesting that self-reported smoking 
history on its own may not be a very useful prognostic indicator of MT in OPMD  
(Reibel, 2003; Liu et al., 2010; Liu et al., 2011; Ho et al., 2012; Rock et al., 2018). 
To compensate for the lack of prognostic utility of existing risk-stratification methods, 
several different molecular assays were assessed in this study with the intent to 
augment the prognostic ability of existing methods. Although a multitude of 
biomarkers in OPMDs have been studied, there has been no breakthrough with most 
biomarkers showing either inconsistent results or prognostic power that is not much 
better than OED grading (Smith et al., 2009; Lingen et al., 2011; Nankivell and 
Mehanna, 2011; Zhang et al., 2012; Sperandio et al., 2013; Nikitakis et al., 2018). 
LOH and DNA ploidy analysis are currently the two most promising biomarkers 
(Pitiyage et al., 2009; Smith et al., 2009; Lingen et al., 2011; Zhang et al., 2012; 
Sperandio et al., 2013; Nikitakis et al., 2018; Speight et al., 2018). In the current 
study, LOH at chromosomal region 3p &/or 9p and the gene signature derived from a 
customised panel of genes were both found to be statistically significant as 
prognostic indicators of MT in OPMD, whilst DNA ploidy status was not statistically 
significant.  
A slight increase in the prognostic ability of Model 2 compared to Model 1 was seen 
due to the addition of LOH (3p &/or 9p) as another variable. Although LOH (3p &/or 
9p) has been shown to have some prognostic utility for OPMDs in this study, sole 
use of LOH analysis for risk-stratification as well as treatment direction would be ill-
advised as its prognostic power has yet to be demonstrated to be superior to OED 
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grading in OPMDs (Rosin et al., 2000; Zhang et al., 2012). Even in this study, the 
binary OED grading system appears to perform either as well or better than LOH 
analysis as a prognostic instrument, depending on the parameters being assessed. 
The current study is the first to compare the prognostic utility of LOH analysis and the 
binary OED grading in OPMDs. 
The landmark study by Zhang et al (2012) that purportedly validated LOH profile as 
an independent predictor of disease progression in OED only assessed the utility of 
LOH profiles in non-dysplastic and low-grade (mild/moderate) OED cases thus their 
findings should not be generalised for all OPMD cases (Zhang et al., 2012). Another 
point to consider regarding the prognostic models constructed in the study by Zhang 
et al (2012) that highlighted the potential value of LOH profiles in distinguishing high-
risk and low-risk cases, is that their endpoint/event of interest was the progression of 
the cases to either severe OED, carcinoma in-situ or OSCC and not just malignant 
transformation of cases. The data for sub-analysis utilising only development of 
OSCC as the endpoint/event of interest was not presented in their manuscript (Zhang 
et al., 2012). Unlike the current study, OED grading was also found to be non-
significant in their univariate analysis of variables. This could be due to one of two 
reasons; because only low-grade/non-dysplastic cases were included in the study or 
due to the usage of the WHO 2005 version of OED grading that has more than two 
categories.  
Although the performance of Model 2 was better than Model 1, it was still inferior to 
the gene-signature derived from the NanoString Customised CodeSet Panel 
experiment detailed in Chapter 6. The gene-signature that was developed appears to 
have good discriminatory value in determining OPMD that underwent MT and those 
that did not. Model 3 that was constructed with the addition of the gene-signature to 
the previous demographic, clinical and histopathological parameters showed much 
better prognostic utility than the other prognostic models highlighting the potential of 
gene expression-based methods in prognosticating clinical outcome.  
Our findings are somewhat similar to the findings reported by Saintigny et al (2011) 
where the authors showed that gene-expression based methods were superior to 
clinical and histological variables in determining clinical outcome in OPMD patients 
(Saintigny et al., 2011). In their study, Saintigny et al (2011) compared microarray 
derived gene-expression based models against a model that contained only age, 
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histology (dysplasia vs hyperplasia) and two biomarkers (ΔNp63 and podoplanin) 
(Saintigny et al., 2011). The two models with microarray data in their study showed 
much better performance compared to the model without any microarray data. Their 
final model, which combined the microarray data with clinical and pathological 
covariates, showed a slight improvement compared to the model with only microarray 
data (Saintigny et al., 2011). Interestingly, only nine transcripts were similar between 
the two models with microarray data, highlighting the rather unstable methodology 
employed in constructing their prognostic model. This could also be one of the 
reasons why their prognostic model has yet to be validated. Aside from that, other 
major differences between the current study and the study by Saintigny et al (2011) 
are the type of tissue material used, the platform utilised to obtain the gene-
expression data as well as the methodology used to arrive at the final gene-
expression profile/signature.  
In the current study, FFPE tissue was successfully used for all the assays whilst 
Saintigny et al (2011) used fresh frozen tissue. Although fresh tissue may provide 
better quality RNA for gene expression studies compared to archived FFPE tissue, 
current next generation sequencing platforms have been shown to produce good 
results even when RNA derived from FFPE tissue is used despite the degradation 
that often accompanies formalin fixation and paraffin embedding of tissues (von 
Ahlfen et al., 2007; Geiss et al., 2008; Mittempergher et al., 2011; Carey et al., 2015; 
Conway et al., 2015; Eikrem et al., 2016; Wimmer et al., 2018). The current study 
also adds to the increasing body of work on utilisation of FFPE material for gene 
expression studies. Another point to consider is that the patients in the Saintigny et al 
(2011) study were enrolled in a clinical trial in which some of the patients received 
active intervention in the form of drugs that may have influenced clinical outcome and 
gene expression (Saintigny et al., 2011). The stepwise method employed in the 
current study, from whole transcriptome sequencing to a final customised list of target 
genes, covered a larger number of transcripts/genes compared to the microarray 
method employed by Saintigny et al (2011). The clinical and histological parameters 
included in the model construction for the current study are also more detailed 
compared to their study. 
Even though the current study has demonstrated the value of a molecularly-driven 
multivariate prognostic model over traditional risk-stratification methods for OPMD 
patients, molecular based methods are not without their drawbacks. The existence of 
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inter- and intra-tumour heterogeneity in OSCC as well as heterogeneity in OPMD 
pose a major problem when it comes to gene-expression studies (Hirsch et al., 1983; 
Perou et al., 2000; Chung et al., 2004; Diwakar et al., 2005; Russnes et al., 2011; 
Marusyk et al., 2012; Fisher et al., 2013; De Cecco et al., 2015; Gomes et al., 2015; 
Gay et al., 2016; Mroz and Rocco, 2016). Another major issue is that the material 
used for gene-expression based assays only provide a snapshot of the transcriptome 
that may not be truly representative of the underlying dynamic pathological process 
(Hirsch et al., 1983; Perou et al., 2000; Chung et al., 2004; Diwakar et al., 2005; 
Russnes et al., 2011; Marusyk et al., 2012; Fisher et al., 2013; De Cecco et al., 2015; 
Gomes et al., 2015; Gay et al., 2016; Mroz and Rocco, 2016). The same can also be 
inferred for LOH analysis as information regarding LOH at one point in time may not 
be adequate to prognosticate clinical outcome over prolonged time-frames and as 
such, these molecular assays may need to be repeated periodically in high-risk 
patients.  
A major limitation of the current study is the sample size and the almost equal 
number of MT and NT cases that is not truly representative of the population where 
MT occurs in approximately 10% of cases with OED (Shariff and Zavras, 2015). 
However, this study was designed to be a proof-of-principle study to explore the 
possibility of using FFPE derived material to construct a molecularly-driven 
multivariate prognostic model for OPMD patients that is superior to traditional 
methods of risk-stratification in these patients. As such, it is acknowledged that this 
study is but a first step in the development of a final gene-expression based 
prognostic model for OPMD patients.  
The issues mentioned earlier highlight the importance and need for clinical validation 
of the prognostic model using an independent patient cohort and preferably by an 
independent research team (Koscielny, 2010; Brulard and Chibon, 2013; Chibon, 
2013). Although the findings from this study have successfully shown that the 
prognostic model developed is indeed superior to conventional risk-stratification 
methods in a validation cohort, the validation cohort was obtained in a retrospective 
manner and the size of the cohort was also rather small. Going forward, it may be 
wiser to assess the prognostic model in a prospective clinical trial setting. 
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7.5 Conclusions 
A prognostic model for OPMD patients composed of clinical, histopathological and 
molecular parameters was constructed and compared against conventional risk-
stratification methods. The gene-signature developed has good prognostic utility 
even as a stand-alone biomarker for OPMD patients with its’ prognostic ability being 
augmented with the addition of clinical and histopathological parameters. The 
molecular methods included in the final model were performed using FFPE material, 
once again highlighting that FFPE-derived material is more than adequate for 
molecular based assays. The current prognostic model however needs to be 
assessed in a larger external cohort to validate its prognostic efficacy. 
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Table 7.1 Demographic, clinical and histopathological characteristics of cases 
selected for prognostic modelling (n = 44) 
Characteristic Non-
transforming 
(NT) 
n = 24 
Malignant 
transforming 
(MT) 
n = 20 
p-value 
Age at diagnosis in 
years 
Mean [SD] 
(Range) 
59.67 
[13.38] 
(34 - 89) 
61.30 
[12.58] 
(35 – 92) 
0.681Ϯ 
Age at 
diagnosis 
£ 50 years 9 2 0.078* 
> 50 years 15 18 
Sex Male 14 13 0.760* 
 Female 10 7 
Site of 
OPMD 
Tongue 4 11 0.011* 
 Other sites 20 9 
WHO 2017 
OED 
grading 
Mild 15 8 0.140** 
 Moderate 5 3 
Severe 4 9 
Binary 
OED 
grading 
Low-grade 
 
20 8 0.005* 
 
High-grade 4 12 
Ϯ Independent t-test; *Fisher’s Exact test; **Pearson’s Chi-square test; SD = Standard 
deviation 
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Table 7.2 Results from molecular parameters for training cohort (n = 44) 
Characteristic Non-
transforming 
(NT) 
n = 24 
Malignant 
transforming 
(MT) 
n = 20 
p-value 
LOH (3p &/or 
9p &/or 17p) 
No LOH 22 12 0.027* 
LOH 2 8 
LOH (3p &/or 
9p) 
No LOH 23 13 0.015* 
 LOH 1 7 
Dichotomised 
gene-
signature 
based score 
 
Low-risk 22 6  
 
< 0.001* High-risk 2 14 
*Fisher’s Exact test 
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Table 7.3 Univariate analysis of selected variables using Cox proportional-hazards 
regression analysis (CRA) (n = 44) 
Variable HR (95% CI) p-value 
Age at diagnosis (> 50 years) 4.02 (0.93, 17.38) 0.063 
Binary OED grading (High-grade) 3.58 (1.43, 8.96) 0.007 
Site of index OPMD (Tongue) 2.86 (1.18, 6.93) 0.020 
LOH (3p &/or 9p &/or 17p) 3.00 (1.22, 7.42) 0.017 
LOH (3p &/or 9p) 3.74 (1.47, 9.57) 0.006 
Dichotomised gene-signature based score 
 
9.36 (3.47, 25.27) < 0.001 
HR = Hazard ratio; CI = Confidence interval 
 
 
 
Table 7.4 Results from Cox proportional-hazards regression analysis (CRA) utilising 
only demographic, clinical and histopathological parameters. (Model 1; n = 44) 
Variable b-coefficient HR (95% CI) 
 
p-value 
 
Age at diagnosis (> 50 years) NA NA > 0.05 
Site of index OPMD (Tongue) NA NA > 0.05 
Binary OED grading (High-grade) 1.275 3.58 (1.43, 8.96) 0.007 
HR = Hazard ratio; CI = Confidence interval; NA = not applicable. Variables included 
for multivariate analysis: age at diagnosis, site of OPMD and binary OED grading. 
Concordance index of 0.63 (CI: 0.52, 0.74) 
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Table 7.5 Results from Cox proportional-hazards regression analysis (CRA) utilising 
age at diagnosis, site of OPMD, binary OED grading and LOH at chromosomal 
regions 3p &/or 9p. (Model 2; n = 44) 
Variable b-coefficient HR (95% CI) 
 
p-value 
 
Age at diagnosis (> 50 years) NA NA > 0.05 
Site of index OPMD (Tongue) NA NA > 0.05 
Binary OED grading (High-grade) 1.066 2.90 (1.11, 7.57) 0.029 
LOH at 3p &/or 9p 1.008 2.74 (1.03, 7.57) 0.043 
HR = Hazard ratio; CI = Confidence interval; NA = not applicable. Variables included 
for multivariate analysis: age at diagnosis, site of OPMD, binary OED grading and 
LOH at chromosomal regions 3p &/or 9p. Concordance index of 0.67 (CI: 0.56, 0.79). 
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Table 7.6 Cox proportional-hazards regression analysis (CRA) utilising age at 
diagnosis, site of OPMD, binary OED grading, LOH at chromosomal region 3p &/or 
9p and dichotomised gene-signature based scores. (Model 3; n = 44) 
Variable b-
coefficient 
HR  
(95% CI) 
 
p-value 
 
Age at diagnosis (> 50 years) 1.650 5.21  
(1.14, 23.84) 
0.0334 
Site of index OPMD (Tongue) 0.959 2.61  
(1.02, 6.67) 
0.0453 
Binary OED grading (High-grade) 1.005 2.73  
(1.00, 7.45) 
0.0496 
Dichotomised gene-signature based 
score 
(High-risk) 
 
2.506 12.26  
(4.09, 36.76) 
< 0.0001 
LOH at 3p &/or 9p NA NA > 0.05 
HR = Hazard ratio; CI = Confidence interval; NA = not applicable. Variables included 
for multivariate analysis: age at diagnosis, site of OPMD, binary OED grading, LOH 
at chromosomal region 3p &/or 9p and dichotomised gene-signature based scores. 
Concordance index of 0.85 (CI: 0.72, 0.98). 
 
. 
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Table 7.7 Comparison between Models 1, 2 and 3 as prognostic instruments for 
clinical outcome in training cohort of OPMD patients (n = 44) 
Statistic Dichotomised 
Model 1 
 
Dichotomised 
Model 2 
Dichotomised 
Model 3 
Sensitivity 60.0% 70.0% 90.0% 
Specificity 83.3% 79.2% 83.3% 
Accuracy 72.7% 75.0% 86.4% 
*Positive 
predictive 
value 
29.7% 28.3% 38.7% 
*Negative 
predictive 
value 
94.7% 95.7% 98.6% 
*Value based on 10.5% prevalence rate of MT in OED as all cases in this cohort had 
some level of OED (Shariff and Zavras, 2015). Model scores were dichotomised 
according to median into low-risk and high-risk for MT. 
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Table 7.8 Demographic, clinical and histopathological characteristics of the validation 
cohort (n = 44) 
Characteristic Non-
transforming 
(NT) 
n = 23 
Malignant 
transforming 
(MT) 
n = 21 
p-value 
Age at diagnosis in years 
Mean [SD] 
(Range) 
55.39 
[13.00] 
(33 - 82) 
61.90 
[11.12] 
(43 – 81) 
0.083Ϯ 
Age at 
diagnosis 
£ 50 years 10 2 0.017* 
> 50 years 13 19 
Sex Male 14 12 1.000* 
 Female 9 9 
Site of OPMD Tongue 6 11 0.011* 
 Other sites 17 10 
Binary OED 
grading 
Low-grade 21 10 0.002* 
 High-grade 2 11 
WHO 2017 
OED grading 
Mild 18 7 0.001** 
Moderate 5 6 
Severe 0 8 
Dichotomised 
gene-
signature 
based score 
 
Low-risk 20 9  
 
0.004* High-risk 3 12 
LOH (3p &/or 
9p) 
No LOH 23 17 0.044* 
 LOH 0 4 
 
Ϯ Independent t-test; *Fisher’s Exact test; **Pearson’s Chi-square test; SD = standard 
deviation 
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Figure 7.1 Kaplan-Meier time to event analysis comparing MT in the OPMD cohort 
stratified according to age at diagnosis.  
The analysis shows that patients aged > 50 years at diagnosis of OPMD underwent 
malignant change of OPMDs more rapidly than those aged £ 50 years. (Log rank 
test; c2 = 4.13, df =1, p = 0.042). Patients aged £ 50 years at diagnosis of index 
OPMD = blue line; Patients aged > 50 years at diagnosis of index OPMD = red line. 
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Figure 7.2 Kaplan-Meier time to event analysis comparing MT in the OPMD cohort 
stratified according to site of index OPMD.  
The analysis shows that patients with OPMD of the tongue underwent malignant 
change of OPMDs more rapidly than those with OPMD at other sites (Log rank test; 
c2 = 6.03, df =1, p = 0.014). OPMD at other oral sites = blue line; OPMD of the 
tongue = red line. 
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Figure 7.3 Kaplan-Meier time to event analysis comparing MT in the OPMD cohort 
stratified according to binary OED grading.  
The analysis shows that patients with a high-grade OED underwent malignant 
change of OPMDs more rapidly than those with low-grade OED (Log rank test; c2 = 
8.52, df =1, p = 0.004). Low-grade OED = blue line; High-grade OED = red line. 
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Figure 7.4 Kaplan-Meier time to event analysis comparing malignant transformation 
in the OPMD cohort stratified according to LOH (3p &/or 9p &/or 17p) analysis 
results.  
The analysis shows that patients with LOH at 3p &/or 9p &/or 17p underwent 
malignant change of OPMDs more rapidly than those with no LOH (Log rank test; c2 
= 6.39, df =1, p = 0.011). No LOH = blue line; LOH at 3p &/or 9p &/or 17p = red line 
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Figure 7.5 Kaplan-Meier time to event analysis comparing malignant transformation 
in the OPMD cohort stratified according to LOH (3p &/or 9p) analysis results.  
The analysis shows that patients with LOH at 3p &/or 9p underwent malignant 
change of OPMDs more rapidly than those with no LOH (Log rank test; c2 = 8.91, df 
=1, p = 0.003). No LOH = blue line; LOH at 3p &/or 9p= red line 
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Figure 7.6 Kaplan-Meier time to event analysis comparing malignant transformation 
in the OPMD cohort stratified according to the dichotomised gene-signature score. 
The analysis shows that patients with a high-risk score underwent malignant change 
of OPMDs more rapidly than those with a low-risk score (Log rank test; c2 = 27.56, df 
=1, p < 0.001). Concordance index = 0.76 (CI: 0.66, 0.86). Low-risk score = blue line; 
High-risk score = red line 
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Source of 
curve 
Area 
under 
curve 
Standard 
error 
Asymptotic 
significance 
Asymptotic 95% Confidence 
Interval 
Lower  
Bound 
Upper 
Bound 
Model 1 0.717 0.081 0.014 0.559 0.875 
Model 2 0.771 0.074 0.002 0.629 0.916 
Dichotomised 
gene-
signature 
based score 
0.808 0.071 < 0.001 0.669 0.947 
Figure 7.7 Receiver operating characteristic (ROC) curves comparing efficacy of 
Models 1 and 2 in prognosticating clinical outcome for the OPMD cohort. 
Model 2 which has the addition of a molecular parameter (LOH) outperformed Model 
1. However, both Model 1 and 2 were still inferior to the dichotomised gene-signature 
based score in prognosticating clinical outcome. Blue line: Model 1; Green line: 
Model 2; Red line: Dichotomised gene-signature based score 
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Source of curve Area under 
curve 
Standard 
error 
Asymptotic 
significance 
Asymptotic 95% Confidence 
Interval 
Lower  
Bound 
Upper 
Bound 
Model 1 0.717 0.081 0.014 0.559 0.875 
Model 3  0.947 0.033 < 0.001 0.882 1.000 
 
Figure 7.8 Receiver operating characteristic (ROC) curves comparing efficacy of 
Models 1 and 3 in prognosticating clinical outcome for the OPMD training cohort.  
Model 3 was found to outperform Model 1 as a prognostic model for clinical outcome 
in the training cohort of OPMD patients. Model 3 had a concordance index of 0.85 
(CI: 0.72, 0.98) in relation to clinical outcome. Blue line: Model 1; Purple line: Model 3 
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Figure 7.9 Kaplan-Meier time to event analysis comparing malignant transformation 
in the OPMD training cohort stratified according to dichotomised Model 3 scores. 
The analysis shows that patients with a high-risk score underwent malignant change 
of OPMDs more rapidly than those with a low-risk score (Log rank test; c2 = 26.35, df 
=1, p < 0.0001). Low-risk score = blue line; High-risk score = red line 
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Source of curve Area under 
curve 
Standard 
error 
Asymptotic 
significance 
Asymptotic 95% Confidence 
Interval 
Lower  
Bound 
Upper 
Bound 
Model 3 0.902 0.045 < 0.0001 0.813 0.990 
Binary OED 
grading 
0.718 0.080 0.013 0.562 0.875 
 
Figure 7.10 Receiver operating characteristic (ROC) curves assessing efficacy of 
Model 3 in prognosticating clinical outcome in the validation cohort.  
Model 3 was found to outperform binary OED grading in prognosticating clinical 
outcome for the validation cohort with a concordance index of 0.76 (CI: 0.67, 093) in 
relation to clinical outcome. 
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 Discussion 
 
8.1 Introduction 
Delayed detection of OSCC is thought to be one of the major contributors to the 
mortality and morbidity associated with OSCC (Barnes et al., 2005; Warnakulasuriya, 
2009; Goodson and Thomson, 2011). Early detection of OSCC is thought to be 
feasible because a proportion of OSCC are preceded by clinically identifiable lesions 
termed ‘oral potentially malignant disorders’ (OPMDs), however the precise number 
of OSCC arising from OPMDs is as yet unclear (Warnakulasuriya et al., 2007; van 
der Waal, 2009; El-Naggar et al., 2017; Speight et al., 2018). The majority of OPMDs 
do not undergo MT and at this point in time there exists no validated method to 
determine the clinical behaviour of OPMDs to a high degree of accuracy (Napier and 
Speight, 2008; Mehanna et al., 2009; Shariff and Zavras, 2015; Warnakulasuriya and 
Ariyawardana, 2016; El-Naggar et al., 2017). 
The current study was undertaken to address the need for an objective method to 
risk-stratify OPMD patients using FFPE tissue to improve their management as well 
as clinical outcome. The prognostic classifier developed from this study may pave 
the way for more personalised management protocols for individual patients with 
OPMDs to improve clinical outcome. This chapter will focus on the key findings from 
the current study. The limitations and future directions of the research will also be 
discussed. 
8.2 Key Findings 
8.2.1 Demographic and clinical features are weakly associated with clinical 
outcome in OPMD patients 
In the current study, demographic and clinical features were largely found to have a 
minor association with clinical outcome of OPMD patients. Although age at diagnosis 
(> 50 years) and site of index OPMD were two features that were found to have 
some prognostic value in the smaller sub-cohort selected for molecular experiments 
(65 patients), the strength of the association appears to be diminished when 
assessed in the larger overall cohort of 166 patients (Tables 3.1 and 3.2). Numerous 
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studies have looked at the association of demographic and clinical features with 
clinical outcome in OPMD patients with varying results (Gupta et al., 1980; 
Schepman et al., 1998; Amagasa et al., 2006; Hsue et al., 2007; Napier and Speight, 
2008; Arduino et al., 2009; Mehanna et al., 2009; van der Waal, 2009; 
Warnakulasuriya et al., 2011; Ho et al., 2012; Bates et al., 2016; Warnakulasuriya 
and Ariyawardana, 2016; Speight et al., 2018). The variation in results between 
studies could largely be due to geographic variation, with different populations having 
differing risk factor habits such as smoking, reverse-smoking and betel-quid chewing 
that may influence the incidence and clinical outcome of OPMDs (Gupta et al., 1980; 
Warnakulasuriya and Ariyawardana, 2016; El-Naggar et al., 2017; Speight et al., 
2018).  
One of the limitations of the current study was the inability to assess the association 
of risk factor habits in MT of OPMDs for this group of patients due to incomplete 
medical records regarding these features. However, the true value of such habits can 
only be assessed if objective assessment of the exposure to the said risk factor 
habits can be performed. This is not usually possible as most data on risk factor 
habits are obtained through clinical history taking reliant on self-reporting which may 
not accurately represent the true exposure to the risk factor habit (Murray et al., 
2002; Hald et al., 2003; Connor Gorber et al., 2009; Warren et al., 2012; Morales et 
al., 2013; Alberg et al., 2015; Khariwala et al., 2015). As such, self-reported risk 
factor history on its own may not be a very useful prognostic indicator of MT in OPMD 
(Reibel, 2003; Liu et al., 2010; Liu et al., 2011; Ho et al., 2012; Rock et al., 2018). 
The lack of association between clinico-demographic features and clinical outcome 
highlights the importance of including other parameters such as OED grading when 
risk-stratifying OPMD patients or formulating management strategies for these 
patients. Although experienced clinicians may defer biopsies for well-recognised 
clinical entities such as nicotinic stomatitis or median rhomboid glossitis, the majority 
of white, red or mixed red-white oral lesions should be biopsied for histopathological 
assessment; risk-stratification based solely on demographic and clinical features is 
not recommended (Epstein et al., 2012; Forman et al., 2015; National Institute for 
Health and Care Excellence, 2015a). 
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8.2.2 The binary OED grading system is a good prognostic marker for clinical 
outcome in OPMD 
Oral epithelial dysplasia (OED) grading is currently considered the “gold-standard” for 
prognosticating clinical outcome in OPMD cases and its’ presence and severity is 
frequently used to direct treatment and management of OPMDs (Warnakulasuriya, 
2001; Barnes et al., 2005; Warnakulasuriya et al., 2008; van der Waal, 2009; van der 
Waal, 2010; Sperandio et al., 2013; El-Naggar et al., 2017; Speight et al., 2018). Two 
different grading systems were described in the recent edition of the WHO text on 
head and neck pathology; the three-tiered traditional grading system and the binary 
grading system (El-Naggar et al., 2017).  
The findings from the current study show that the binary grading system is a better 
indicator for clinical outcome in OPMD cases compared to the three-tiered WHO 
2017 system (Tables 3.3 and 3.6). Not only did it have better prognostic utility, it also 
showed improved inter-observer variability compared to the WHO 2017 grading 
system. One major advantage of the binary OED grading system over the three-
tiered grading systems from a clinician’s perspective may well be the lack of 
uncertainty caused by the “moderate OED” grading in traditional grading systems 
that cause much ambiguity with regard to patient management. This grading system 
also appears to have good consistency with regard to its prognostic ability as it was 
shown to give similar values when assessed in both the training and validation 
cohorts unlike the WHO 2017 grading system that was statistically significant in the 
validation cohort but not in the training cohort. 
However, although the presence and severity of OED is believed to be associated 
with clinical outcome of OPMDs, only between 10 – 12 % of OED undergo MT and 
conversely non-dysplastic lesions have been reported to undergo malignant change, 
demonstrating its’ lack of prognostic utility (Mattsson et al., 2002; Hsue et al., 2007; 
van der Meij et al., 2007; Mehanna et al., 2009; Bagan et al., 2011; Shariff and 
Zavras, 2015). OED grading by itself will possibly never have excellent prognostic 
utility as it is a snapshot of a supposedly “representative” portion of an oral lesion; a 
lesion may evolve over time and also the biopsy specimen may not actually be 
representative of the overall pathology. Despite being superior to the WHO 2017 
system in this cohort, the sensitivity and specificity levels for the binary grading 
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system were still found to be lacking and it requires further validation using larger 
cohorts before it can be recommended for routine clinical usage. 
8.2.3 Presence of OPMD associated leukocytes (OPAL) does not correlate with 
clinical outcome 
Data from the current study suggests that presence of OPAL are not significantly 
associated with clinical outcome in OPMD patients. Importantly however, the 
presence of OED in cases with increased leukocytic infiltrate may be overlooked as 
atypia due to the inflammatory component and these lesions can also mimic chronic 
inflammatory lesions such as oral lichen planus to the untrained eye resulting in 
possible mismanagement of such cases (Krutchkoff and Eisenberg, 1985; Muller, 
2011; Gillenwater et al., 2014; Muller, 2017; Muller, 2018). It is as yet unclear as to 
whether the presence of increased leukocytic infiltrate is a response to atypia in the 
epithelium or as an inducer of MT in OPMDs or a precursor to invasive carcinoma. 
Further exploration using molecular methods to accurately identify the sub-population 
of leukocytes present in OPMDs will need to be performed before such questions can 
be answered.  
8.2.4 Prognostic utility of DNA ploidy status in OPMD patients using incisional 
biopsy specimens is limited 
There was no obvious association between DNA ploidy status and clinical outcome in 
this cohort of patients and a large number of samples also failed DNA ploidy analysis 
due to inadequate tissue. This poses a major problem for OPMD cases as the 
majority of initial incisional biopsy specimens that are provided to obtain a “working 
diagnosis” are rather small in size. Although larger excision specimens may be 
available at centres where lesions are excised, this is not commonplace as surgical 
excisions are currently not the standard of care for all OPMDs (van der Waal, 2009; 
Balasundaram et al., 2014; Lodi et al., 2016). As such, DNA ploidy analysis may not 
be a feasible biomarker for small incisional biopsies that are routinely available for 
most OPMD cases. In this cohort, binary OED grading performed much better than 
DNA ploidy status in discriminating cases with differing clinical outcome (Tables 4.1 
and 4.4). However, it is acknowledged that our results should be interpreted with 
caution as the number of cases analysed were small.  
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8.2.5 Loss of heterozygosity at chromosomal regions 3p &/or 9p shows 
promise as a prognostic biomarker for clinical outcome in OPMD 
Loss of heterozygosity (LOH) analysis was assessed at three chromosomal regions 
in the current study; 3p, 9p and 17p. Both the sample preparation methods showed 
comparable results, though the number of cases assessed was limited. Manual 
microdissection is a much more feasible and cost-effective sample preparation 
method as it does not require specialised hardware and software. However, LCM has 
the advantage of minimising contamination due to its “non-contact” tissue 
manipulation technique.  
LOH status was found to have significant association with clinical outcome in this 
cohort of patients. Further statistical analysis showed that LOH at 3p &/or 9p has 
better utility than LOH at chromosomal regions 3p &/or 9p &/or 17p in terms of 
prognostic ability. In agreement with most studies, LOH analysis does appear to 
show promise as a prognostic biomarker for clinical outcome in OPMDs (Mao et al., 
1996; Rosin et al., 2000; Bremmer et al., 2009; Graveland et al., 2013; William et al., 
2016). Interestingly, when sensitivity and specificity analysis was performed and LOH 
status was compared to binary OED grading, it was found that LOH status had better 
specificity whilst binary OED grading had better sensitivity, thus hinting at the 
possibility that a combination of both parameters may improve prognostic strength. 
This was proven when prognostic Model 2 that was developed by combining LOH 
with other conventional risk-stratification methods did show an increase in prognostic 
power compared to Model 1 (conventional risk-stratification method) (Figure 7.7). 
However, the improvement observed was only marginal and still inferior to the 
developed gene-signature.  
8.2.6 Several novel candidate genes with possible roles in malignant 
transformation of OPMDs were identified  
A number of novel candidate genes associated with oral carcinogenesis were 
identified using two different gene expression analysis platforms (RNASeq and 
NanoString nCounter). Although the final gene-signature developed only contained 
one novel gene (CCNE1), the other candidate genes identified are worth exploring 
further, especially TLX1. The T-cell leukaemia homeobox 1 (TLX1) gene was the 
only gene that was significantly differentially expressed between malignant 
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transforming and non-transforming OPMDs in both gene expression analysis 
platforms (Tables 6.2 and 6.4). Preliminary work to explore TLX1 protein expression 
in OPMD in archived FFPE tissue using immunohistochemistry (IHC) was undertaken 
following the results of the gene expression assays. The results showed that TLX1 
protein expression was seen in oral epithelial tissue as well as amongst the 
leukocytic infiltrate in the connective tissue. Though down-regulation of TLX1 protein 
expression was seen in OPMDs that underwent MT, the findings were not statistically 
significant (data not shown).  
8.2.7 The developed gene-signature was superior to other clinico-pathological 
and molecular parameters in prognosticating clinical outcome 
A novel method utilising a tiered approach from whole transcriptome to targeted 
transcriptome assessment to generate a prognostic gene-signature for OPMD 
patients was used in the current study. The gene-signature composed of NOTCH1, 
CCNE1 and TP63 showed promising results in being able to discriminate OPMD with 
differing clinical outcome in the current study. Addition of the gene-signature to 
conventional risk-stratification methods served to create a highly useful prognostic 
model (Model 3) which was validated on an external cohort of OPMD patients. 
Although the gene-signature may have strong prognostic utility on its own, at this 
point in time it would be best to take into consideration clinico-pathological features 
and include the gene-signature as an additional parameter as the gene-signature has 
yet to be adequately validated.  
8.2.8 Archived FFPE material can be successfully used for molecular assays 
Several molecular techniques were explored using archived FFPE tissue in the 
current study. It was shown that FFPE-based material, though degraded, can still 
prove useful for molecular-based assays. Adequate RNA was successfully obtained 
from FFPE material and the amount of tissue required to obtain valid results from 
gene expression studies was much lower than that required for DNA ploidy and LOH 
analysis (Table 2.1). It is also interesting to note that OED grading uses much less 
FFPE tissue than both DNA ploidy analysis and LOH analysis but provides almost 
equal prognostic information to these molecular techniques (Tables 4.4 and 5.5). 
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8.2.9 Molecular assay driven prognostic model for OPMD patients performed 
better than conventional risk-stratification methods 
Construction of the multivariate prognostic model in the current study was guided by 
the recommendations described in the “Transparent Reporting of a multivariable 
prediction model for Individual Prognosis or Diagnosis (TRIPOD) Statement” as well 
as the recommendations described in the “Reporting Recommendations for Tumour 
Marker Prognostic Studies (REMARK)” studies (McShane et al., 2005; Collins et al., 
2015; Moons et al., 2015). The two prognostic models that had the addition of 
molecular parameters (Model 2 and Model 3) performed better than conventional 
risk-stratification methods based on clinico-demographic and histopathological 
parameters (Model 1). The final model (Model 3) also showed good results in an 
external validation cohort.  
Despite having shown a marked increase in prognostic utility over conventional risk-
stratification methods, there are several limitations to molecularly-driven prognostic 
classifiers. Heterogeneity of OPMDs pose a great problem for molecular analysis as 
does the temporal nature of OPMDs; different areas of a lesion can have a different 
molecular profile and lesions can evolve over time (Hirsch et al., 1983; Perou et al., 
2000; Chung et al., 2004; Diwakar et al., 2005; Napier and Speight, 2008; Liu et al., 
2011; Russnes et al., 2011; Marusyk et al., 2012; Fisher et al., 2013; De Cecco et al., 
2015; Gomes et al., 2015; Gay et al., 2016; Mroz and Rocco, 2016). However, this 
problem also affects histopathological and clinical parameters, necessitating the 
need for repeat biopsies and analysis over time. In situations where multiple biopsies 
may be necessary, minimally invasive biopsy techniques such as brush biopsies may 
prove to be useful (Lingen et al., 2008).  
One limitation of the current study was the small sample size that was not truly 
representative of the population, wherein MT occurs in approximately only 10-12% of 
cases with OED. However, the prevalence rate was taken into consideration for the 
statistical analysis and the final prognostic classifier was still found to be superior to 
conventional risk-stratification methods. Even though validation using an external 
cohort was performed, the size of the validation cohort was also rather small and 
further validation using a larger cohort will need to be performed to ascertain the true 
worth of this prognostic model. 
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8.3 Future Work 
Numerous parameters were assessed during the development of the prognostic 
classifier resulting in many possible avenues for further research. The consistent 
results shown by the binary OED grading regardless of the sample size is a good 
reason to encourage other pathologists to begin concurrent usage of this grading 
system together with the WHO 2017 system to enable comparisons to be made 
using larger cohorts from multiple centres. Another avenue for further validation 
would be to utilise both grading systems for future clinical trials. Routine sole usage 
of only the binary OED grading system however is not encouraged as it does require 
further assessment and validation in clinical practice. 
As there were very few cases of HR-HPV associated OED encountered in the current 
study, the role of HR-HPV in clinical outcome could not be elucidated. Due to the 
possible difference in aetiopathogenesis between HR-HPV associated OED and 
conventional OED, the transcriptomic profile of the two types of OED may be entirely 
different. As such, future work looking at differential gene expression between HR-
HPV associated OED and conventional OED with differing clinical outcome should be 
performed in a step-wise manner, using both whole transcriptome profiling as well as 
targeted transcriptome profiling.  
The role and relationship of sub-epithelial leukocytic infiltrate with the overlying 
epithelium as well as clinical outcome in OPMD has yet to be fully understood. There 
are numerous areas that require further investigation, from sub-typing the 
inflammatory infiltrate to looking at the influence of OPAL in different types of OPMD. 
Hanahan & Weinberg (2011) recently highlighted the importance of inflammation as 
an enabling factor for carcinogenesis and whether this holds true for malignant 
transformation of OPMD is yet inconclusive (Hanahan and Weinberg, 2011). If sub-
epithelial inflammation does indeed facilitate malignant transformation, it does not 
explain the relatively low malignant transformation rates seen in inflammatory lesions 
such as oral lichen planus (Fitzpatrick et al., 2014a; Aghbari et al., 2017; Giuliani et 
al., 2018). It is obvious that the relationship between OPAL and malignant 
transformation is not something that is so simplistic as to be dependent on only the 
intensity of the inflammatory infiltrate. 
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Further exploration of DNA ploidy analysis is warranted as the technique may prove 
to be more useful when assessed in a larger cohort using larger biopsy specimens. 
As the parameter assessed is different from both OED grading and LOH analysis, 
addition of DNA ploidy status and LOH status to conventional risk-stratification that 
uses clinico-pathological features may provide an added dimension to risk-
stratification as well as increased prognostic strength of the model. 
The work from the current study has shown that a reduced microsatellite panel for 
LOH analysis may actually reduce the number of false positives. The possible utility 
of a reduced panel will need to be assessed in a larger cohort that is more 
representative of the OPMD patient population. Combined use with DNA ploidy as 
mentioned earlier is of course an avenue that should be explored further. 
The differential gene expression (DGE) experiments performed yielded several novel 
candidate genes that may potentially be involved in oral carcinogenesis. Further work 
to investigate these candidates have already begun starting with TLX1 using 
immunohistochemistry (IHC) to assess TLX1 protein expression. Further DGE 
experiments should also be undertaken to better understand the transcriptomic 
profile in various sub-populations of OPMD. For example, one could evaluate the 
DGE between low-grade OED and high-grade OED cases that undergo malignant 
transformation. Another example would be to assess the DGE in the different types 
of OPMDs which was not possible in our cohort as the vast majority of cases were 
oral leukoplakias. Future collaborative studies with centres in other parts of the world 
such as South Asia and East Asia that have high rates of oral submucous fibrosis 
may provide a way forward to obtain adequate samples from other types of OPMDs. 
As the molecular assays being utilised have been shown to perform well with FFPE 
tissue, global collaborations can easily be carried out as most pathology laboratories 
worldwide have vast numbers of archived FFPE material. 
The gene-signature as well as prognostic classifier that were developed should be 
assessed in a larger cohort of OPMD patients with known clinical outcomes and 
adequate follow-up. This once again can be facilitated through a collaborative 
approach. In summary, though the findings from this study look promising, there is a 
need to validate it using a larger, preferably multicentre cohort that would be more 
representative of the population. 
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8.4 Conclusions 
a) Age at diagnosis (> 50 years) and site of index OPMD (tongue) appear to be 
the clinical features more likely to be associated with malignant transformation. 
However, clinical features were not as good at prognosticating clinical 
outcome for OPMD patients as the binary OED grading system. 
b) The binary OED grading system has better prognostic utility than the three-
tiered WHO 2017 grading system for discriminating OPMD cases with differing 
clinical outcomes. It also appears to have better clinical utility than both DNA 
ploidy and LOH status in terms of prognosticating clinical outcome for OPMD 
patients. 
c) There was no clear association between OPMD associated leukocytes (OPAL) 
and clinical outcome.  
d) DNA ploidy status was not significantly associated with clinical outcome of 
OPMD cases in this cohort. As DNA ploidy requires a fairly large amount of 
tissue for successful analysis, it may not be suitable for small incisional biopsy 
specimens. 
e) Loss of heterozygosity (LOH) was proven to have significant prognostic utility 
in discriminating OPMD cases with differing clinical outcomes. However, its’ 
prognostic ability is not very much better than binary OED grading. LOH at 
chromosomal regions 3p &/or 9p has better utility than LOH at chromosomal 
regions 3p &/or 9p &/or 17p in terms of prognostic ability. Both manual 
microdissection and LASER capture microdissection methods are suitable for 
LOH analysis. 
f) The gene-signature that was developed had better prognostic utility than 
conventional prognostic features such as demographic, clinical and 
histopathological parameters. It also performed better than DNA ploidy and 
LOH analysis. 
g) Several novel candidate genes with possible roles in malignant transformation 
of OPMD as well as oral carcinogenesis have been identified using RNA 
derived from FFPE tissue.  
h) FFPE tissue can be successfully used for molecular assays. 
i) A prognostic classifier composed of demographic (age at diagnosis), clinical 
(site of index OPMD), histopathological (binary OED grading) and molecular 
(dichotomised gene-signature derived score) parameters outperformed 
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conventional prognostic classifiers in terms of discriminating OPMD cases with 
differing clinical outcomes. 
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Appendix A. Reporting recommendations for tumour marker 
prognostic studies (REMARK) checklist 
The Reporting Recommendations for Tumour Marker Prognostic Studies (REMARK) 
Checklist 
Item to be reported Page 
no. 
INTRODUCTION  
1 State the marker examined, the study objectives, and any pre-specified 
hypotheses.   
 
MATERIALS AND METHODS  
Patients  
2 Describe the characteristics (e.g., disease stage or co-morbidities) of the study 
patients, including their source and inclusion and exclusion criteria.   
 
3 Describe treatments received and how chosen (e.g., randomized or rule-based).    
Specimen characteristics  
4 Describe type of biological material used (including control samples) and methods 
of preservation and storage. 
 
Assay methods  
5 Specify the assay method used and provide (or reference) a detailed protocol, 
including specific reagents or kits used, quality control procedures, reproducibility 
assessments, quantitation methods, and scoring and reporting protocols. Specify 
whether and how assays were performed blinded to the study endpoint. 
 
Study design  
6 State the method of case selection, including whether prospective or retrospective 
and whether stratification or matching (e.g., by stage of disease or age) was used. 
Specify the time period from which cases were taken, the end of the follow-up 
period, and the median follow-up time.   
 
7 Precisely define all clinical endpoints examined.   
8 List all candidate variables initially examined or considered for inclusion in models.   
9 Give rationale for sample size; if the study was designed to detect a specified effect 
size, give the target power and effect size.  
 
Statistical analysis methods  
10 Specify all statistical methods, including details of any variable selection 
procedures and other model-building issues, how model assumptions were 
verified, and how missing data were handled.  
 
11 Clarify how marker values were handled in the analyses; if relevant, describe 
methods used for cutpoint determination. 
 
RESULTS  
Data   
12 Describe the flow of patients through the study, including the number of patients 
included in each stage of the analysis (a diagram may be helpful) and reasons for 
dropout. Specifically, both overall and for each subgroup extensively examined 
report the numbers of patients and the number of events. 
 
13 Report distributions of basic demographic characteristics (at least age and sex), 
standard (disease-specific) prognostic variables, and tumor marker, including 
numbers of missing values.  
 
Analysis and presentation   
14 Show the relation of the marker to standard prognostic variables.  
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15 Present univariable analyses showing the relation between the marker and 
outcome, with the estimated effect (e.g., hazard ratio and survival probability). 
Preferably provide similar analyses for all other variables being analyzed. For the 
effect of a tumor marker on a time-to-event outcome, a Kaplan-Meier plot is 
recommended.  
 
16 For key multivariable analyses, report estimated effects (e.g., hazard ratio) with 
confidence intervals for the marker and, at least for the final model, all other 
variables in the model.  
 
17 Among reported results, provide estimated effects with confidence intervals from 
an analysis in which the marker and standard prognostic variables are included, 
regardless of their statistical significance.  
 
18 If done, report results of further investigations, such as checking assumptions, 
sensitivity analyses, and internal validation. 
 
DISCUSSION  
19 Interpret the results in the context of the pre-specified hypotheses and other 
relevant studies; include a discussion of limitations of the study. 
 
20 Discuss implications for future research and clinical value.   
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Appendix B. Transparent reporting of a multivariable prediction 
model for individual prognosis or diagnosis (TRIPOD) statement 
checklist 
TRIPOD Checklist: Prediction Model Development and Validation 
Section/Topic Item  Checklist Item Page 
Title and abstract 
Title 1 D;V Identify the study as developing and/or validating a multivariable 
prediction model, the target population, and the outcome to be predicted. 
 
Abstract 2 D;V Provide a summary of objectives, study design, setting, participants, 
sample size, predictors, outcome, statistical analysis, results, and 
conclusions. 
 
Introduction 
Background 
and objectives 
3a D;V Explain the medical context (including whether diagnostic or prognostic) 
and rationale for developing or validating the multivariable prediction 
model, including references to existing models. 
 
3b D;V Specify the objectives, including whether the study describes the 
development or validation of the model or both. 
 
Methods 
Source of data 4a D;V Describe the study design or source of data (e.g., randomized trial, 
cohort, or registry data), separately for the development and validation 
data sets, if applicable. 
 
4b D;V Specify the key study dates, including start of accrual; end of accrual; 
and, if applicable, end of follow-up.  
 
Participants 5a D;V Specify key elements of the study setting (e.g., primary care, secondary 
care, general population) including number and location of centres. 
 
5b D;V Describe eligibility criteria for participants.   
5c D;V Give details of treatments received, if relevant.   
Outcome 6a D;V Clearly define the outcome that is predicted by the prediction model, 
including how and when assessed.  
 
6b D;V Report any actions to blind assessment of the outcome to be predicted.   
Predictors 7a D;V Clearly define all predictors used in developing or validating the 
multivariable prediction model, including how and when they were 
measured. 
 
7b D;V Report any actions to blind assessment of predictors for the outcome and 
other predictors.  
 
Sample size 8 D;V Explain how the study size was arrived at.  
Missing data 9 D;V Describe how missing data were handled (e.g., complete-case analysis, 
single imputation, multiple imputation) with details of any imputation 
method.  
 
Statistical 
analysis 
methods 
10a D Describe how predictors were handled in the analyses.   
10b D Specify type of model, all model-building procedures (including any 
predictor selection), and method for internal validation. 
 
10c V For validation, describe how the predictions were calculated.   
10d D;V Specify all measures used to assess model performance and, if relevant, 
to compare multiple models.  
 
10e V Describe any model updating (e.g., recalibration) arising from the 
validation, if done. 
 
Risk groups 11 D;V Provide details on how risk groups were created, if done.   
Development 
vs. validation 
12 V For validation, identify any differences from the development data in 
setting, eligibility criteria, outcome, and predictors.  
 
Results 
Participants 13a D;V Describe the flow of participants through the study, including the number 
of participants with and without the outcome and, if applicable, a 
summary of the follow-up time. A diagram may be helpful.  
 
13b D;V Describe the characteristics of the participants (basic demographics, 
clinical features, available predictors), including the number of 
participants with missing data for predictors and outcome.  
 
13c V For validation, show a comparison with the development data of the 
distribution of important variables (demographics, predictors and 
outcome).  
 
Model 
development  
14a D Specify the number of participants and outcome events in each analysis.   
14b D If done, report the unadjusted association between each candidate 
predictor and outcome. 
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Model 
specification 
15a D Present the full prediction model to allow predictions for individuals (i.e., 
all regression coefficients, and model intercept or baseline survival at a 
given time point). 
 
15b D Explain how to the use the prediction model.  
Model 
performance 
16 D;V Report performance measures (with CIs) for the prediction model.  
Model-updating 17 V If done, report the results from any model updating (i.e., model 
specification, model performance). 
 
Discussion 
Limitations 18 D;V Discuss any limitations of the study (such as nonrepresentative sample, 
few events per predictor, missing data).  
 
Interpretation 19a V For validation, discuss the results with reference to performance in the 
development data, and any other validation data.  
 
19b D;V Give an overall interpretation of the results, considering objectives, 
limitations, results from similar studies, and other relevant evidence.  
 
Implications 20 D;V Discuss the potential clinical use of the model and implications for future 
research.  
 
Other information 
Supplementary 
information 
21 D;V Provide information about the availability of supplementary resources, 
such as study protocol, Web calculator, and data sets.  
 
Funding 22 D;V Give the source of funding and the role of the funders for the present 
study.  
 
*Items relevant only to the development of a prediction model are denoted by D, 
items relating solely to a validation of a prediction model are denoted by V, and items 
relating to both are denoted D;V.   
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Appendix C. Protocol for RNA extraction from formalin-fixed 
paraffin-embedded tissue 
Protocol for RNA extraction and purification using the QIAGEN RNeasy FFPE kit 
following the manufacturer's protocol (QIAGEN, Manchester, UK). 
i. 160μl (1 - 2 FFPE sections) or 320μl (> 2 FFPE sections) of Deparaffinization 
Solution (QIAGEN, Germany), was added to the sample and vortexed 
vigorously for 10s and centrifuged briefly to bring the sample to the bottom of 
the tube. 
ii. The sample was then incubated at 56°C for 3 minutes and allowed to cool to 
room temperature. 
iii. 150μl (1 - 2 FFPE sections) or 240μl (> 2 FFPE sections) Buffer PKD was added 
and mixed by vortexing. 
iv. The samples were then centrifuged for 1 minutes at 11,000 x g. 
v. 10μl proteinase K was then added to the lower (clear) phase and mixed gently 
by pipetting up and down. 
vi. The samples were incubated at 56°C for 15 minutes, and then at 80°C for 15 
minutes in heating blocks with a shaking function. 
vii. After incubation, the lower (uncoloured) phase was transferred into a new 2ml 
microcentrifuge tube and left to incubate on ice for 3 minutes. 
viii. The samples were then centrifuged for 15 minutes at 20,000 x g. 
ix. The supernatant was then transferred to a new 2ml microcentrifuge tube  
x. DNase Booster Buffer equivalent to a tenth of the total sample volume and 10μl 
DNase I stock solution was then added to the sample and mixed by inverting 
the tube. The tube was then centrifuged briefly to collect residual liquid from the 
sides of the tube. 
xi. The sample was then incubated at room temperature for 15 minutes. 
xii. After incubation, 320μl (1 - 2 FFPE sections) or 500μl (> 2 FFPE sections) of 
Buffer RBC was added to the sample and the lysate was mixed thoroughly. 
xiii. 720μl (1 - 2 FFPE sections) or 1200μl (> 2 FFPE sections) of ethanol (100%) 
was added to the sample and mixed well by pipetting.  
xiv. 700μl of the sample was then transferred to a RNeasy MinElute spin column 
placed in a 2ml collection tube and centrifuged for 15 s at ≥8000 x g. The flow-
  
    
258 
through was discarded. This step was repeated until the entire sample has 
passed through the RNeasy MinElute spin column. 
xv. 500μl Buffer RPE was then added to the RNeasy MinElute spin column and 
centrifuged for 15 s at ≥8000 x g. The flow-through was discarded. 
xvi. 500μl Buffer RPE was then added to the RNeasy MinElute spin column and 
centrifuged for 2 minutes at ≥8000 x g to wash the sample. After centrifugation, 
the RNeasy MinElute spin column was carefully removed from the collection 
tube so that the column did not contact the flow-through. The collection tube 
with the flow-through was then discarded.  
xvii. The RNeasy MinElute spin column was then placed in a new 2ml collection 
tube. The tube was the centrifuged at full speed for 5 minutes with lid of the spin 
column being left open (to dry the spin column membrane as residual ethanol 
may interfere with downstream reactions). The collection tube with the flow-
through was then discarded. 
xviii. The RNeasy MinElute spin column was then placed into new 1.5ml collection 
tube.  
xix. 16μl of RNase-free water was then placed directly onto the spin column 
membrane and the tubes were centrifuged for 1 minute at full speed to elute the 
RNA. 
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Appendix D. Additional target genes for PanCancer Pathways Panel 
Plus 
List of additional targets for PanCancer Pathways Panel Plus 
 
Ensembl gene ID HGNC 
symbol 
Log2 fold 
change 
FDR 
[BH p-value] 
ENSG00000196805 SPRR2B 2.478102 0.014621 
ENSG00000115844 DLX2 2.301966 0.014621 
ENSG00000223802 CERS1 2.187502 0.043672 
ENSG00000139292 LGR5 -1.83 0.046 
ENSG00000166165 CKB 2.11 0.015 
ENSG00000177707 NECTIN3 -2.01 0.036 
ENSG00000066248 NGEF 1.58 0.031 
ENSG00000115112 TFCP2L1 -2.22 0.015 
ENSG00000111640 §GAPDH NA NA 
ENSG00000198807 *PAX9 NA NA 
§GAPDH was included as an additional housekeeping gene *PAX9 was included 
based on previous work performed by the Newcastle University Oral Cancer 
Research Group (OCRG). FDR = False discovery rate; BH = Benjamini-Hochberg; 
HGNC = Human Genome Organisation Gene Nomenclature Committee; NA = not 
available 
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Appendix E. Laboratory workflow for PanCancer Pathways Panel 
Plus 
Summarised laboratory workflow for the NanoString nCounter assay using the 
PanCancer Pathways Panel Plus is listed below: 
i. Aliquots of Reporter CodeSet, Capture ProbeSet, and Plus reagents were 
removed from the freezer to thaw at room temperature. Reagents were inverted 
several times to mix well and then spun down. 
ii. 28 μl of Reporter Plus reagent was added to the thawed Reporter CodeSet in 
the supplied 12-well strip tubes. Reagents were inverted several times to mix 
well and then spun down. 
iii. A master mix was created by adding 70μl of hybridization buffer to the tubes 
containing the Reporter CodeSet and Reporter Plus reagents. The tube with 
master mix was inverted several times to mix well and then spun down 
iv. The hybridisation tubes were labelled.  
v. 10μl of master mix (made up of 3μl Reporter CodeSet, 2μl Reporter Plus and 
5μl hybridisation buffer) was added to each tube. 
vi. 5μl of sample was added to each tube. 
vii. When necessary, RNase-free water was added to bring the volume of each 
assay to 15 μl. 
viii. 14 μl of Capture Plus reagent was added to the thawed aliquot of Capture 
ProbeSet. Reagents were inverted several times to mix well and then spun 
down. 
ix. 3 μl of Capture ProbeSet & Capture Plus reagent mix was added to each tube. 
Tube caps were closed, and reagents were mixed by inverting the tubes several 
times and flicking with a finger (to ensure complete mixing).  
x. The tubes were briefly spun down and placed in a pre-heated 65°C thermal 
cycler. 
xi. Reactions were left to incubate for at least 16 hours.  
xii. Samples were then processed the following day on the “nCounter MAX/FLEX 
Prep Station” (NanoString Technologies, Seattle, USA). The nCounter 
MAX/FLEX Prep Station is a multi-channel pipetting robot.  
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xiii. Sample cartridges were removed from -20°C storage and allowed to equilibrate 
to room temperature. Prep plates were removed from -4°C storage and 
centrifuged at 2000xg for 2 minutes and then allowed to equilibrate to room 
temperature. The last row of the plates was checked to confirm presence of 
magnetic beads. 
xiv. The prep plates were placed on the prep deck with the green labels facing 
forwards. The lids were discarded, and tips were loaded.  
xv. The foil from the cartridge was removed and the cartridge was placed under the 
electrode fixture and electrodes were lowered into the cartridge. 
xvi. Empty NanoString strip tubes were placed into the heater block. 
xvii. Sample tubes were un-capped and placed into the metal tube holder. The 
heater lid was then closed and processing on the nCounter MAX/FLEX Prep 
Station was initiated (hybridised samples were purified and immobilised on the 
MAX/FLEX Prep Station). 
xviii. After completing the run on the nCounter MAX/FLEX Prep Station, the 
cartridges were covered to prevent evaporation of liquids. 
xix. The Reporter Library File (RLF) was then uploaded to the nCounter MAX/FLEX 
Digital Analyzer 
xx. The Sample Cartridges (each containing 12 samples) were then transferred 
from the nCounter MAX/FLEX Prep Station to the “nCounter MAX/FLEX Digital 
Analyzer” (NanoString Technologies, Seattle, USA) to obtain the target probe 
counts. The nCounter MAX/FLEX Digital Analyzer is a multi-channel 
epifluorescence scanner. 
xxi. The probe counts were tabulated in a comma separated value (CSV) format for 
data analysis. 
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Appendix F. Gene list for Customised CodeSet Panel 
List of genes for NanoString Customised CodeSet Panel experiment 
 
Ensembl Gene ID HGNC gene 
symbol 
Designation 
ENSG00000107807 TLX1 TARGET 
ENSG00000148053 NTRK2 TARGET 
ENSG00000198807 PAX9 TARGET 
ENSG00000146648 EGFR TARGET 
ENSG00000100985 MMP9 TARGET 
ENSG00000196611 MMP1 TARGET 
ENSG00000087245 MMP2 TARGET 
ENSG00000089685 BIRC5 TARGET 
ENSG00000162493 PDPN TARGET 
ENSG00000148400 NOTCH1 TARGET 
ENSG00000141510 TP53 TARGET 
ENSG00000147889 CDKN2A TARGET 
ENSG00000189283 FHIT TARGET 
ENSG00000078900 TP73 TARGET 
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Ensembl Gene ID HGNC gene 
symbol 
Designation 
ENSG00000073282 TP63 TARGET 
ENSG00000120217 PDL1 TARGET 
ENSG00000073111 MCM2 TARGET 
ENSG00000135047 CTSL TARGET 
ENSG00000122512 PMS2 TARGET 
ENSG00000076242 MLH1 TARGET 
ENSG00000095002 MSH2 TARGET 
ENSG00000116062 MSH6 TARGET 
ENSG00000183765 CHEK2 TARGET 
ENSG00000029559 IBSP TARGET 
ENSG00000152591 DSPP TARGET 
ENSG00000115844 DLX2 TARGET 
ENSG00000223802 CERS1 TARGET 
ENSG00000139292 LGR5 TARGET 
ENSG00000196805 SPRR2B TARGET 
ENSG00000177707 NECTIN3 TARGET 
ENSG00000188089 PLA2G4E TARGET 
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Ensembl Gene ID HGNC gene 
symbol 
Designation 
ENSG00000105855 ITGB8 TARGET 
ENSG00000188153 COL4A5 TARGET 
ENSG00000138166 DUSP5 TARGET 
ENSG00000171791 BCL2 TARGET 
ENSG00000125398 SOX9 TARGET 
ENSG00000105173 CCNE1 TARGET 
ENSG00000153956 CACNA2D1 TARGET 
ENSG00000167553 TUBA6 HOUSEKEEPING 
ENSG00000075624 ACTB HOUSEKEEPING 
ENSG00000111640 GAPDH HOUSEKEEPING 
ENSG00000073578 SDHA HOUSEKEEPING 
HGNC = Human Genome Organisation Gene Nomenclature Committee 
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Appendix G. Laboratory workflow for Customised CodeSet Panel 
Summarised laboratory workflow for the Customised CodeSet Panel gene expression 
assay is listed in below: 
i. Aliquots of Reporter CodeSet, and Capture ProbeSet were removed from the 
freezer to thaw at room temperature. Reagents were inverted several times to 
mix well and then spun down. 
ii. A master mix was created by adding 70μL of hybridization buffer to the 
Reporter CodeSet in the supplied 12-well strip tubes. The tubes with master 
mix was inverted several times to mix well and then spun down 
iii. The hybridisation tubes were labelled.  
iv. 8μl of master mix (made up of 3μl Reporter CodeSet and 5μl hybridisation 
buffer) was added to each tube. 
v. 5μl of sample was added to each tube. 
vi. When necessary, RNase-free water was added to bring the volume of each 
assay to 13μl. 
vii. Capture ProbeSet tube was inverted several times to mix well and then spun 
down. 
viii. 2 μl of Capture ProbeSet was added to each tube. Tube caps were closed, 
and reagents were mixed by inverting the tubes several times and flicking with 
a finger (to ensure complete mixing). 
ix. The tubes were briefly spun down and placed in a pre-heated 65°C thermal 
cycler. 
x. Reactions were left to incubate for at least 16 hours.  
xi. Samples were then processed the following day on the “nCounter MAX/FLEX 
Prep Station” (NanoString Technologies, Seattle, USA). The nCounter 
MAX/FLEX Prep Station is a multi-channel pipetting robot.  
xii. Sample cartridges were removed from -20°C storage and allowed to 
equilibrate to room temperature. Prep plates were removed from -4°C storage 
and centrifuged at 2000xg for 2 minutes and then allowed to equilibrate to 
room temperature. The last row of the plates was checked to confirm presence 
of magnetic beads. 
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xiii. The prep plates were placed on the prep deck with the green labels facing 
forwards. The lids were discarded, and tips were loaded.  
xiv. The foil from the cartridge was removed and the cartridge was placed under 
the electrode fixture and electrodes were lowered into the cartridge. 
xv. Empty NanoString strip tubes were placed into the heater block. 
xvi. Sample tubes were un-capped and placed into the metal tube holder. The 
heater lid was then closed and processing on the nCounter MAX/FLEX Prep 
Station was initiated (hybridised samples were purified and immobilised on the 
MAX/FLEX Prep Station). 
xvii. After completing the run on the nCounter MAX/FLEX Prep Station, the 
cartridges were covered to prevent evaporation of liquids. 
xviii. The Reporter Library File (RLF) was then uploaded to the nCounter 
MAX/FLEX Digital Analyzer 
xix. The Sample Cartridges (each containing 12 samples) were then transferred 
from the nCounter MAX/FLEX Prep Station to the “nCounter MAX/FLEX 
Digital Analyzer” (NanoString Technologies, Seattle,USA) to obtain the target 
probe counts. The nCounter MAX/FLEX Digital Analyzer is a multi-channel 
epifluorescence scanner. 
xx. The probe counts were tabulated in a comma separated value (CSV) format 
for data analysis. 
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Appendix H. Associated Kyoto Encylopaedia of Genes and 
Genomes (KEGG) pathways 
Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathways of top five cancer-
related pathways from PanCancer Pathways Panel Plus experiment (n = 48). 
For each KEGG pathway, genes within the panel are mapped to the pathway and 
differential expression information is overlaid on the protein-based KEGG pathway 
image. Pathway nodes shown in white have no genes in the panel that map to them. 
Pathway nodes in grey have corresponding genes in the panel, however no 
significant differential expression is observed. Nodes in green denote downregulation 
in malignant transforming cases relative to non-transforming cases, whereas nodes 
in red denote upregulation in malignant transforming cases relative to non-
transforming cases. 
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